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«L'acqua che tocchi de' fiumi è l'ultima di quelle che andò e la prima di quella che 
viene. Così il tempo presente.» 
 
“In rivers, the water that you touch is the last of what has passed and the first of which 
comes; so with present time” 
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Intracerebral hemorrhage (ICH) is the second most common subtype of stroke. The prognosis 
is poor. However, it is to a large degree a preventable disease. The aim of our study was to 
analyse the association between cardiovascular risk factors and risk of ICH, and to assess the 
impact of changes in risk factor levels over time on incidence rates of ICH. In addition, we 
aimed to analyse short- and long-term mortality after ICH. The Tromsø study is an ongoing, 
longitudinal population-based study with repeated health surveys, with >45,000 attendees, 
providing an unique opportunity to assess longitudinal data on ICH epidemiology in a general 
population in a well-defined geographical area. Age, male sex, systolic and diastolic blood 
pressure were significantly associated with increased risk of ICH. Incidence rates were stable 
in the overall population in the period 1995-2013. In women incidence rates decreased, 
whereas incidence rates in men were stable. Lower blood pressure levels, and a steeper 
decrease in blood pressure in women may have contributed to the difference in trends. 
Despite an increase in treatment of hypertension, less than half of attendees of the last survey 
who had hypertension were on blood pressure-lowering drugs. Of these, two-thirds had 
uncontrolled hypertension. One-month case fatality and 5-year mortality rates remained 
stable. Participants who survived the first 30 days after ICH had a more than 60% increased 
5-year risk of death compared with controls matched by birth-year and sex. The main cause of 
death was cardiovascular disease. Smoking, serum cholesterol and use of anticoagulant drugs 
at time of ICH were associated with increased risk of 5-year mortality after ICH.  
Our results indicate that there is a need for improved primary prevention of ICH. The 
stable short- and long-term mortality rates probably reflect the limited treatment possibilities 
of ICH and emphasize the urge for improved treatment strategies in the acute phase and a 






Intracerebral blødning (ICB) er den nest hyppigste type av hjerneslag. Prognosen etter ICB er 
alvorlig, men det er en sykdom som i stor grad kan forebygges. Vi ønsket å undersøke hvilke 
risikofaktorer som øker risikoen for ICB, og om endringer i risikofaktorer over tid har 
påvirket forekomsten av ICB. I tillegg ønsket vi å undersøke kort- og langtidsdødelighet etter 
ICB. Tromsøundersøkelsen er en pågående longitudinell populasjonsbasert studie med 
repeterte målinger med over 45,000 deltakere. Undersøkelsen gir en unik mulighet til å 
analysere endringer over tid i insidens og dødelighet og risiko-faktorer for ICB i  
befolkningen. Vi fant at alder, mannlig kjønn, systolisk og diastolisk blodtrykk var signifikant 
assosiert med risikoen for ICB. Insidensraten av ICB var stabil i den samlede befolkningen i 
perioden 1995-2013. Vi observerte imidlertid en nedgang i insidens av ICB hos kvinner. 
Insidensratene hos menn var stabile. Lavere blodtrykksnivåer og en større nedgang i 
blodtrykk hos kvinner kan ha bidratt til forskjellen i trend. Blant deltakere med hypertensjon 
økte andelen som ble behandlet og hadde velregulert blodtrykk. Til tross for dette var mindre 
enn halvparten av deltakere med hypertensjon i siste del av studien medikamentelt behandlet. 
To tredeler av disse hadde ukontrollert hypertensjon. Det var ingen endring i 30-dagers 
fatalitet og 5-års dødelighet. Blant deltakere som var i live 30 dager etter ICB var risikoen for 
død i løpet av 5 år mer enn 60% høyere sammenlignet med kontroller matchet for fødselsår og 
kjønn. Forskjellen kunne forklares av en økt risiko for død av kardiovaskulær sykdom hos 
pasienter med ICB. Røyking, serum kolesterol og bruk av antikoagulantia på 
blødningstidspunktet var assosiert med økt risiko for 5-års dødelighet.   
De stabile insidensratene viser at det er behov for en forbedret forebygging av ICB. 
Stabile trender i kort- og langtidsdødelighet indikerer at det er et behov for mer effektiv 
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1.1 Stroke and stroke epidemiology 
Stroke is the second leading cause of death and disability worldwide.1 In Norway, stroke 
is the third leading cause of death.2, 3 A stroke is caused by blockage (ischemic stroke (IS)) or 
rupture (hemorrhagic stroke) of a brain artery, leading to a sudden death of brain cells.4 
Hemorrhagic stroke can be further classified into intracerebral hemorrhage (ICH; bleeding 
into the brain parenchyma and/or into the ventricular system) and subarachnoid hemorrhage 
(SAH; bleeding into the subarachnoid space). Worldwide, 73-90% of strokes were ischemic, 
9-27% ICH and 1-10% SAH in the period 2000-2008, with the highest proportion of 
hemorrhagic strokes in low-to middle income countries.5 The symptoms of a stroke depend on 
the area of the brain affected, with limb paresis, speech disturbances and facial palsy being the 
most common in IS and ICH,6, 7 and sudden headache the most common in SAH.8 The 
symptoms of IS and ICH are similar, and brain imaging by computed tomography (CT) / 
magnetic resonance imaging (MRI) or autopsy are essential to differentiate the different types 
of stroke (Figure 1).6 
Figure 1. CT scans of stroke subtypes  
     
 
 
Ischemic stroke Intracerebral hemorrhage Subarachnoid hemorrhage 






1.1.1 A historical perspective on stroke 
The disease was first described by Hippocrates in 400 BC, including symptoms as acute brain 
pain, diplopia, vertigo, ataxia, saliva, urine loss and fecal incontinence, and by Hippocrates 
referred to by the term apoplexia (“to strike down”).9 Apoplexia, however, encompassed 
several different neurologic diseases in addition to what we today would define as a stroke.9 
Hippocrates linked the pathogenesis of apoplexia to the humoral theory; where it was 
believed that blood held the spirit of humans, and that an interference with the flow of the 
spirit to the brain would result in apoplexy.10 His proponent, Galen (born AD 131) believed 
that the causes of apoplexy were due to an influx of blood into the brain or from accumulation 
of phlegm and black bile in the cerebral ventricles blocking the transmission of the animal 
spirit.11 The first recorded use of ‘stroke’ as a lay term was in 1599, attributing the sudden 
onset of symptoms to a ‘stroke of God’s hand’.10 In 1658 Johan Jakob Webfer published four 
cases observing the association with apoplexy and cerebral hemorrhage.12 In later scientific 
publications, based on an increasing amount of autopsies, apoplexy was associated with 
cerebral hemorrhage, tumors and cerebral abscesses.13 In 1689 the term stroke was introduced 
into medicine by William Cole in “A physio-medical essay concerning the late frequencies of 
apoplexies”.14 In the early 19th century a link between arterial occlusive disease and areas of 
cerebral softening was recognised,15 and in the early 20th century causes of apoplexy were 
reclassified as hemorrhagic or ischemic.13 In the 1960s, a stroke was defined as a sudden, 
focal neurological deficit of vascular origin with a neurological deficit remaining for more 
than seven days.16 Symptoms lasting less than 24 hours were defined as a transient ischemic 
attack (TIA) and those lasting between 24 hours and 7 days as a reversible ischemic 
neurological deficit (RIND).16 In 1970, the World Health Organization (WHO) defined stroke 





lasting more than 24 hours or leading to death, with no apparent cause other than of vascular 
origin.17 Recently, a new definition of IS that incorporates tissue criteria based on brain 
imaging in individuals with symptoms lasting <24 hours has been included in the 
International classification of diseases for mortality and morbidity statistics (ICD) 11 criteria 
of IS.18  




1.1.2 Stoke epidemiology 
 Stroke is a major challenge for public health; in 2017 there were 11.9 million 
incident stroke cases, 104.2 million prevalent stroke cases, 6.2 million stroke deaths and 132 
million stroke-related disability adjusted life years (DALYs) worldwide.1 In addition to the 
Miniature from a textbook of surgery written by the Arab physician Abu al-_Qasim Khalaf Ibn Abbas az-Zahrawi, born in the 10th century  (ABU´L 
QASIM, Codex Series Nova 2641, Fol 6ra. Reprinted in: (1979) Chirurgia). From: 





direct consequences of a stroke for the individuals affected and their families, it contributes to 
a large economic burden for society with yearly expenses in Europe estimated to 60 billion 
Euro and in Norway to 926 million Euro.19  
 Globally, the age-adjusted stroke incidence, prevalence, mortality and DALYs 
decreased in the period 1990-2017.1 Despite this, the absolute number of people with incident 
stroke and people who died, survived or remained disabled from stroke almost doubled.1 
There are regional differences in incidence rates and time trends. Previously, highest 
incidence rates of stroke were observed in high-income countries.5 Since the 1970s, an 
epidemiological transition has been observed with a decrease in incidence and mortality rates 
in high-income countries and a concomitant increase in low- and middle-income countries.5 
After 2000, the overall stroke incidence rates in low- to middle-income countries have 
exceeded the level of stroke incidence in high-income countries, probably due to health and 
demographic transitions.5 Currently, approximately 80% of strokes, 87% of stroke-related 
deaths and 89% DALYs occur in low- and middle-income countries.1 Patients in low- and 
middle-income countries are younger at stroke onset, have more severe strokes with a higher 
proportion of ICH.20 In addition, access to health services is lower in these countries.20 Global 
age-standardised stroke incidence and mortality rates in 2017 are shown in Figure 3. 
In addition to differences according to country income levels, trends may vary 
between countries within income groups. An example of this is a study from Sweden, 
showing stable incidence and mortality rates of stroke during the period 1987 to 2006 despite 
reports of a decrease in incidence and mortality in other high-income countries.21  
In Norway, a decrease in stroke mortality has been observed since the 1960´s.22 At 
initiation of the present study, it was unknown if the decrease was due to lower incidence 





with mandatory registration of hospitalised strokes in Norway.23 Before this, data on stroke 
incidence and case fatality from well-defined Norwegian cohorts were few.24, 25   
 
Figure 3. Global age-standardised stroke incidence and death rates per 100,000 people in 2017.  
 
Reprinted from Krishnamurthi R, V, Ikeda T, Feigin V,L: Global, Regional and Country-Specific Burden of Ischaemic Stroke, 
Intracerebral Haemorrhage and Subarachnoid Haemorrhage: A Systematic Analysis of the Global Burden of Disease Study 2017. 





1.2 Intracerebral hemorrhage 
An ICH is caused by a rupture of a blood vessel which causes a hemorrhage in the 
cerebral parenchyma; in some cases with extension into the ventricles and/or into the 
subarachnoid and dural spaces. Despite accounting for only 9-27 % of all strokes worldwide,5 
ICH contributes largely to the burden of stroke.  Hemorrhagic strokes (ICH and SAH 
combined) are associated with greater worldwide DALYs lost compared with IS and 
contribute to approximately half of all stroke deaths.26 Only 12%-39% live independently 
after an ICH.27 One-month case fatality rates of ICH range between 13%-61% with a median 
of 40%.27 Five-year survival rates have been estimated to 29%.28   
 
1.2.1 Pathophysiology 
Intracerbral hemorrhage is a heterogeneous condition. The most frequent causes are deep 
perforating vasculopathy and sporadic cerebral amyloid angiopathy (CAA).29 A lower 
proportion is secondary bleedings caused by trauma, underlying lesions (e.g. brain tumors, 
vascular lesions and IS) or hematologic disease.29 Intracerebral hemorrhage may be classified 
as non-lobar and lobar ICH (Figure 4). Non-lobar ICH are mainly due to deep perforating 
vasculopathy caused by hypertension,30 and are located in subcortical structures, basal 
ganglia, thalamus, brainstem or cerebellum. Lobar ICH are located to cortico-subcortical 
areas of the brain lobes, often near or reaching the cerebral convexities. The most common 
cause of lobar ICH is CAA, which is a chronic degenerative process in leptomeningeal and 
cortical blood vessels causing a progressive loss of smooth muscle cells and a simultaneous 







Figure 4. The most common locations of intracerebral hemorrhage (ICH) 
 
 
1.2.2 Mechanisms of brain injury 
In the acute phase after an ICH the hematoma causes damage of brain cells by different 
mechanisms. Mass effect of the hematoma may cause twisting of surrounding tissue with 
successively tearing of other diseased microvessels causing further rupture of blood vessels 
and enlargement of the hematoma.32 In addition, degradation products of extravasated blood 
Lobar ICH: Lobar areas of the brain, originating from penetrating cortical branches of the anterior, middle, or 
posterior cerebral arteries (A). 
Non-lobar ICH: Basal ganglia, originating from ascending lenticulostriate branches of the middle cerebral artery 
(B). Thalamus, branches originating from ascending thalmogeniculate branches of the posterior cerebral artery (C). 
The pons, originating from paramedian branches of the basilar artery (D). The cerebellum, originating from 
penetrating branches of the posterior inferior, anterior inferior, or superior cerebellar arteries (E).   
Reproduced with permission from (Quereshi AI, Tuhrim S, Broderick JP, Batjer H, Hondo H and Hanley DF. Spontaneous 






(heme, iron and thrombin) may trigger toxic and inflammatory cascades, which in turn may 
cause an edema surrounding the hemorrhage.32 Mass effect of the hemorrhage and edema in 
addition to hydrocephalus caused by intraventricular hemorrhage, may cause an increase in 
intracranial pressure, which may lead to further death of brain cells, and to death. Death 
within the first phase after an ICH is mainly a direct consequence of the ICH.33 High age, low 
Glasgow Coma Scale score (GCS), infratentorial origin of ICH, high ICH volume and 
presence of intraventricular hemorrhage have been associated with an increased risk of one-
month case fatality after ICH.34 In addition, use of antithrombotic drugs at time of ICH 
increases the risk of hematoma expansion and early death.35, 36  
Figure 5. ICH with high volume and extension into the cerebral ventricles 
 






Treatment possibilities of ICH are few. Stroke unit care has been associated with a 
significant decrease in short- and long-term mortality after an ICH.37, 38 In ICH associated 
with use of anticoagulants, reversal of anticoagulant drugs may reduce hematoma expansion 
and mortality.39  Lowering of blood pressure in the first hours after ICH may improve 
functional outcome, but has not shown any effect on mortality.40 Surgery is indicated in 
selected ICH patients.41 However, randomised controlled studies (RCT) have failed to 
demonstrate benefit in terms of mortality or functional outcome.41  
 
1.2.4 Risk factors  
Non-modifiable risk factors  
Age 
Increasing age is a strong risk factor for ICH.42  The association may be explained by 
changes in the cardiovascular system caused by ageing in addition to a cumulative effect of a 
long-term exposure of risk factors.42  
 
Sex 
Studies on differences in ICH incidence according to sex are diverging, with some studies 
showing an excess risk in men, and others similar risk between sexes.27, 43, 44 In a meta-
analysis of epidemiological studies, men had higher overall incidence rates of ICH, but there 
were geographical variations.44 Interactions between sex, ethnicity and age have been 








Asian countries have the highest incidence rates of ICH.27 In US, Blacks, American 
Indians and Hispanic/Latino Americans have a higher incidence of ICH compared with 
Whites42 and in New Zeeland, incidence rates are higher among Maori/Pacifics and Asians 
compared with Whites.45 Among Blacks and Hispanics in US, the excess risk has been most 
pronounced in young and middle-aged individuals.42 The association between race and risk of 
ICH is complex, and it remains unclear whether differences between races are genetic, 
environmental, or an interaction between the two.42 Higher prevalence of and poorer control 
of risk factors, e.g. blood pressure, have been suggested as a contributing factors to the 
observed differences. 45-47  
 
Genetics 
Studies indicate that up to 44% of ICH risk can be explained by genetic variation.48 
However, few genes have been linked to the risk of ICH.48 The most common and well 
documented genetic risk factor for ICH is APOE.48 The APOE ε2 and ε4 alleles are 
associated with amyloid biology, and both have been associated with an increased risk of 
first-ever and recurrent lobar ICH.49-51  Locuses 1q22, 2q33 and 13q34, which have been 
linked to the risk of white matter hyperintensities, have been associated with non-lobar 
ICH.49, 52  In addition, genetic variations within the genes COL4A1 and COL4A2 have been 
associated with an increased risk of ICH.49 A high burden of risk alleles for elevated blood 
pressure has been associated with an increased risk of deep ICH and of presence of 
hypertension in a population of European ancestry,53 and an increased risk of ICH in carriers 
of a genetic variant associated with high levels of high density lipoprotein (HDL)-cholesterol 





A small minority of ICH cases are caused by Mendelian forms of ICH.49 These tend to 
appear at a younger age and affects Whites more often.49  Examples of these forms are 
familial CAA, usually affecting the beta-amyloid precursor protein gene, and mutations in the 
COL4A1 gene, causing autosomal dominant syndromes with perinatal ICH and porencephaly, 
adult-onset ICH, microbleeds, lacunar strokes and leukoaraiosis.49  
 
Modifiable risk factors 
Hypertension 
Hypertension is the single most important modifiable risk factor for ICH.42, 55, 56 In a meta-
analysis on 11 case control studies, individuals with hypertension had a more than 3.5-fold 
increased risk of ICH compared with individuals with normal blood pressure.55 The risk of 
ICH increases with increasing blood pressure levels and treatment of hypertension is the most 
effective measure for preventing ICH.42, 55  
 
Serum cholesterol and use of statins 
Studies on the association between serum cholesterol and ICH have been diverging. An 
inverse relationship with total cholesterol, HDL and low-density lipoprotein (LDL) has been 
reported in several studies,55, 57 whereas others have found no association.55, 58, 59  A possible 
association with use of statins and risk of ICH has been debated.60, 61 In the vast majority 
of trials there has been no association between statin treatment and hemorrhagic stroke.60 
 
Diabetes mellitus 
Studies on the risk of ICH in individuals with diabetes mellitus (DM) have been inconsistent. 





found no association.63 The authors of a large, multinational case control study 
(INTERSTROKE), including 3,059 ICH patients, reported an inverse association with DM.56 
In a meta-analysis on 19 case-control studies and three cohort-studies, an association with 
DM was found in unadjusted data from case-control studies.64 When analysing data of sixteen 
of the case-control studies in which cases and controls were comparable for age and sex, the 




Studies on the association between smoking and ICH have been conflicting.42 In the 
INTERSTROKE study, there was no association between smoking and ICH.56 Contrary to 
this, the authors of recent published review concluded that cigarette smokers have an 
increased risk of ICH.65 In another review, current smoking was associated with ICH in three 
cohort studies, but not in 10 case control studies.55  
 
Physical activity 
Studies on the association with physical activity and hemorrhagic stroke are limited. In the 
INTERSTROKE study, as well as in a large meta-analysis on physical activity and stroke, 
with 31 observational studies included, high level compared with low level physical activity 
reduced the risk of ICH/hemorrhagic stroke.56, 66  
 
Antithrombotic drugs 
Use of antithrombotic drugs are probably not a direct cause of ICH, but exacerbate 





antithrombotic drugs; antiplatelet and anticoagulant drugs. Antiplatelet drugs have been 
associated with a small increase in the risk of ICH, with a higher risk associated with dual 
antiplatelet therapy. 68 Up to the last decade, vitamin K antagonists (VKA) were the only oral 
anticoagulants available. The relative risk of ICH in individuals on VKA is approximately 7-
10 compared with the general population.69 The risk increases with increasing levels of 
international normalized ratio (INR).69 The last decade, treatment with direct oral 
anticoagulant drugs (DOACs) has been approved.70  Use of DOACs has been associated with 
a lower risk of ICH compared with use of VKA, with an annual risk of 0.3-0.6% in VKA 
users and 0.1-0.2% in DOAC users, respectively.67 In a Norwegian study based on the 
Norwegian Patient Registry and Norwegian Prescription Database, the risk of ICH associated 
with use of antithrombotic drugs was higher than in RCTs.71 Combination therapies with 
warfarin plus aspirin and clopidogrel, warfarin plus aspirin, rivaroxaban plus aspirin, and 
aspirin-dypiridamole plus clopidogrel were associated with the highest risks of ICH.71 
 
Alcohol intake  
An increased risk of ICH associated with high use of alcohol has been suggested in several 
studies.56, 72 In a review on eight case control studies, high alcohol intake was associated with 
ICH, with a dose-response effect.55 However, in the three cohort studies included, there was 
no association with alcohol intake and ICH.55 In addition to a possible increased risk in 
individuals with prolonged heavy drinking, an immediate increased risk of ICH within the 








Body mass index  
The association between body mass index (BMI) and ICH has not been clear. Associations 
between high as well as low BMI in addition to an inverse association with BMI and risk of 
ICH have been reported.63, 74, 75  In other studies there has been no association with BMI and 
ICH.76 
   
Illicit drugs  
Use of illicit sympathomimetic drugs, particularly cocaine and amphetamines, has been 
associated with increased risk of ICH.77 This relationship may be due to drug-induced 
hypertension, vasculitis or vasospasm.77  
 
Risk factors according to ICH location 
Few studies have assessed the association with risk factors according to ICH location.78-84 
Whereas hypertension has been strongly linked to non-lobar ICH, its role in lobar ICH has 
been less clear.85 A probable, although less strong association with lobar ICH has been 
suggested.85 The associations with other cardiovascular risk factors have been diverging.78-84 
In a recent, large meta-analysis, encompassing 42 studies with a total of 26,174 ICH patients, 
hypertension, DM, male sex, alcohol overuse, underweight and being Black or Hispanic 
compared with being White were associated with non-lobar ICH.84 Hypertension was the only 








1.2.5 Incidence rates and time trends in incidence of ICH 
Incidence rates of ICH vary between populations.27 In the period 1980 to 2008, an 
incidence rate of 24.6 per 100 000 person-years, ranging between 1.8 and 129.6 per 100,000 
person-years was reported, with the highest incidence rates in Asian people.27 Studies on time 
trends in incidence rates of ICH over the last three decades have shown diverging results. The 
majority of studies have shown stable or decreasing incidence rates.5, 27, 83, 86-97 In a few 
studies, an increase in ICH incidence has been observed.98, 99    
Two large meta-analyses of 56 and 36 studies, showed stable global ICH incidence 
rates in 1980-2006 and 1980-2008, respectively.5, 27 The authors of a review from the Global 
Burden of Disease Study reported a decrease in incidence of hemorrhagic stroke (ICH and 
SAH combined) in high-income countries and a significant increase in low- to middle-income 
countries between 1990 and 2010.100 At initiation of our study there were two Norwegian 
publications on ICH incidence.24, 25 In a population-based study from Innherred, covering the 
years 1994-1996, incidence rate of ICH adjusted to the European population was 0.32 per 
1,000.24 In a hospital-based study from southern Norway covering the years 2005-2009 
adjusted incidence rates of ICH were 0.13 per 1,000.25 This could indicate a fall in incidence 
rates between the two study periods. However, due to differences in study-design direct 
comparisons between these studies are limited. 
 
1.2.6 The impact of risk factor trends on incidence trends of 
ICH  
During the last decades systolic blood pressure (SBP) levels have decreased in several 
countries globally, with the largest declines occurring in high-income countries of 





the prevalence of smoking, and cholesterol levels in Western Countries.101 BMI and DM 
prevalence have increased.101 Time trends in alcohol use have been less clear.101 Use of blood 
pressure-lowering, antithrombotic and lipid-lowering drugs have increased.101-104   
Most studies on the association between risk factor trends and stroke incidence have 
covered trends in total stroke incidence.96, 105 Few studies have used individual data from 
repeated surveys with registration of premorbid risk factors.96, 97, 105 Studies on the impact of 
changes in risk factors on ICH incidence are scarce.21, 83, 92, 93, 97 Hypertension has consistently 
been shown to be the strongest modifiable risk factor for ICH.42 Despite a decrease in blood 
pressure levels, stable incidence rates of ICH have been reported in several studies during the 
last three decades.5, 27, 83, 86, 87, 92, 93, 95, 97 The authors of two European studies have raised a 
concern that a change in risk factor profile of ICH with an increase in ICH associated with an 
increased use of antithrombotic drugs in the elderly may have outweighed the effect of a 
decrease in ICH associated with hypertension.93, 97  
 
 
1.2.7 Time trends in 1-month case fatality rates 
Studies on trends in 1-month case fatality are scarce and have shown diverging results. 
Whereas some studies have shown stable case fatality rates, 27, 88, 90, 95, 106 others have shown 
decreasing rates.89, 91, 98, 107-110 In two large meta-analyses on 36 and 30 studies and with a 
total of 8,145 and 7,736 ICH patients, respectively, 1-month case fatality rates were stable in 
the periods 1983-2006 and 1985-2015.27, 106 In two Norwegian studies covering the periods 
1994-1996 and 2005-2009, unadjusted 1-month case fatality rates were 37.8 and 36.6, 






1.2.8 Long-term survival  
There are few studies on long-term survival after ICH.28, 88, 107, 108, 111 The majority of early 
deaths are a direct consequence of the ICH event, whereas other causes of death contribute to 
a larger degree in ICH survivors.33 Despite this, studies on ICH patients who survive the early 
phase are scarce.28 Cumulative 5-year survival rates in ICH patients have ranged between 27 
and 57%.28, 112-114 Few studies have assessed temporal trends in long-term mortality rates and 
the results have been diverging.28, 88, 107, 108, 111 Most of the studies were published after 
initiation of the present study. The components of the ICH score are the most studied 
prognostic factors for long-term survival, and there is limited knowledge on the impact of 
traditional cardiovascular risk factors.28, 34  
 
1.3 Knowledge gaps and rationale for the thesis  
In summary, stroke is to a large degree a preventable disease.56 Studies on trends in 
incidence, case fatality and long-term mortality rates of stroke are important to assess the 
impact of preventive measurements, to identify emerging risk factors and to assess the effect 
of therapeutic interventions. Ischemic stroke and ICH have different risk factor profiles and 
outcome after ICH is poorer compared to IS.26, 42 Knowledge on trends in incidence, 1-month 
case fatality and long-term survival in ICH patients is limited. Although the pathophysiology 
differs according to ICH location, there are few studies on cardiovascular risk factors 
according to ICH location. There is little knowledge on the impact of risk factor trends on 
ICH incidence. Data on long-term survival after ICH, especially in ICH survivor cohorts are 
few. The lack of Norwegian data on time trends in incidence, 1-month case fatality and long-






2 Aims of the thesis 
The objectives of this theses were 
1. To analyse trends in incidence and 1-month case fatality rates of ICH over time, in a 
well-defined general Norwegian population. 
2. To analyse the association with risk factors and ICH overall and according to ICH 
location, and the impact of risk factor trends on time trends in ICH incidence.   
3. To compare differences in long-term survival rates, causes of death and risk factors for 
death in 30-day survivors of ICH and the general population, and to analyse time trend 






3 Subjects and Methods 
3.1 The Tromsø-study 
3.1.1 Study design and study population 
The Tromsø Study is an ongoing, longitudinal population-based cohort study with 
repeated health surveys.115 The study was initiated in 1974 with the primary aim to assess the 
increasing coronary heart disease mortality which was observed in the years 1951-1970.116 
Tromsø is the regional center in Northern Norway and is located 400 km north of the Arctic 
Circle at 69° N (Figure 6). The population has increased from 42,200 in 1974 to the current 
population of 77,000 inhabitants,117 the majority living in the city centre. The increase in 
population has been mainly due to the establishment of large educational institutions, health 
care institutions and other knowledge based industries.116 The vast majority of the inhabitants 
are of Caucasian origin.118 The municipality is served by one hospital; The University 
Hospital of North Norway (UNN). The distances in the area are long and the nearest hospital 
in the county, outside Tromsø municipality, is located 300 km away by road, 134 km by air. 
Since the initiation of the Tromsø Study, seven surveys have been conducted (Tromsø 
1-7); in 1974, 1979-1980, 1986-1987, 1994-1995, 2001-2002, 2007-2008 and 2015-2016, 
respectively. Eligible for the present thesis were attendendees of Tromsø 1-6. Based on the 
official population registry, full birth cohorts and random samples of residents in the 
municipality of Tromsø have been invited to attend the surveys.119 A total of 40,051 
individuals have attended at least one of Tromsø 1-6.119 Table 1 shows attendance rates, age- 






 To the first survey (Tromsø 1), only men aged 20-49 years were invited. From the 
second surveys and onwards both sexes have attended. The age span of invited attendees has 
varied between the surveys. From the fourth study and onwards elderly have been invited. In 
the 5th and 6th studies the lower age limit has been 30 years. The 4th study, carried out in 1994-
1995, was the largest of the surveys. The attendance rates to the study have generally been 
high, although there has been a decrease from approximately 75% in the first surveys to 66% 
in the 6th survey.119 Repeated measurements are available for a large part of the attendees with 
23,342 individuals attending two or more of the 1st-6th surveys.119   
The surveys include questionnaire data (Appendix), clinical measurements and 
sampling of biological specimens (Table 2). Since the 4th survey, additional clinically oriented 
examinations have been performed on large subgroups (N= 7,965, 5,939 and 7,307 in Tromsø 
4, 5 and 6, respectively), in addition to the core protocol. Variables registered in the different 
surveys are available at the NESSTAR website of the Tromsø study 
(http://tromsoundersokelsen.uit.no/tromso/).   
 
Survey year Men Women 












1974 20-49 6,595 74.4 - - - 
1979-80 20-54 8,477 73.8 20-49 8,143 81.8 
1986-87 12-64 10,963 71.8 12-67 10,863 79.0 
1994-95 25-97 12,865 69.6 25-97 14,294 74.9 
2001-02 30-89 3,511 75.7 30-89 4,619 80.9 
2007-08 30-87 6,054 62.9 30-87 6,930 68.4 
 
Table 1. Year of survey, age, number and attendance rate of eligible participants in the 1st -6th surveys 





Table 2. Overiew of data collected in the 1st – 6th surveys of The Tromsø Study. 
After inclusion in the study, the participants are continuously followed up with 
registration of several clinical end points, including cardiovascular diseases (CVD) and 
death.119 The longitudinal design with repeated surveys gives an unique possibility to study 
trends in prevalence of risk factors and incidence rates of diseases in a cohort in a well-
defined geographical area. Since the 1970´s, the differences in CVD mortality in Norway 
have decreased, and the rates in North Norway are now similar to the rest of the country.120 
 Tromsø Study survey number 
Type of information 1 2 3 4 5 6 
Marital status, age, sex x x x x x x 
Questionnaire data x x x x x x 
Interview x x x x x x 
Measured weight and height x x x x x x 
Measured waist and hip circumference    x x x 
Measured blood pressure x x x x x x 
Blood samples* x x x x x x 
Electrocardiography (ECG) †   x x x x 
Echocardiography†     x x x 
Ultrasound examination of the carotid artery†    x x x 
Ultrasound examination of the abdominal aorta†    x x  
Spirometry†     x x 
Bone mineral densitometry†    x x x 
Urinary analyses†    x x x 
Examination of vision acuity†     x x 
Cognitive testing†     x x 
Eye examination†      x 
Pain sensitivity      x 
*Analyses of blood lipids were performed in all surveys. Other blood samples differed between studies, please see 
http://tromsoundersokelsen.uit.no/tromso/). 










Individuals who had attended at least one of the 1st-6th Tromsø were eligible for Paper I. 
Selection of participants is shown in Figure 7. Of the 53,731 individuals who were invited, 
40,051 attended at least 1 of the 6 surveys (Table 1, Figure 7). Individuals who were not 
officially registered as inhabitants of the Tromsø municipality at the date of enrolment 
(n=162), individuals who were younger than 20 years at enrolment and did not attend later 
studies (n=785), those who did not have valid written consent to medical research (n=225), 
Source: Kartverket 





and individuals who had prevalent ICH (n=18) or unclassified stroke (n=45) were excluded. 
Because older birth cohorts were not enrolled in the earliest surveys, and individuals <30 
years were not enrolled in the two latest surveys, analyses were limited to individuals aged ≥ 
30 years in the period 1 January 1995 to 31 December 2012. Individuals who emigrated out of 
the municipality (n=5,145), died (n=788) or suffered an ICH (n=24) before 1995 or did not 
reach 30 years of age during follow-up (n=329) were censored, leaving 32,530 individuals 
(16,771 women and 15,759 men) to be included. For individuals who were younger than 30 
years when first attending a survey, start of follow-up was assigned from the date they turned 
30 years. Participants were followed up until the first-ever ICH event, emigration out of the 
municipality, death or end of study (31 December 2012). 
 
Paper II-III 
Eligible for paper II-III were participants who attended at least one of the 4th- 6th surveys 
performed in 1994-1995, 2001 and 2007-2008 (n=30,586) (Table 1, Figure 7). Participants 
who were not officially registered as inhabitants of Tromsø municipality (n=23) at date of 
inclusion and participants without valid written consent (n=206) were excluded. In addition, 
we excluded participants aged <30 years (n=2,106) and participants with prevalent ICH 
(n=26) or unclassified stroke (n=58), leaving 28,167 individuals (14,794 women and 13,373 
men) to be included. The endpoint registry had been updated since Paper I, and participants in 
Paper II and III were followed up with registration of first-ever ICH until 31 December 2013, 
and with registration of date of death and cause of death until 31 December 2016. During this 
period 219 ICH were registered. In paper III, the 219 ICH cases were matched 1:5 with 

























Invited to T1-T6, N=53,731 
Attended T1-T6, N=40,051 
Did not attend, N=13,680 
At enrollment:  
Not inhabitant of Tromsø, N=162 
<20 years. Did not attend later 
surveys, N=785 
Without valid consent, N=225 
Prevalent ICH, N=18 
Prevalent unclassified stroke, N=45 
N=38,816 
At start of follow-up 1995: 
Not inhabitant of Tromsø, N=5,145 
Dead, N=788 
Prevalent ICH, N=24 









Did not attend T4, T5 or T6, N=9,465 
At enrollment:  
Not inhabitant of Tromsø, N=23 
Without valid consent, N=206 
Age <30 years, N=2,106 
Prevalent ICH, N=26 




Matching 1:5  
Excluded: N=26,853 
Paper III 
ICH, N=219 No ICH, N=27,948 
Controls, N=1,095 
 






The Tromsø Study has been approved by the Regional Committee for Medical and Health 
Research Ethics (REK) (REK nr 2009/2536 og 2006/121) and the Data Inspectorate of 
Norway, In addition the study has an approved biobank (biobanknumber 277 and 2397). Data 
collected may only be used for approved research purposes, and projects must have their own 
approval from the REK. Research on incidence and mortality of stroke, and on CVD risk 
factors are covered by the existing approvals of the Tromsø study. All data are anonymised 
and every individual has a unique code, which is blinded for the researchers. The regulations 
for consent to research has changed since the initiation of the study, with stricter regulations 
during the last decades. Written consent has been used since Tromsø 4th. The attendees have 
the possibility to withdraw from the study at any time point and without being required to 
provide their reason for withdrawal. Information on the possibility to withdraw consent is 
available in the invitations to the study in addition to the homepage for the Tromsø study 
(https://uit.no/research/tromsostudy). Employees of the Tromsø study have a duty of 
confidentiality. The attendees have not received compensation for attending the study.  
 
3.1.3 Funding 
The study has been funded by UiT The Arctic University of Norway since the first survey in 
1974. In addition, there have been contributions from the National Screening Services, the 
Research Council of Norway, the Northern Norway Regional Health Authority, the 
Norwegian Council on Cardiovascular Diseases, the Odd Berg Research Foundation, the Dam 







3.2 Ascertainment of risk factors  
3.2.1 Data from clinical examinations and blood samples 
Blood pressure 
Blood pressure was measured with three recordings separated by a 1-minute interval, after a 
2-minute seated rest, using Dinamap Vital Signs monitor 1846 (Criticon inc. Tampa, FL, 
USA) in the 1994-1995 and 2001 surveys and Dinamap Pro care 300 Monitor (GE 
Healthcare, Norway) in the 2007-08 survey. The proper cuff size was selected based on the 
circumference of the upper right arm in the individual participant. We used the mean value of 
the two last recordings. Hypertension was defined as SBP ≥140 mm Hg and/or DBP ≥90 mm 
Hg and/or use of blood pressure-lowering drugs.  
 
BMI 
Weight was measured with light clothing and no footwear. Height was measured in standing 
position. BMI was calculated as weight divided by the square of height (kg/m2).  
 
Serum cholesterol, HDL and triglycerides 
Non-fasting blood samples were drawn at date of attendance. Serum cholesterol, HDL and 
triglycerides were analysed by standard enzymatic colorimetric methods at UNN.  
 
3.2.2 Data from questionnaires 
Information on previous and current diseases, smoking status, use of alcohol and physical 
activity, as well as use of blood pressure-lowering, lipid-lowering, antidiabetic and 
antithrombotic drugs were collected through standardised questionnaires (Appendix).  In 





of medication, written by the participants and checked by health personnel at the study site. In 
order to supplement the information from the questionnaires, a short interview was included 
in the surveys with topics as family history of coronary heart disease, current and former use 
of medications etc.  
 
Diabetes mellitus 
Diabetes mellitus was self-reported in questionnaires by answering the question: Do you 
have, or have you had DM? Serum glucose and HbA1c were measured in the 5th-6th surveys, 
but not in the surveys prior to these, and was therefore not included in the definition of DM. 
 
Smoking 
Smoking status was asked for in questionnaires and defined as daily current smoker 
(cigarettes and/or pipe and/or cigarillos/cigars).  
 
Alcohol consumption 
Alcohol consumption was asked for in questionnaires. The questions concerning the amount 
of alcohol intake differed between the surveys and alcohol consumption was categorised as 
teetotalism yes/no in the overall analysis on the association of alcohol consumption and risk 
of ICH, and on time trend in alcohol consumption. Additional analyses on the association 
between the amount of alcohol consumption and risk of ICH were performed based on 
answers from questionnaires in the the 5th-6th surveys. In these analyses, the amount of 
alcohol intake was categorised as teetotalism, moderate alcohol consumption (1-7 glasses per 
week in women, 1-14 glasses per week in men) and high alcohol consumption (>7 glasses per 






Information on physical activity was self-reported in questionnaires and defined as strenuous 
leisure physical activity (i.e. become sweaty and out of breath) for at least 1 hour per week.  
 
Use of blood pressure-lowering, lipid-lowering and antithrombotic drugs 
Use of blood pressure-lowering drugs at attendance was self-reported in questionnaires by 
answering the following question: Do you use blood pressure-lowering drugs? Response 
categories: 1) Now, 2) Previously, but not now, 3) Never. Use of lipid-lowering drugs was 
self-reported in questionnaires by answering the following question: Have you during the last 
14 days used lipid-lowering drugs? Response categories: 1) Yes 2) No. In 1994-95 this 
question was limited to individuals aged <70 years, and information from additional list of the 
brand names of medication used on regular basis was available only for participants aged 55-
74 years and selected 5-10% samples of participants aged 25-54 and 75-85 years. In 2001-
2002 and 2007-2008, use of lipid-lowering drugs was asked for in all age groups. Use of 
antithrombotic drugs at attendance was collected through lists of the brand names of 
medication used on regular basis written by participants and checked by health personnel at 
the study site. Data were collected for attendees of the second visit of the survey in 1994-
1995, and in all attendees of the surveys in 2001 and 2007-2008.  
 
3.2.3 Data from medical records 
Information on use of antithrombotic drugs at time of ICH was obtained 
retrospectively from the medical record of each subject suffering an ICH during follow-up. 
Antithrombotic drugs were further divided into antiplatelet drugs and anticoagulant drugs. 





high dose heparin or high dose low molecular weighted heparin, or thrombolytic treatment of 
indications other than IS. 
 
3.3 Ascertainment of clinical endpoints 
3.3.1 Case ascertainment and definition of ICH 
All attendees were continuously followed up with registration of first-ever ICH. Follow-up 
time was assigned from date of first attendance until first-ever ICH, death, emigration from 
Tromsø or to end of follow-up (31 December 2012 in Paper I, and 31 December 2013 in 
Paper II-III), whichever came first. Stroke was defined according to the WHO definition; 
“rapidly developing clinical signs of focal or global disturbance of cerebral function, with 
symptoms lasting ≥24 hours or leading to death, with no apparent cause other than vascular 
origin”.17 Strokes were registered by linkage to the discharge and out-patients diagnosis 
registry at UNN, using unique 11-digit personal identification numbers. Searches were 
performed for ICD versions 8 and 9 diagnosis codes 430–438, and ICD-10 diagnosis codes 
I60–I69 (cerebrovascular disease (CVD)). From 2006, ICD-10 codes G45 (TIA), G46 
(vascular syndromes of brain in cerebrovascular diseases) and G81 (hemiplegia) were added 
to the search. In addition, systematic text searches were made for the words ‘stroke’, 
‘ischemic stroke’ and ‘intracerebral hemorrhage’ in the medical records of all participants 
with ICD-8 to ICD-10 diagnosis codes 410–414 and I20–I25 (ischemic heart disease), 
798/R96 (sudden death, cause unknown), R98 (unattended death) and 799/R99 (other ill-
defined and unknown causes of morbidity and mortality). An independent endpoint 
committee reviewed all cases separately by use of medical records from the hospital 
(including autopsy reports). Cases retrieved from the National Causes of Death registry were 





emergency services and/or death certificates, when available. We included ICH diagnosed by 
CT, MRI and/or autopsy. Strokes where imaging or autopsy had not been conducted in the 
acute stage were categorised as unclassified. ICH caused by hemorrhagic transformation of 
IS, trauma, brain surgery, hematologic disease or brain tumor were excluded. An independent 
endpoint committee reviewed each case separately by use of hospital medical records 
(including autopsy reports).  
Registration of ICH location 
All CT and MRI scans in ICH patients were assessed retrospectively by the author, who is a 
senior consultant in neurology. ICH location was defined using a validated rating instrument 
(CHARTS; Figures 8 and 9).121  In cases where radiologic examinations were not available 
(n=35), location was assessed by radiology reports and/or autopsy reports. In uncertain cases, 
the scans were additionally validated by a neuroradiologist at UNN, and consensus made in 
cooperation with a senior consultant in neurology at UNN. ICH location was categorised as 
lobar, non-lobar (deep/infratentorial), uncertain and other location (intraventricular or located 
to the corpus callosum). Intracerebral hemorrhages with uncertain location were further 
categorised as probably lobar, probably deep, and holohemispheric. In analyses stratified on 
location, probable lobar and probable deep ICH were included in the analyses as lobar and 
non-lobar ICH, respectively. Cases with multiple ICH affecting solely lobar (n=7) or non-
lobar (n=3) regions were categorised according to location. Multiple ICH affecting both 
regions (n=1), ICH located to the corpus callosum (n=2), intraventricular ICH (n=3), 
holohemispheric ICH (n=13) and ICH with missing location (the radiologic examination and 
radiologic report were not available at the time of the retrospective assessment) (n=1) were 
included in analyses of ICH overall, but excluded from analyses stratified on location. All 









*Presumed epicentres of the main bulk of ICH, in the slice with the largest axial ICH diameter 
Reprinted from Journal of the Neurological Sciences, Vol 372, Charidimou A et.al. The Cerebral Haemorrhage  
Anatomical RaTing inStrument (CHARTS): Development and assessment of reliability, Pages No.178-183. 





Figure 9. The Cerebral Haemorrhage Anatomical RaTing inStrument (CHARTS) rating form 
 
Reprinted from Journal of the Neurological Sciences, Vol 372, Charidimou A et.al. The Cerebral Haemorrhage Anatomical 
RaTing inStrument (CHARTS): Development and assessment of reliability, Pages No.178-183. 





3.3.2 Dates of death and causes of death 
Dates for death and emigration out of the municipality were obtained from the Population 
Registry of Norway. Causes of death were retrieved from the Norwegian Cause of Death 
Registry through 31 December, 2016. Causes of death were defined as CVD (ICD 9 codes 
390-459 and ICD 10 codes I00-I99), malignancy (ICD 9 codes 140-208 and ICD 10 codes 
C00-C97) and chronic lower respiratory diseases (asthma excluded) (ICD 9 490-492, 494 and 
496 and ICD 10 codes J40-44 and J47). CVD was further classified as ischemic heart disease 
(ICD 9 codes 410-414 ICD 10 codes I20-I25), IS (ICD 9 code 434 and ICD 10 code I63), 
ICH (ICD 9 code 431 and ICD 10 code I61), unspecified stroke (ICD 9 code 436 and ICD 10 
code I64), stroke sequelae (ICD 9 code 439 and ICD 10 code I69) and “other”. Causes of 
death not classified as CVD, malignancy or chronic lower respiratory diseases were classified 
as “other”. 
 
3.4 Statistical methods 
Statistical analyses were performed using STATA version 13.0 (StataCorp LP, College 
Station, Tex., USA) (Paper I), StataCorp (2015. Stata Statistical Software: Release 14. 
College Station, TX: StataCorp LP) (Paper II) and StataCorp. (2017. Stata Statistical 
Software: Release 15. College Station, TX: StataCorp LLC.), (Paper III). For all analyses, a 
two-sided p value <0.05 was considered significant.  
 Crude incidence rates of ICH per 1,000 person-years were calculated (Paper I and II). 
In addition, age- and sex adjusted incidence rates were calculated by the direct method using 
the European standard population of 1976 (Paper I) and 2013 (Paper II) as references. Age 
adjusted incidence rate ratios (IRR) between men and women were calculated. Time trends in 





(Paper I and II). Incidence rates ratios were calculated from each Poisson regression model 
(Paper I and II).  
 Thirty-day case fatality rates were calculated (Paper I and III). Analysis of time trend 
in 30-day case fatality rates was performed using a logistic regression model, adjusted for age 
and sex, and odds ratio (OR) for time trend was calculated (Paper I). 
 Hazard ratios (HR) for the association between risk factors and ICH overall and 
according to ICH location (lobar and non-lobar) were assessed by Cox proportional hazards 
models (Paper II). To account for dependencies between repeated measurements, trends in 
risk factors and use of blood pressure-lowering, lipid-lowering and antithrombotic drugs were 
analysed in age- and sex-adjusted general estimated equations models (GEE) (Paper II).  Odds 
ratio for treatment with antithrombotic drugs at time of ICH was calculated by logistic 
regression and adjusted for age and sex (Paper II). 
In paper III, cumulative survival rates in ICH cases and controls matched for birth year 
and sex were assessed by Kaplan Meier estimates. Hazard ratios for mortality between cases 
and controls during follow-up through 2016, and HR of risk factors for 5-year mortality in 30-
day survivors were analysed by stratified univariate and multivariable Cox proportional 
hazards regression models. Differences in effect of a risk factor between cases and controls 
were assessed by including interaction terms between ICH status (yes/no) and each risk factor 
(e.g. ICH status x SBP). Model selection was performed using backward selection. When 
interaction was significant, separate HRs were calculated for cases and controls. Analyses on 
risk of death in cases according to ICH location and use of antithrombotic drugs were 
performed using a Cox proportional hazard model adjusted for cardiovascular risk factors. 





controls. Time trend in 5-year survival rates in cases was assessed using logistic regression 
adjusted for age and sex.  
In analyses of time trends in incidence, 30-day case fatality and 5-year mortality rates, 
tests of linearity were performed using fractional polynomials (Paper I-III). Tests of 
interaction between age and time and sex and time were performed by including two-way 
interaction terms (age × time and sex × time) in regression models (Paper I-III).   


















4 Main results – summary of papers 
4.1 Paper I 
In paper I, 32,530 individuals were followed-up with registration of first-ever primary ICH 
during the period 1995-2012. A total of 226 first-ever ICH (122 in men, 104 in women) were 
registered during 453,152 person-years. The crude and age- and sex-adjusted incidence rates 
in the overall population were 0.50, 95% CI 0.44–0.57 and 0.42, 95% CI 0.37– 0.48 per 1,000 
person-years, respectively. Incidence rates increased steeply with increasing age;  compared 
with the age group 45-54 years, individuals in age groups 65-74 years and ≥85 years had a 9-
fold and 30-fold higher risk of ICH, respectively (crude incidence rates 0.12, 95% CI 0.07-
0.20, 1.08, 95% CI 0.85-1.39 and 3.65, 95% CI 2.61-5.11 per 1,000 person-years.)  Women 
were on average 5 years older than men at the time of ICH. Age-adjusted incidence rates were 
higher in men compared with women 0.53, 95% CI 0.43-0.62 and 0.33, 95% CI 0.26-0.39 per 
1,000 person-years respectively.  Incidence rates in the overall population remained stable 
over time: IRR 0.73, 95% CI 0.47–1.12. There was no significant time trend in incidence 
rates in analyses stratified on sex or on age, although a borderline significant decrease in 
incidence rates in women was observed: IRR 0.52, 95% CI 0.27–1.00. Among the 226 
individuals with ICH, 54 died within the first 30 days after the ICH event, resulting in a 30-
day case fatality rate of 23.9%, 95% CI 18.3–29.5. The risk of death was highest within the 
first days after the ICH; of the individuals who died within the first 30 days, 48.2% died 
within the first two days and 74.1% died within the first seven days. Thirty-day case fatality 
rate was higher in the elderly; 34.3%, 95% CI 25.1–43.5 in individuals aged ≥75 years to be 
compared with 14.9%, 95% CI 8.4–21.3 in individuals aged <75 years. There was no change 






4.2 Paper II 
In paper II, 28,167 individuals were followed-up with registration of ICH during the period 
1994-2013. We registered 219 first-ever ICH (96 women and 123 men) during a follow-up of 
396,976 person-years. ICH location was lobar in 40% non-lobar in 51%, and 
holohemispheric/other location in 9%. Individuals with ICH were older, more likely to be 
males, and had higher age- and sex-adjusted blood pressure levels at baseline compared with 
ICH-free individuals. The crude prevalence of hypertension in ICH patients was 84%. 
Twenty-five percent used anticoagulant drugs and 28% antiplatelet drugs at time of ICH. 
None of the ICH cases were on DOACs.  
Age, male sex, SBP, DBP, and hypertension were independently associated with the risk 
of ICH, whereas there was no association between total cholesterol, HDL-cholesterol, 
triglycerides, BMI, DM, daily smoking, teetotalism or physical activity and risk of ICH.  
There was no significant dose-dependent association with alcohol intake and risk of ICH. 
Individuals with drug-treated hypertension and blood pressure levels <140/90 mm Hg, had no 
significantly increased risk of ICH compared with individuals without hypertension (HR 1.74, 
95% CI 0.79-3.84), whereas individuals who were on blood pressure-lowering drugs, but with 
SBP levels ≥140 mm Hg and/or DBP levels ≥90 mm Hg had a similar risk for ICH as 
individuals with untreated hypertension (HR 3,43, 95% CI 2.12-5.55 and HR 3.36, 95% CI 
2.24-5.03, respectively).   
In analyses stratified on ICH location, we found a significant association with age, SBP, 





significantly associated with non-lobar ICH only. Hypertension was stronger associated with 
non-lobar (HR 5.08, 95% CI 2.86–9.01) than with lobar (HR 1.91, 95% CI 1.12–3.25) ICH.  
During the study period blood pressure levels, serum lipid levels and smoking prevalence 
decreased significantly. Contrary to this, BMI levels and DM prevalence increased. The 
proportion of physically active individuals increased, and the rate of teetotalers decreased. 
There was an increase in use of blood pressure-lowering, lipid-lowering and antithrombotic 
drugs. Among individuals with hypertension, the proportion of individuals treated with blood 
pressure-lowering drugs increased from 18% in 1994-1995 to 46% in 2007-2008. The rate of 
individuals with well controlled hypertension increased from 21% in 1994-1995 to 35% in 
2007-2008. Blood pressure levels were lower and the SBP decrease was steeper in women 
compared with men; from 138.2 (95% CI 137.7-138.5) to 131.0 mm Hg (95% CI 130.2-
131.8) in women and from 140.5 (95% CI 140.1-140.8) to 136.1 mm Hg (95% CI 135.2-
136.9) in men. The increase in use of blood pressure-lowering drugs was similar in men and 
women; in 1994-1995, 6.2% of men used blood pressure-lowering drugs to be compared with 
15.6% in Tromsø 2007-2008. In women, corresponding rates were 5.6% and 15.0%. We did 
not observe any significant change in use of antithrombotic drugs at ICH onset over time; OR 
1.84, 95% CI 0.90-3.76 for use of antithrombotic drugs at time of ICH in 2008-2013 with 
1994-2001 as reference (p for trend=0.10).  
Incidence rates in the overall population remained stable during the observation period 
(IRR 0.81, 95% CI 0.52–1.27). In analyses stratified on sex there was a significant, 54% 
decrease in incidence rates in women (IRR 0.46, 96% CI 0.23-0.90), whereas incidence rates 
in men (IRR 1.27, 95% CI 0.69-2.31) were stable. Incidence trends according to age group 





<75 years and ≥75 years, respectively). Interaction analyses revealed a significant interaction 
between sex and location. In analyses stratified on sex and location a decrease of non-lobar 
ICH in women (IRR 0.26, 95% CI 0.09-0.71) was observed, whereas the incidence rate in 
lobar ICH in women were stable (IRR 1.17, 95% CI 0.42-3.26). In men, incidence rates of 
both non-lobar (IRR 1.34, 95% CI 0.60-3.02) and lobar ICH (IRR 1.58, 95% CI 0.58-4.29) 
were stable.  
 
4.3 Paper III 
In paper III, a total of 219 ICH cases and 1,095 controls, randomly chosen from the 
original cohort and matched for birth-year and sex, were followed up with registration of date 
of death and causes of death during long-term follow-up (median follow-up 4.8 years, 
maximum follow-up 21.4 years). Mean age at ICH was 74 years (SD 11).  Individuals with 
ICH had higher SBP levels and a higher prevalence of hypertension, whereas other 
cardiovascular risk factors were similar distributed between cases and controls. In cases, the 
risk of death was highest during the initial phase after the ICH, and thereafter levelled off. 
Thirty day-case fatality rates were 24.2% (n=53) in cases and 0.6% (n=6) in controls, 
respectively. Cumulative 1-, 5-, 10-, 15- and 20-years survival rates were 65%, 47%, 25%, 
15% and 6% in cases and 94%, 70%, 51%, 33% and 22% in controls. In 30-day survivors, 
cumulative 1-, 5-, 10-, 15- and 20-years survival rates were 86%, 62%, 34%, 20% and 8% in 
cases and 95%, 73%, 55%, 36% and 25% in controls. The risk of death was significantly 
higher in 30-day survivors of ICH compared with controls (HR 1.62, 95% CI 1.27-2.06) 





In both cases and controls, the major cause of death was CVD, with a significantly 
higher proportion in cases; accounting for 61% and 34 % of all deaths, respectively. In cases, 
the increased risk of death of CVD was driven by death from ICH and stroke sequelae. The 
risk of death by malignancy was significantly higher in controls than in cases. There was no 
difference in the risk of death by chronic obstructive respiratory diseases or other causes of 
death. 
Smoking was associated with the risk of death within five years in both cases and 
controls, whereas there was no association with SBP or DM. Serum cholesterol was 
associated with risk of death in cases but not in controls. Risk of death did not differ 
according to ICH location. Of the four patients with holohemispheric ICH, three died during 
5-year follow-up. Individuals on anticoagulant drugs at time of ICH had a significantly 
increased risk of death within five years, whereas there was no increased risk in individuals 
on antiplatelet drugs. There was no change in 5-year mortality rates during the study period 










5.1 Methodological considerations 
Epidemiology is a science that studies disease occurrence and health states in human 
populations.122 Epidemiological studies aim to measure how population health indicators as 
disease frequency vary according to factors such as age, sex, geographic areas, race/ethnicity 
and time, and assesses the effect of exposures on the occurrence of diseases.122  
 
5.1.1 Validity 
Accuracy is essential for an epidemiological study to produce knowledge which is reliable 
and generalisable. There are several steps during a study where errors may occur. Errors in a 
study may be referred to as random or systematic.123 Random errors may lead to lower 
precision of the estimates, and to an increased variability.123 However, they usually do not 
threat validity.123 Systematic errors, on the other hand, may lead to bias.124 In epidemiological 
research, validity refers to the absence of bias, and depends on the accuracy of the methods 
used.124 There are two types of validity: internal and external.123 
 
Internal validity 
Internal validity is the extent to which the observed results represent the truth in the study 
population (comparability) and is a prerequisite for external validity (representativeness).123, 
124 The internal validity may be threatened by measurement errors, errors in the selection of 
participants and in the way the data are interpreted.123 These factors are often referred to as 
bias. Bias may be classified as selection bias (population), information bias (collection, 






Selection bias  
Selection bias occurs when the study sample differs from the overall population in a way that 
the conclusions drawn are not representative for the population intended to study.123 This may 
result in differences between study participants and non-participants in regard to the exposure 
and outcome of interest. Selection bias can result from the procedures used to select study 
participants or by factors influencing the study participation.123 Selection bias can be further 
divided into non-respondent bias, attrition bias (loss to follow-up bias), and the healthy 
entrant effect.  
 
Non-respondent bias   
Non-respondent bias occurs when those that respond differ from those that do not respond.125 
In a population-based study validity may be threatened by low attendance rates. The Tromsø 
Study has aimed to include large, representative samples of the Tromsø population. Full birth 
cohorts and random samples of the residents in Tromsø municipality have been invited to 
attend.119 The invitations are based on the official population registry.119 Non-attendees were 
given one reminder.119 The attendance rates to the surveys of the Tromsø Study have been 
high; in the 1st – 5th surveys, attendance rates were >75%, but somewhat lower in the 6th 
survey with an attendance rate of 66%.119 In accordance with this, there has been a decrease in 
attendance rates in other comparable health surveys in Norway as well as internationally.126, 
127 The attendance rates in the 6th survey was however higher compared with other 
comparable health surveys in Norway.128 Attendance rates were lower among the youngest 
and oldest (aged ≥80 years), among men and non-married.119, 128 We cannot exclude that this 






Attrition bias (loss to follow-up bias) 
Attrition bias occurs due to drops out or death.123 Differential losses to follow-up is observed 
if the persons who are lost to follow up differ from those who remain under observation up to 
the event occurrence or termination of the study.124 If the characteristics of those who were 
lost to follow-up are associated with the outcome measures, or if individuals lost to follow-up 
differ according to the distribution of exposure, attrition bias will be a particular problem.123 
All participants of the Tromsø Study are being followed-up with regard to disease incidence 
and mortality by linkage to the discharge and outpatient diagnosis registers at UNN, to the 
National Population Registry and to the National Causes of Death Registry by use of the 
Norwegian, unique 11-digit identification numbers.119 The loss of follow-up in the Tromsø 
study can be considered as negligible.  
 
The healthy entrant effect  
Attendandees of epidemiologic studies are more likely to have favourable health profiles 
compared with non-attendees, which may bias estimates of prevalence, incidence and 
associations between exoposure and disease.127 The healthy entrant effect may occur as a 
consequence of lower attendance rates among the sickest. Due to legal restrictions by the 
Norwegian Data inspectorate, analyses on morbidity and mortality among non-participants in 
the Tromsø Study have been precluded.119 Previous analyses have shown lower mortality 
rates among individuals who attended all Tromsø 2-4 surveys compared with individuals who 
had been invited to all three, but only attended Tromsø 4.119 In a publication from the 
Norwegian, population-based HUNT study, non-participants had lower socioeconomic status, 
higher mortality and higher prevalence of several chronic diseases compared with participants 





association and causal studies due to non-participation.129 We cannot exclude that a healthy 
entrant effect may have led to lower incidence rates of ICH (Paper I and II) and higher 
survival rates (Paper I and III). A possible healthy entrant effect is less likely to have 
influenced analyses of trends over time (Paper I-III) or of comparisons between cases with 
ICH and controls (Paper III).  
 
Information bias  
Information bias (measurement bias) occurs when the data is being recorded inaccurately, or 
when the study population report incorrect information.125 Information bias may place the 
participants in incorrect exposure, covariate or outcome category. If the measurement errors 
occur in a systematic manner; e.g. by use of non-calibrated equipment, they may lead to 
information bias.123 Misclassification bias may be further categorised as differential (error that 
depends on the actual values of other variables) and non-differential (error that does not 
depend on the actual values of other variables).122 Nondifferential errors will most often 
weaken a true association and thus to a degree have predictable consequences. Differential 
misclassification can alter estimations in any direction, and is more serious compared with 
nondifferential misclassification.124 In a prospective cohort study, exposures are ascertained 
prior to the outcome of interest, and errors in classification tend to be similar distributed 
according to disease status, resulting in nondifferential misclassification.124  
One measure to reduce misclassification bias is by use of standardised, validated 
assessment tools. In the Tromsø study, measurements of blood pressure, weight and height 
were performed by standardised methods and by trained personnel.128 The equipment used 
was calibrated, limiting the risk of information bias on these parameters. Total cholesterol, 





samples were non-fasting. However, the changes in lipid-levels in response to normal food 
intake are small, and fasting cholesterol levels may not be superior to non-fasting samples in 
assessing risk of CVD.130 
Data on DM, smoking status, alcohol consumption, use of medications and physical 
activity were collected through self-administered questionnaires. Questionnaires are subject to 
errors in recall and reporting, and may introduce information bias. In a Norwegian study the 
concordance of self-reported DM was high.131 Individuals with undiagnosed DM were not 
registered in our study, which may have led to lower prevalence rates of DM. We cannot 
exclude that this may have led to a dilution of a possible association with DM and outcomes 
of interest. Self-reported smoking status and alcohol consumption may be prone to 
underreporting.132, 133 However, in a recent Finnish study, comparing serum contine level with 
self-reported smoking status the validity of self-reported smoking status was high..132 Self-
reported physical activity is often influenced by variations in recall accuracy.134 A previous 
publication from the Tromsø Study showed a high correlation between self-reported and 
objectively measured leisure physical activity in attendees of the Tromsø Study.134  
We may have missed some cases of ICH. However, UNN is the only hospital in the 
region. Due to long distances to other hospitals, admissions to other hospitals are unlikely. 
There is a possibility that non-hospitalised, non-fatal cases may not have been identified, e.g. 
due to sparse symptomatology or old age leading to non-referral/non-detection. Increasing 
treatment possibilities and an increased awareness of stroke may have led to higher admission 
rates, and a relative underestimation of incidence rates in the first part of the observation 
period. There is a possibility for an increased use of neuroimaging (CT and MRI) in the 





higher incidence rates in the end of the study. However, CT which has been considered the 
golden standard for diagnostics of ICH, has been available at the UNN since 1977.  
All stroke cases were validated by an independent end point committee reducing the 
risk of misclassification. ICH location was registered using a validated instrument. We regard 
the validity of ICH diagnosis and ICH location in the study as high.  
Information on causes of death was based on data from the Norwegian Causes of 
Death Registry, which encompasses all residents, irrespective of whether they die in Norway 
or abroad.135 The degree of coverage and completeness in the registry is near-complete. There 
is a risk of misclassification of causes of death. There have been few validation studies of the 
Norwegian Causes of Death Registry.135 A previous publication showed a substantial 




The term confounding is derived from latin and means “to mix together”.125 Confounding 
may result in an association between a given exposure and an outcome as a result of influence 
of a third variable; a confounder (Figure 10).124 A confounder has to be associated with both 
the exposure and outcome.124 The association may be either causal or non-causal.124 The 


















Confounding may result in a misleading association (overestimation, underestimation or 
reversal of the direction of an effect), which is due to a confounder, and not due to the risk 
factor of interest.124 In order to have an impact the confounder must be unequally distributed 
in the groups being compared.124 Known confounders can to some degree be handled by 
statistical methods; i.e. randomisation (study-participants are randomly allocated to the study-
groups), excluding those with a confounding factor, matching (choosing two groups that are 
similar with the respect of the confounding factor, for example age and sex), stratification 
(dividing into two groups based on the confounding variable) and multivariable analyses 
(controlling for multiple factors in statistical analyses).125, 137 Multivariable analyses were 
used in Paper I-III. Despite use of multivariable analyses, there may be possible confounders 
that we have not adjusted for. We performed analyses stratified on age and sex in paper I-II, 
and analyses stratified on ICH location in paper II. In Paper III, matching on birth-year and 







Unidirectional arrow indicates a causal association. A bidirectional arrow indicates a non-causal association. 






External validity refers to which degree the study results apply to similar individuals outside 
the study population, and thus is generalisable.123 The data in a study are collected from a 
study population. For the data to be valid outside the study population, the study population 
has to be representative for the population intended to study. External validity can be 
improved by using random selection.124 The invitation to the Tromsø study was performed 
inviting randomly selected inhabitants of the municipality, as described earlier. The age and 
sex distribution of the Tromsø Study mirrors the Tromsø population in general, and risk factor 
levels and incidence of CVD among participants of the Tromsø study have been similar to 
other Western populations. The study population may be seen as representative for a Western, 
mostly urban, Caucasian population in a high-income country with high education levels, and 
high access to social services.  
   
 
5.1.2 Interaction (effect modification) 
Interaction describes a situation where the direction or strength of an association between two 
variables depend on the value of one or more other independent variables.124  For 
dichotomous variables, interaction means that the effect of the exposure on the outcome 
differs depending on whether the categorical variable is present or not.124 For continuous 
variables the effect of exposure on outcome depends on the level of the continuous variable if 
interaction is present.124 Interaction may be assessed by including an interaction term (product 
of two or more independent variables) in a multivariable model.138 Analyses of interactions 
were used in all papers. In paper I-II, interaction terms were used to assess differences in time 





interaction were performed when comparing the association of cardiovascular risk factors and 
risk for five-year mortality between cases and controls and to assess differences in time trends 
of five-year mortality, according to age and sex.  
 
5.1.3 Missing data 
Missing data is a limitation in the majority of studies, and may have different reasons. 
Missing data may be categorised as missing completely at random (MCAR), missing at 
random (MAR) and missing not at random (MNAR).139 There are different measures to 
handle missing data. Complete subject analysis refers to the deletion of records with missing 
data in analyses which involves variables for which the records have missing data. The results 
of these analyses will be valid if cases with complete data have been randomly sampled from 
all the subjects in the study; i.e. the data are missing completely at random.139 If a large 
proportion of subjects have missing data, this may lead to reduced power, which in turn may 
cause unreliable estimates despite being MCAR.139 In these cases, alternative methods may be 
used.139 In paper II, physical activity was the risk factor with most missing data (n=1,137) 
among the 27,948 individuals without ICH. For other cardiovascular risk factors the number 
of individuals with missing data ranged between 0-244. Among ICH cases, data on DM was 
missing in one, physical activity in two and data on ICH location in one. In multivariable 
analyses on the association between cardiovascular risk factors and risk of ICH with inclusion 
of all risk factors (model 2) in paper II, a total of 1,211 controls (4.3%) and 2 ICH cases 
(0.9%) were excluded due to missing data. Among 30-day survivors in paper III, data on DM 
were missing in one case and three controls. Smoking status was missing in one control. Data 





missing data were few, and considered to be MCAR. Complete subject analyses were used in 
all papers.    
 
5.1.4 Repeated measurements  
The Tromsø study is a longitudinal study with repeated surveys. A high proportion of 
attendees have attended more than one survey, and thus contribute with repeated measures of 
cardiovascular risk factors.119 Repeated measurements within one individual are correlated, 
and may lead to incorrect estimation of the variances and incorrect inferences about the 
regression coefficients in statistical analyses which assume independent associations (e.g. 
linear regression and logistic regression).140 To account for this, GEE were used in analyses of 
time trends in risk factors.  Generalized estimating equations is a statistical method which 
permits specification of a “working correlation matrix” that accounts for the form of within-
subject correlation of responses on dependent variables and thus corrects for the dependency 
of observations.140 
 
5.1.5 Statistical power 
Despite being a large population-based study, the number of incident ICH cases in our 
study was limited.  Low statistical power may increase the probability of type II errors 
(incorrect acceptance of the null hypothesis).122 In our study this could mean failing to 
observe a change in time trend, when there is one. A low statistical power may also lead to an 
increased risk that statistically significant results will be falsely positive.122 One possibility to 
increase the power of the study could have been to merge data with other similar Norwegian 





possible. Another possibility could have been to present results from the overall stroke 
population in the Tromsø study. However, ICH and IS have different risk factor profiles and 
outcome, and we believe that it is important to report data stratified on stroke subtype. There 
is a need for data from well conducted studies with validated ICH cases, and despite the 
limited number of cases, we believe that our study contributes to the knowledge on ICH.   
 
5.2 Discussion of main results 
5.2.1 Association between cardiovascular risk factors and risk 
of ICH 
Age, male sex, SBP, DBP and hypertension were associated with the risk of ICH, 
whereas there was no association with total cholesterol, HDL-cholesterol, triglycerides, BMI, 
DM, smoking, alcohol intake or physical activity.  
The association with age and blood pressure and risk of ICH is in line with previous 
studies.42 Hypertension was present in 84% of ICH patients. Individuals with hypertension 
who were on blood pressure-lowering drugs and reached a blood pressure level <140/90 mm 
Hg, had no significant increased risk of ICH compared with individuals without hypertension. 
This finding reflects the results from previous RCTs on primary prevention of ICH which 
have shown a significant decreased risk of ICH in patients with hypertension treated with 
blood pressure-lowering drugs.141   
Studies on the association with sex and risk of ICH have been diverging. Whereas 
some studies have shown similar risk between sexes, others have shown an increased risk in 
men.27, 43, 44 In a recent meta-analysis, men had a higher overall ICH incidence.44 However, 





incidence rates between sexes, with the exception of Greece and Norway, where a male 
preponderance has been observed.44  
There was no association with total cholesterol, triglycerides or HDL-cholesterol and 
the risk of ICH. Several publications have reported an inverse association with cholesterol and 
risk of ICH,55, 57 whereas others have found no association.55, 58, 59  
Alcohol intake was not associated with the risk of ICH. In some previous studies, a 
dose-dependent relationship with alcohol intake and risk of ICH has been reported.56, 72 We 
performed analyses with alcohol intake categorised as teetotalism yes/no. This may have 
diluted a possible association according to amount of alcohol intake. Questions on alcohol 
intake differed between surveys, and analyses on the association between amount of alcohol 
intake and risk of ICH was limited to individuals attending the 5th and 6th surveys. These 
analyses did not show any dose-dependent association with alcohol intake and risk of ICH. 
However, due to a smaller sample size the power of these analyses may have been limited.  
We found no association with BMI, DM or smoking and risk of ICH. Previous studies 
on the association with BMI, DM and smoking and the risk of ICH have been diverging.42, 55, 
62-64, 74-76 We used self-reported data on DM, and there is a possibility that we may have 
missed some cases with undiagnosed, untreated DM.  
There are few studies on the association with physical activity and risk of ICH. In a 
large case control study as well as in a recent meta-analysis on observational studies, high 
level leisure time physical activity had a protective effect on risk of ICH/hemorrhagic 
stroke.56, 66 Due to differences in the questionnaires according to level of physical activity we 





of breath) for at least 1 hour per week. We cannot exclude that there may be a possible 
association with higher levels of physical activity, which we were not able to identify.   
Previous studies have indicated an association with use of illicit drugs and risk of 
ICH.77 We did not have information on use of illicit drugs in our study-population.  
One of the major strengths of this study is the use of individual data from repeated 
surveys with registration of premorbid risk factors. In individuals, who attended more than 
one study, measurements from the latest attendance before the ICH event were used. There is 
a possibility that risk factor levels may have changed after attendance in some individuals. 
However, a previous study from the Tromsø Study showed that changes in risk factors 
between surveys have been small and little likely to affect risk estimates for myocardial 
infarction and deep venous thrombosis to a larger degree.142 The authors suggested that risk 
estimates based on a single measurement are generally reliable in cohort studies with long 
follow-up.142   
 
Risk factors according to ICH location 
Age, SBP and DBP were significantly associated with both lobar- and non-lobar ICH. 
The association with blood pressure was however substantially stronger with non-lobar than 
with lobar ICH. Previous studies on risk factors according to ICH location are few, and the 
results have been diverging.78-84  
 In a meta-analysis, an excess of hypertension was found in ICH patients with deep 
versus lobar ICH.85 However, a concern was raised about methodologically issues of the 
studies as blinding for hypertension status when reporting ICH location, uncertain reliability 
of the classification of hemorrhage location and variable rates of investigation for secondary 





location was performed blinded for risk factors. We excluded individuals with ICH caused by 
hemorrhagic transformation of IS, trauma, brain surgery, hematologic disease and brain 
tumor. In addition, a validated instrument was used for assessment of ICH location.121  
We found an association between male sex and risk of non-lobar, but not lobar ICH, 
which has been previously reported in studies from the US, and Mexico.44 In a large meta-
analysis on risk factors according to ICH location, the risk ratio of male sex on non-lobar ICH 
was 1.63, 95% CI  1.25-2.14, whereas there was no association with lobar ICH.84 The reason 
for this association is not clear. In our population, the association with male sex and non-lobar 
ICH remained significant after adjusting for cardiovascular risk factors. We found no 
association with other cardiovascular risk factors and ICH, regardless of location.  
 
5.2.2 Time trends in risk factors 
Blood pressure levels, prevalence of hypertension, serum lipid levels and smoking prevalence 
decreased significantly during the study-period. BMI levels and prevalence of DM increased. 
The proportion of physically active individuals increased. The rate of teetotalers decreased. 
There was an increase in use of blood pressure-lowering, lipid-lowering and antithrombotic 
drugs during the study period. Women had lower blood pressure levels than men in all 
surveys, and the decrease in blood pressure was steeper in women than in men.  
In accordance with our study, there has been a decrease in blood pressure levels in 
several Western countries during the last decades.101 In Norway, a similar decrease in blood 
pressure levels has been observed in the HUNT study.143 Higher blood pressure levels in men 
has been reported in other high income countries.144 In line with our results, a steeper 





previous publication from the Tromsø Study in addition to two large cross-sectional studies 
with pooled analyses.145-147 In the Norwegian HUNT-study, the difference in time trend in 
blood pressure levels between men and women was less pronounced.143 Use of blood 
pressure-lowering drugs increased. However, previous publications from the Tromsø Study 
and the HUNT study have suggested that the observed decrease in blood pressure levels 
cannot be fully explained by an increased use of blood pressure-lowering drugs, but to a 
degree are due to changes in blood pressure in the population.143, 145 The reason for this is not 
known. There was an increase in the proportion of individuals with hypertension treated with 
blood pressure-lowering drugs, and an increase in the proportion with well-controlled 
hypertension. Despite an increase in treatment of hypertension, less than half of individuals 
who fulfilled the criteria for hypertension in the last survey were on blood pressure-lowering 
drugs. Of these, two-thirds had uncontrolled hypertension. Similar results have been reported 
in large, multinational studies,144, 148 and underline the need for further improvements of 
primary prevention of ICH.  A decrease in serum lipids levels, daily smoking, and increase in 
BMI levels and in prevalence of DM has been observed in other Western countries, including 
the Norwegian HUNT study.101, 143 In accordance with several previous studies from Western 
countries, use of lipid-lowering and antithrombotic drugs increased.101-104  
 
5.2.3 Incidence rates of and time trends in incidence of ICH 
Incidence rates increased with increasing age and were higher in men compared with women. 
Incidence rates in Paper I, adjusted to the European population of 1974, were 0.42, 95% CI 
0.37– 0.48 per 1,000 person-years, which is higher compared to a previous meta-analysis 





Norwegian publications, where adjusted incidence rates ranged between 0.13-0.32 per 
1,000.24, 25, 149 Our study was limited to individuals aged ≥30 years, whereas the majority of 
other studies have included younger age groups, or had no lower age limit, which may have 
contributed to the higher incidence rates in our study.  
Incidence rates of ICH in the overall population were stable in the period 1995-2013. 
The majority of studies from other populations have shown stable or decreasing incidence 
rates of ICH.83, 86-97 In accordance with our findings, incidence rates were stable in two 
previous meta-analyses covering the periods 1980-2006 and 1980-2008, respectively.5, 27 The 
authors of the Global Burden of Diseases reported a decrease in incidence of hemorrhagic 
stroke (ICH and SAH combined) in high-income countries between 1990 and 2010.100 In a 
recent review on stroke incidence in high-income countries, a significant decrease in ICH 
incidence was observed in the period 1990-2000.150 During the period 2001-2010 the decrease 
was less pronounced, and no longer statistical significant.150 In a Norwegian study on trend in 
stroke incidence during the period 2010-2015, based on data from the National Patient 
Registry and the National Cause of Death Registry, incidence rates of ICH were stable, 
whereas a significant decrease in IS incidence was observed.151 The study included both first-
ever and recurrent strokes.151 A trend towards an increased burden of primary ICH in high-
income countries was reported in the latest article on stroke incidence from The Global 
Burden of Disease Study, underlining the importance of further surveillance of this stroke 
entity.1  
Trends in incidence rates diverged between sexes. Incidence rates in men were stable, 
but tended to decrease over time in women. The decrease in ICH incidence in women was 
driven by a 74% decrease in non-lobar ICH. There are few previous studies on sex-specific 





knowledge, our study is the first study reporting incidence trends according to sex, stratified 
on ICH location.   
There was no difference in incidence trends according to age-group in our population. 
Previous studies have not been consistent. In a study from the Netherlands, incidence rates 
were stable in individuals aged ≥75 years, whereas incidence rates in the younger 
decreased.152 In two UK and French studies incidence rates increased in the elderly, and 
decreased in the younger.93, 97 Contrary to this, decreasing incidence rates in individuals aged 
≥75 years, and stable incidence rates in individuals aged 45–59 years was found in an US 
study.88  
 
5.2.4 The impact of risk factor trends on incidence trends of 
ICH 
Hypertension was the only modifiable risk factor associated with ICH and was more 
strongly associated with non-lobar than lobar ICH. Despite a decrease in blood pressure 
levels, incidence rates of ICH remained stable in the overall population. However, the trend 
diverged between sexes with a decreasing trend in women, driven by a decrease in non-lobar 
ICH. Lower blood pressure levels and a steeper blood pressure decrease in women compared 
with men may have contributed to the differences between sexes.  
Previous studies on the association with changes in risk factor levels and incidence 
trends in ICH are few.21, 83, 92, 93, 97 In addition to an association with hypertension, use of 
anticoagulant drugs has been associated with the risk of ICH, with a higher risk associated 
with vitamin K antagonists compared with DOACs.67 Antiplatelet drugs probably increase the 





antithrombotic drugs in the elderly may have outweighed a decrease in hypertension 
associated ICH.93, 97 In two UK and French studies on 107 and 441 ICH patients, covering the 
periods 1981-2006 and 1985-2008, respectively, an increase in incidence rates in individuals 
aged ≥75 years was observed, whereas incidence rates in younger age groups decreased.93, 97 
In the French study, the increase in the elderly was driven by an increase in lobar ICH, 
concomitant with an increase in use of antithrombotic drugs.93 In a study from the US, the 
annual incidence of anticoagulant-associated ICH increased during the period 1988-1999.153 
Contrary to these studies, a Finnish study reported stable incidence rates of ICH associated 
with use of anticoagulant drugs despite a 3.6-fold increase of warfarin users in the population 
during the period 1993-2008.102 During this period admission INR values above the 
therapeutic range decreased, suggesting improved control of anticoagulant therapy over 
time.102 We did not observe any significant trend according to age-group or in incidence of 
lobar ICH, and there was no significant increase in ICH associated with use of antithrombotic 
drugs. We did not have data on INR in VKA users in our study-population. In Norway, 
DOACs received marketing authorization in 2011, and during the last years they have taken 
over for VKAs.70 None of the ICH cases in our study population were on DOACs at time of 
ICH.  
 
5.2.5 Time trend in 30-day case fatality rates 
Case fatality rates in our population were approximately 24%, which is in the lower range 
compared with previous publications.27 Thirty-day case fatality rates remained stable during 
the period 1995-2012. This is in line with several studies, including two meta-analyses 
including 36 and 30 studies, with a total of 8,145 and 7,736 ICH patients, respecively.27, 88, 90, 





authors of a study from the Netherlands reported diverging trends according to age group with 
a decrease in case fatality among individuals younger than 75 years, and stable case fatality 
rates in individuals aged 75 years and older.152 We found no difference in time trend 
according to age group. In a French study, the reduction in one-month case fatality was 
observed during the period 1985-2011.110 The decrease was observed between 48 hours and 
30 days, whereas the risk of death within the first 48 hours was stable. The authors concluded 
that the decrease probably was an effect of implementation of dedicated stroke networks, 
organised intensive care units and guidelines dedicated to the management of ICH patients, 
and that stable 1-month case fatality rates in the initial 48 hours after the ICH might be 
explained by limited treatment opportunities in the acute phase of an ICH.110 The stroke unit 
at UNN was established in 1993, and a possible effect of this may not have been detected in 
our study. We cannot exclude that there may be changes in 30-day case fatality rates in our 
population which we did not detect due to limited power. In three previous Norwegian studies 
performed in 1994-1996, 2005 to 2009 and 2010-2014, respectively, 1-month case fatality 
rates ranged between 37% and 40%, 24, 25, 149 which may support our finding of stable 1-month 
case fatality rates during the last decades. The rates in these studies are however crude, which 
limits direct comparisons.  
 In the majority of cases, death during the first month after an ICH is a direct 
consequence of the ICH.33 The components of the ICH score (high age, low GCS, 
infratentorial origin of ICH, high ICH volume and presence of intraventricular hemorrhage) 
have been associated with an increased risk of early death after ICH.34 Use of anticoagulant 
drugs at time of ICH has been associated with an increased risk of early death.154 In addition, 





caused by a limitation of active treatment in these patients.155 We had limited data on the 
components of the ICH score, and did not have data on DNR orders.  
Due to the relatively low 30-day case fatality rates in our population, we compared our 
results with data on 30-day case fatality in ICH patients living in Tromsø municipality who 
were habituated in Tromsø and registered as hospitalised at UNN with a first-ever ICH in the 
Norwegian Stroke Registry for the period 2012-2016 (n=79). In these patients, 30-day case 
fatality rate was 31.6% (personal communication, Stein Harald Johnsen), which is lower 
compared with previous Norwegian studies,24, 25, 149 but higher than in our study. We cannot 
exclude that the lower 30-day case fatality rate in our study-population may be due to a 
healthy bias effect. This is, however, less likely to have had an impact on analyses in trends in 
case fatality rates.  
 
5.2.6 Long-term survival  
In paper III we report data on long-term survival in ICH patients and their controls, 
matched for birth-year and sex. Whereas death in the acute phase after ICH often is a direct 
consequence of the ICH, other causes of death play a larger part in ICH survivors. 33 There 
are few previous studies on ICH survivor cohorts, and there is little data on the impact of 
cardiovascular risk factors on risk long-term mortality.28 In addition, data on trends in long-
term mortality rates are scarce.28, 88, 107, 108, 111 We aimed to compare long-term survival rates, 
causes of death and the impact of cardiovascular risk factors on long-term mortality in 30-day 
survivors of ICH and the general population. As shown in paper I, the risk of death after ICH 
was high in the acute phase after the ICH. After the initial phase, the risk of death flattened 





day survivors of ICH compared to controls. The finding of an increased risk of death during 
long-term follow-up is in line with previous studies on ICH survivors.33, 112, 156, 157  
Among 30-day survivors, 5-year survival rate was 62% in ICH cases to be compared 
with 73% in controls. 10-year survival rates were and 34% and 55%, respectively. After 20 
years of follow-up, 8% of ICH cases and 25% of controls were alive. 
Few studies have assessed long-term survival in ICH survivor cohorts, and start of 
follow-up after ICH has varied.  The authors of the Finnish study reported a 7-year survival 
rate of 67% among 3-month survivors of ICH.156 In a Swedish study 5- and 10-year survival 
rates were 74% and 43% among 1-year survivors.112  
The major cause of death was CVD in both cases and controls, accounting for 61% 
and 34% of all deaths, respectively. The risk of death by CVD was significantly higher in 
ICH patients compared with controls, driven by an increased risk of ICH and stroke sequelae. 
Controls had a higher risk of death by malignancy compared with cases, whereas there was no 
difference in risk of death by other causes. In line with our findings, CVD was the major 
cause of death in two previous studies on ICH survivors, with rates of 56% and 58%, 
respectively.33, 112  
The increased risk of death by ICH and stroke sequelae probably mirrors high 
dependency rates after an ICH in addition to ICH recurrence.27, 33, 113, 156-158 We did not have 
data on functional outcome after ICH, or on recurrence rates of ICH in our cases. The risk of 
IS in ICH patients is similar to the risk of ICH recurrence.28, 157 The risk of death by IS was 
however not higher compared with the general population in our study. In a recently 





ICH of which 59% were fatal, 4.2% had IS, of which 20% were fatal, and 10.1% had 
unclassified stroke, of which 22% were fatal.157 
Previous studies on risk factors for long-term mortality after ICH are heterogenous, 
and the majority have included individuals who died within the first month after the ICH.28 
We found a significant association with smoking and all-cause mortality in both cases and 
controls. Previous studies on the association between smoking and long-term mortality have 
been inconsistent.33, 156, 159 Serum cholesterol was associated with an increased risk of death in 
ICH patients, but not in controls. An inverse association with serum cholesterol and risk of 
ICH has been suggested in several studies, but not all.55, 57-59 We analysed risk factors for ICH 
in paper II, and found no association with serum cholesterol and risk of ICH in our study-
population. Data on serum cholesterol and risk of long-term mortality are few. In a Danish 
study, an inverse association with serum cholesterol and risk of death was reported in 7-day 
survivors of ICH.160 However, the risk was no longer significant after adjusting for statin 
use.160 We did not have data on statin use at time of ICH. It is unknown if statins should be 
withheld or started in ICH patients.60 In some studies, use of statins has been associated with 
improved outcome, and reduced long-term mortality after ICH.60 In a recent Swedish 
observational study on data from the Swedish Stroke Register, ICH patients who were 
prescribed statins at discharge, had a reduced risk of death.161 Use of statins was not 
associated with recurrence of ICH.161 However, studies based on observational data may be 
prone to confounding by indication bias. An association with statins and lobar ICH has been 
suggested,61 and there is a possibility that risk of statin use may differ according to the 
underlying ICH pathology. There is a need for RCTs to increase the understanding on use of 
statins as secondary prevention in ICH patients, and possible differences between subgroups 





Despite being a strong risk factor for both incident and recurrent ICH,42, 162 blood 
pressure was not associated with the risk of death within five years, neither in ICH cases nor 
in controls. This is in line with previous studies, failing to show an association with 
hypertension and long-term mortality in ICH patients.25, 28, 33, 112, 156 There is a possibility that 
initiation of blood pressure-lowering treatment in ICH patients may have attenuated a 
possible association with premorbid SBP and risk of long-term mortality. We had little data 
on use of blood pressure-lowering drugs and blood pressure levels after the ICH in our cohort. 
There are few data on blood pressure-lowering and risk of all-cause mortality in ICH patients, 
and studies on blood pressure-lowering on all-cause mortality in stroke overall have been 
conflicting.163, 164 Despite our results, lowering of blood pressure remains an important 
measure for secondary prevention after an ICH, as it reduces the risk of ICH recurrence as 
well as risk of other CVD significantly.162, 165  
We found no association with DM and risk of death neither in cases nor in controls. 
Previous studies on the association with DM and long-term mortality after ICH have not been 
consistent.28, 33, 112, 156, 159  
In analyses restricted to ICH patients, we found a significant association with use of 
anticoagulant drugs, but not antiplatelet drugs, at time of ICH and risk of 5-year mortality. 
There was no difference in risk of death according to ICH location. Studies on the association 
between anticoagulant drugs and long-term mortality in ICH survivor cohorts have shown 
diverging results.33, 112, 156, 159 ICH patients on anticoagulant drugs have an increased risk 
larger hematoma size and of hematoma expansion,154 which may increase the risk of poor 
outcome. Whether an association with anticoagulant drugs and long-term mortality after ICH 





anticoagulant drugs, an increased risk of ICH recurrence in cases where anticoagulant drugs 
were resumed, or by an increased risk of thromboembolic events in patients where 
anticoagulants were withdrawn, or a combination, is unclear. Data on resumption of 
antithrombotic drugs after ICH are limited. However, several ongoing RCTs are addressing 
this question.166 We have limited data on the resumption of antithrombotic drugs. 
Infratentorial location of ICH and hematoma size are predictors for short-term 
mortality after ICH.34  We found no association with ICH location and the risk of death within 
five years. We did not have data on ICH volume. Among the 30-day survivors of ICH four 
had a holohemispheric ICH, which may be considered a proxy for large hematoma size. Of 
these, three died within five years. Previous studies on ICH location and hematoma size have 
not been consistent,28, 33, 112, 159 but they may be of less importance in ICH survivors.33, 112, 159  
There was no change in 5-year mortality rates during follow-up. There are few studies 
on trends in long-term mortality rates after ICH. In a large meta-analysis, 5-year mortality 
rates were stable in the period 1983-1997,28 and in a US study 3-year mortality rates were 
stable between 2000 and 2010.88 Contrary to these results, a decrease in 5-year mortality rates 
in 2004-2008 compared with 1994-1998, was observed in a large Danish register-based study, 
including 24,760 ICH patients, and a decrease in 10-year mortality among 10,480 ICH 
patients during the period 1999-2007 was observed in a Finnish register-based study.108 In a 
Dutch study on 30-day survivors of ICH in patients aged 18-49 years, 5-year mortality rates 
were stable.111 The explanations of stable long-term mortality rates may be complex. 
Treatment possibilities of ICH are limited, and a large proportion of ICH survivors remain 
disabled,27 which may increase the risk of death by medical complications. Stroke unit care 





1993. As the start of follow-up in our study was set to 1994-1995, we may not have been able 




















6 Conclusions, clinical implications and future 
perspectives 
6.1 Conclusions 
Incidence rates of ICH remained stable in the overall population during the study-period. A 
decrease in incidence rates in women was observed, driven by a 74% decrease in non-lobar 
ICH, whereas incidence rates in men were stable, regardless of location. Age, male sex, SBP, 
DBP and hypertension were significantly associated with the risk of ICH. Hypertension was 
stronger associated with non-lobar ICH compared with lobar ICH. Lower blood-pressure 
levels in addition to a steeper decrease in blood-pressure over time in women compared with 
men, may have contributed to the difference between sexes. We observed no change in 
incidence rates according to age group. Despite an increased use of antithrombotic drugs 
during the study-period, there was no significant change in incidence of ICH associated with 
use of antithrombotic drugs. 
Prevention is the most important measure to reduce the burden of ICH. Hypertension 
was the only modifiable cardiovascular risk factor associated with ICH, and was present in 
84% of ICH cases. In the general population, individuals with hypertension, treated with 
blood pressure-lowering drugs, who reached a blood pressure level <140/90 mm Hg had a 
similar risk of ICH compared to controls without hypertension, whereas individuals with 
uncontrolled hypertension, whether treated or not, had a significantly increased risk of ICH. 
Despite an increase in use of blood pressure-lowering drugs, less than half of individuals with 
hypertension attending the last survey were treated and of these, two-thirds did not reach 





Thirty-day case fatality rates remained stable. Individuals who survived the first 30 
days after the ICH event had a significantly increased risk of death during long-term follow-
up compared to controls matched by birth-year and sex. CVD was the major cause of death in 
both cases and controls, with a higher proportion in ICH cases. In ICH patients, the increased 
risk of death by CVD was driven by recurrent ICH and stroke sequelae. Smoking was 
associated with an increased risk of death within five years in both cases and controls, 
whereas serum cholesterol was associated with an increased risk in cases only. In individuals 
with ICH, use of anticoagulant drugs at time of ICH was significantly associated with 5-year 
mortality. ICH location was not associated with risk of death within five years. There was no 
change in 5-year mortality rates during the observation period.  
The high proportion of individuals with untreated hypertension, and of individuals 
who did not reach treatment goals, indicate that there is a need for improved primary 
prevention of ICH. The stable short- and long-term mortality rates probably reflects the 
limited treatment possibilities of ICH, and stresses the urge for improved treatment strategies 
in the acute phase after an ICH. In addition, there is a need for better knowledge on secondary 
prevention after ICH.   
 
6.2 Clinical implications and future perspectives 
6.2.1 Primary prevention 
We have shown that there is a need for improved treatment of hypertension to reduce 
the burden of ICH. Since our study, there has been a further decrease in blood pressure levels 
in the population of Tromsø.167 In a recent publication using data from the 7th wave of the 





and 33% of women with hypertension, and aged 40-69 years.168 In those on blood pressure-
lowering drugs, 62% had well controlled hypertension,168 which is higher compared with our 
study-population. Despite a trend of improved treatment of hypertension, there is still a 
considerable scope for improving the primary prevention of ICH.168  
There has been a continuous increase in the use of antithrombotic drugs.70, 103, 169 Due 
to the similar preventive effect, greater convenience and reduced risk of bleeding, DOACs 
have been increasingly used during the last years. In some countries, including Norway, they 
have overtaken for vitamin K antagonists.67, 70, 169 DOACs were approved in Norway in 2011-
2012.70 None of the anticoagulant users in our ICH-population were on DOACs. This pattern 
could be expected to have changed during the recent years. In addition to changes in 
prescription patterns of anticoagulant drugs, an increase in dual antiplatelet therapy may be 
expected e.g. due to changes in guidelines on secondary prevention of IS.170 
In the most recent publication from the Global Burden of Disease Study, an increasing 
proportion of ICH in high income countries was reported, underlining the importance of 
further surveillance on ICH epidemiology.1 Future studies on trends in ICH incidence and 
possible changes in risk factor profile of ICH are important to assess the effects of trends in 
blood pressure levels and changes in prescription patterns of antithrombotic drugs during the 
recent years.   
 
6.2.2 Acute treatment 
The stable short- and long-term mortality rates in our study stresses the urge for more 
effective treatment opportunities of ICH to reduce early death and ICH sequelae. Treatment in 





anticoagulant drugs may reduce mortality in patients on anticoagulant drugs at time of ICH.39 
Except from this, studies on use of hemostatic drugs, blood pressure-lowering and surgery in 
ICH patients so far have failed to show any clear benefit with respect of mortality.40, 41, 171 
However, sub-analyses suggest that hemostatic drugs may be beneficial in selected patients if 
started early.172 In addition, hematoma evacuation using minimally invasive surgery with 
small residual ICH volume may be a promising treatment strategy.173 Risk of hematoma 
expansion after ICH is largest during the first few hours after an ICH,35 and prehospital 
identification and treatment of ICH may be an important measure to improve outcome after 
ICH. Future studies are warranted to assess timing and subgroups of patients who may benefit 
from different treatment strategies. In addition, there is a need for further research on novel 
treatments for reducing the consequences of edema and toxic effect of degradation products 
of hemoglobin. 
Supportive care on a stroke unit or critical care unit improves outcome after ICH.37, 155 
Early prognostication after ICH is difficult, and it has been suggested that the use of 
prognostic scales may be a self-fulfilling prophesy, decreasing the likelihood of survival after 
ICH.155 Early DNR orders reduces active treatment and increases early death after ICH.155 In 
a recent publication from the UK implementation of a “bundle of care” with a combination of 
anticoagulation reversal, blood pressure-lowering and surgery in selected cases in addition to 
specialised supportive care reduced one-month case fatality substantially.174 A substantial part 
of the effect was mediated through a reduction in early DNR orders.174 These results are 
promising, and further research on implementation of the use of care bundle approach on a 
national level, and on the components to be included in a care bundle are important to assess 





Further studies on short- and long-term mortality rates after ICH will be an important 
tool to assess effects of possible changes in future treatment regimens of ICH.  
  
6.2.3 Secondary prevention 
Secondary prevention with the aim to reduce recurrence rates of ICH and to reduce the risk of 
IS and other serious vascular events in ICH patients are important. We found a significant 
association with smoking, serum cholesterol and use of anticoagulant drugs and long-term 
mortality after ICH. Data on serum cholesterol and use of statins and long-term survival after 
ICH are few,60, 160 and there is a need for further studies to assess this question. In addition, 
there is a need for knowledge on use of antithrombotic drugs in ICH patients.  
Blood pressure-lowering is the most important measure to reduce recurrence rates of 
both lobar and non-lobar ICH.162 Studies, however, indicate that a less than half of patients 
reach treatment goals after a stroke.162, 175 There is a need for research on novel approaches to 
improve the rates of patients reaching treatment goals after a stroke.  
ICH is a heterogeneous disease. Use of antithrombotic drugs, statins, and risk of ICH 
recurrence may differ according to the underlying pathology.61 The increased use of advanced 
imaging techniques, genetic tests in addition to possible novel biomarkers may improve the 
possibilities of early identification of underlying ICH pathology.61 Future studies should focus 
on identifying the underlying pathophysiology and tailoring preventive treatments according 
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 Abstract 
 Background: The aim of this study was to explore temporal trends in incidence and case fa-
tality rates of intracerebral hemorrhage (ICH) over the last two decades in a Norwegian mu-
nicipality.  Methods: Incident cases of primary ICH were registered in the period from 1995 
through 2012 in 32,530 participants of the longitudinal population-based Tromsø Study. Pois-
son regression models were used to obtain incidence rates over time in age- and sex-adjust-
ed and age- and sex-specific models. Case fatality rates were calculated and age- and sex-
adjusted trends over time were estimated using logistic regression.  Results: A total of 226 
ICHs were registered. The age- and sex-adjusted incidence rate [95% confidence interval (CI)] 
in the overall population was 0.42 (0.37–0.48) per 1,000 person-years. Age-adjusted incidence 
rates were 0.53 (0.43–0.62) in men and 0.33 (0.26–0.39) in women. In individuals aged <75 
years, the age- and sex-adjusted incidence rate was 0.27 (0.22–0.32) and in individuals aged 
 ≥ 75 years, it was 2.42 (1.95–2.89) per 1,000 person-years. There was no significant change in 
incidence rates over time. The incidence rate ratio (95% CI) in the overall population was 0.73 
(0.47–1.12) in 2012 compared with 1995. The overall 30-day case fatality (95% CI) was 23.9% 
(18.3–29.5) and did not change substantially over time [odds ratio in 2012 vs. 1995 = 0.83 (95% 
CI 0.27–2.52)].  Conclusion: No significant changes in incidence and case fatality rates of ICH 
were observed during the last two decades.  © 2016 The Author(s)
Published by S. Karger AG, Basel 
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 Introduction 
 Stroke is the second leading cause of death worldwide and the third leading cause of 
death in Norway  [1, 2] . Intracerebral hemorrhage (ICH) accounts for 10–15% of all strokes 
in Western countries, with an incidence rate of 0.1–0.3/1,000/year  [3] . Morbidity and case 
fatality are high: only 12–39% of patients live independently after an ICH and case fatality 
rates at 1 month range between 13 and 61% (median 40%)  [4] . Treatment possibilities for 
ICH are limited  [5] . However, recent studies show that early, intensive lowering of blood 
pressure may improve outcome  [6] .
 Studies of trends in incidence and 1-month case fatality rates of ICH over the last three 
decades have shown divergent results. While some studies have reported stable incidence 
rates, others have found decreasing or increasing rates  [7–16] . Studies of trends in case 
fatality rates have reported stable as well as decreasing rates  [7, 9, 11–14, 16–18] . Reviews 
based on studies published between 1970 and 2008 showed no significant change in inci-
dence and case fatality rates  [4, 19] , while a recent review reported a decrease in incidence 
of intracerebral and subarachnoidal hemorrhage in high-income countries and a significant 
increase in low- to middle-income countries between 1990 and 2010  [20] . The aim of our 
study was to explore temporal trends in incidence and case fatality rates of ICH over the last 
two decades in a Norwegian municipality. 
 Methods 
 Study Population 
 The Tromsø Study is an ongoing, longitudinal population-based study started in 1974. 
The municipality of Tromsø is located in the northern part of Norway. The population has 
increased; from approximately 42,200 in 1974 to the current population of approximately 
73,000 inhabitants  [21, 22] . The vast majority of the population is of Caucasian origin.
 Details of the study have been described earlier  [23, 24] . Based on the official population 
registry, full birth cohorts and random samples of residents in the municipality of Tromsø 
have been invited to attend the surveys. To the first survey (Tromsø 1), only men were invited. 
Of the 53,731 individuals who were invited, 40,051 attended at least 1 of the 6 surveys 
( table 1 )  [24] . Participants are being followed up with regard to incident stroke and cardio-
vascular events. The Tromsø Study has been approved by the Regional Committee for Medical 
and Health Research Ethics and the Data Inspectorate of Norway.
 Individuals who were not officially registered as inhabitants of the Tromsø municipality 
at the date of enrolment (n = 162), individuals who were younger than 20 years at enrolment 
and did not attend later studies (n = 785), those who did not have valid written consent to 
medical research (n = 225), and individuals who had prevalent ICH (n = 18) or unspecified 
stroke (n = 45) were excluded. Because older birth cohorts were not enrolled in the earliest 
surveys, and individuals <30 years were not enrolled in the two latest surveys ( table 1 ), 
analyses were limited to individuals aged  ≥ 30 years in the period January 1, 1995 to December 
31, 2012. Individuals who emigrated out of the municipality (n = 5,145), died (n = 788) or 
suffered an ICH (n = 24) before 1995 or did not reach 30 years of age during follow-up (n = 
329) were censored, leaving 32,530 individuals (16,771 women and 15,759 men) to be 
included. Individuals were followed up with registration of incident stroke from the date of 
first attendance. For individuals who were younger than 30 years when first attending a 
survey, the start of follow-up was assigned from the date they turned 30 years. Participants 
were followed up until the first-ever ICH event, emigration out of the municipality, death or 
end of study (December 31, 2012).
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 Case Ascertainment  
 Cases were retrieved by linking the participation list to the discharge and outpatient 
diagnosis registers at the University Hospital of North Norway, and to the National Causes of 
Death Registry. The University Hospital is the only hospital serving the Tromsø region (the 
nearest hospital in the county being located 300 km away by road, 134 km by air). Cases of 
stroke were retrieved by searching for International Classification of Disease (ICD) versions 
8 and 9 diagnosis codes 430–438, and ICD-10 diagnosis codes I60–I69 (cerebrovascular 
disease). In 2006 through 2007, ICD-10 codes G45 (transitory ischemic attack), G46 (vascular 
syndromes of brain in cerebrovascular diseases) and G81 (hemiplegia) were added to the 
search. In addition, systematic text searches were made for the words ‘stroke’, ‘ischemic 
stroke’ and ‘intracerebral hemorrhage’ in the medical records of all participants with ICD-8 
to ICD-10 diagnosis codes 410–414 and I20–I25 (ischemic heart disease), 798/R96 (sudden 
death, cause unknown), R98 (unattended death) and 799/R99 (other ill-defined and unknown 
causes of morbidity and mortality). 
 Each case was reviewed separately by an independent endpoint committee by use of 
medical records from the hospital (including autopsy reports). Cases retrieved from the 
National Causes of Death registry were additionally validated by medical records from nursing 
homes, general practitioners, emergency services and/or death certificates. Stroke was 
defined according to the WHO criteria: ‘rapidly developed clinical signs of focal (or global) 
disturbance of cerebral function, lasting more than 24 h or leading to death, with no apparent 
cause other than of vascular origin’  [25] . Strokes were defined as an ICH where a parenchymal 
hemorrhage was identified on computed tomography (CT) and/or magnetic resonance 
imaging (MRI) and/or autopsy. ICHs caused by hemorrhagic transformation of ischemic 
stroke, trauma, brain surgery, hematologic disease or brain tumor were excluded. Cases 
where neither imaging nor autopsy was performed in the acute phase were categorized as 
unspecified stroke.
 Dates for death and emigration out of the municipality were obtained from the Popu-
lation Registry of Norway. Linkage to registers was performed using the Norwegian, unique 
11-digit personal identification numbers. 
 Statistical Analyses 
 Statistical analyses were conducted using STATA version 13.0 (StataCorp LP, College 
Station, Tex., USA). Analyses of the overall study population, stratified by age (predefined age 
groups: <75 and  ≥ 75 years) and sex were conducted. The stsplit function in STATA was used 
to produce a new record in the data file for each year a participant was under follow-up, with 
updated calendar time and attained age variables. Crude incidence rates for incident primary 
ICH per 1,000 person-years from January 1, 1995 through December 31, 2012 were calcu-
 Table 1. Year of survey, age, number and attendance rate of eligible participants (the Tromsø Study)













1974 20–49 6,595 74.4 – – –
1979–80 20–54 8,477 73. 8 20–49 8,143 81.8
1986–87 12–64 10,963 71.8 12–67 10,863 79.0
1994–95 25–97 12,865 69.6 25–97 14,293 74.9
2001–02 30–89 3,511 75.7 30–89 4,619 80.8
2007–08 30–87 6,054 62.9 30–87 6,930 68.4
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lated with the number of events registered during the study period as numerator and person-
years at risk as denominator ( table 2 ). Calendar year-specific incidence rates were estimated. 
In addition, crude incidence rates in 10-year age bands were calculated. 
 Incidence rates adjusted for age and sex were calculated by the direct method using the 
European standard population of 1976 as reference. Incidence rate ratios (IRRs) between 
men and women, with women as reference, adjusted for age, were estimated using Poisson 
regression.
 Trends in incidence rates over time, adjusted for age or age and sex ( fig. 1 ,  2 ), were 
obtained from a Poisson regression model. In the overall population, trend was estimated 
with age set at 64 years, while trends were estimated at 62 years in men, 65 in women, 58 in 
individuals <75 years of age and 82 in individuals aged  ≥ 75 years, respectively. In sex-
adjusted models, the mean value of sex was used. To assess a possible nonlinear trend over 
time, the models were fitted with fractional polynomials, with time as covariate  [26] . Powers 
were chosen from the set: φ = (–2, –1, –0.5, 0, 0.5, 1, 2, 3). Model selection was performed by 
comparing a Poisson regression model with a linear time variable with the best fitting first- 
and second-degree models using the Akaike Information Criteria (AIC). In the overall popu-
lation and in all subgroups, the best AIC was observed in the models with a linear time term. 












Men 122 216,279 0.56 (0.47 – 0.67) 0.53 (0.43 – 0.62)
Women 104 236,873 0.44 (0.36 – 0.53) 0.33 (0.26 – 0.39)
Age <75 121 410,607 0.29 (0.25 – 0.35) 0.27 (0.22 – 0.32)
Age ≥75 105 42,545 2.47 (2.04 – 2.99) 2.42 (1.95 – 2.89)
Overall 226 453,152 0.50 (0.44 – 0.57) 0.42 (0.37 – 0.48)
 a Incidence rates adjusted to age/age and sex by the direct method 
using the European standard population of 1976 as reference.
 Table 2. Incidence rates of 
primary ICH per 1,000 person-


























IRR 0.73 (95% CI 0.47–1.12), p for trend 0.15
1995 1997 1999 2001 2003 2005 2007 2009 2011
Year
 Fig. 1. Temporal trend in inci-
dence rates of ICH, overall popu-
lation. The Tromsø Study 1995–
2012. 
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two-way interaction terms (age × time and sex × time) in the regression models. IRRs between 
2012 and 1995 were estimated from each regression model. 
 Case fatality rates were calculated with the number of deaths occurring within 30 days 
after the event as numerator and the total number of ICH cases as denominator ( table 3 ). 
Analysis of temporal trend was performed using a logistic regression model, adjusted for age 
and sex ( fig. 3 ). The adjusted time trend was presented using the mean values of age and sex. 
The model was fitted with fractional polynomials and model selection performed using AIC 
as described earlier. Based on the model selection criteria, time was included as a linear term 
in the logistic regression model. Odds ratio (OR) was calculated for the year 2012 versus 
1995. Tests of interaction between age and time and sex and time were performed by including 
two-way interaction terms (age × time and sex × time) in the model. Additional analyses of 
trends in case fatality were performed by calculating ORs between time periods (1995–2000, 
2001–2006 and 2007–2012), unadjusted and adjusted for age and sex ( table 3 ). 
 For all analyses, a two-sided p value <0.05 was considered significant. Power calculations 
based on the observed person-years at risk, the age-adjusted baseline incidence rate, and a 

























IRR 0.95 (95% CI 0.53–1.72), p for trend 0.88


























IRR 0.92 (95% CI 0.51–1.64), p for trend 0.78


























IRR 0.57 (95% CI 0.30–1.09), p for trend 0.09


























IRR 0.52 (95% CI 0.27–1.00), p for trend 0.05
1995 1997 1999 2001 2003 2005 2007 2009 2011
Yeara b
c d
 Fig. 2. Temporal trends in incidence rates of ICH, stratified by sex ( a ,  b ) or age ( c ,  d ). The Tromsø Study 
1995–2012. 
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power to detect a significantly decreasing incidence trend was IRR = 0.51. In subgroup 
analyses, the population effect size was IRR = 0.52 in men and IRR = 0.35 in women, and
IRR = 0.48 in those <75 years of age and IRR = 0.17 in those  ≥ 75 years of age. Power calcula-
tions based on a baseline case fatality rate of 26.4% and the number of ICH being 226 showed 
that we would have 80% power to detect a significant linear trend in case fatality rates if the 
population trend over 17 years was 0.24 (OR = 0.92 per year). 
 Results 
 We registered 226 incident primary ICHs during a total of 453,152 person-years ( table 2 ). 
The age- and sex-adjusted incidence rate in the overall population was 0.42 (95% CI 0.37–
0.48)  per 1,000 person-years, 0.53 (95% CI 0.43–0.62) in men and 0.33 (95% CI 0.26–0.39) 
in women ( table 2 ). Women were on average 5 years older than men at the time of ICH. 
Adjusted incidence rates were 0.27 (95% CI 0.22–0.32) per 1,000 person-years in individuals 
aged <75 years and 2.42 (95% CI 1.95–2.89) in individuals aged  ≥ 75 years. The incidence 
rates increased steeply with age: compared with the age group 45–54 years, individuals in 
age groups 65–74 years and  ≥ 85 years had a 9-fold and 30-fold higher risk of ICH, respec-






















OR 0.83 (95% CI 0.27–2.52), p for trend 0.74
1995 1997 1999 2001 2003 2005 2007 2009 2011
Year
 Fig. 3. Temporal trend in 30-day 
case fatality rates. The Tromsø 
Study 1995–2012. 
 Table 3. ORs for 30-day case fatality rates of ICH according to time period (the Tromsø Study 1995 – 2012)
Year of ICH
1995 – 2000 2001 – 2006 2007 – 2012
ICH, n 67 79 80
30-day CFR, % (n) 25.37 (17) 24.05 (19) 22.50 (18)
OR (95% CI)a 1 (reference) 0.93 (0.44 – 1.98) 0.85 (0.40 – 1.83)
OR (95% CI)b 1 (reference) 0.83 (0.38 – 1.81) 0.85 (0.39 – 1.88)
CFR = Case fatality rate. a Unadjusted. b Adjusted for age and sex.
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CI 2.61–5.11) per 1,000 person-years]. In the overall population, the incidence rate of ICH was 
significantly higher in men compared with women [IRR 1.63 (95% CI 1.25–2.13)]. In indi-
viduals aged <75 years, this difference remained significant [IRR 1.72 (95% CI 1.19–2.48)], 
while the difference between men and women in individuals aged  ≥ 75 years was nonsignif-
icant [IRR 1.43 (95% CI 0.97–2.11)]. 
 Figures 1 and  2 show trends in incidence rates over time. In the overall population, the 
estimated incidence rate in 2012 was 27% lower than in 1995 [IRR 0.73 (95% CI 0.47–1.12)]. 
In women, there was a decrease by 48% [IRR 0.52 (95% CI 0.27–1.00)] and in individuals 
aged  ≥ 75 years the rates decreased by 43% [IRR 0.57 (95% CI 0.30–1.09)] during the study 
period. However, none of these changes were statistically significant (p value for trend: 0.15, 
0.05 and 0.09, respectively). Incidence rates in men and in individuals aged <75 years 
remained stable [IRR 0.95 (95% CI 0.53–1.72) and 0.92 (95% CI 0.51–1.64), respectively]. 
There were no significant interactions between age and time (p values for the overall popu-
lation 0.06, others ranging between 0.21 and 0.76) or sex and time (p values for the overall 
population 0.21, p values for individuals <75 and  ≥ 75 years of age 0.56 and 0.39, respectively). 
 Among the 226 individuals suffering an ICH, 54 died within the first 30 days after the ICH 
event, resulting in a 30-day case fatality rate of 23.9% (95% CI 18.3–29.5). Of the individuals 
who died within the first 30 days, 48.2% died within the first 2 days and 74.1% died within 
the first 7 days after the event. The case fatality rate was higher in individuals aged  ≥ 75 years 
compared with individuals aged <75 years [34.3% (95% CI 25.1–43.5) vs. 14.9% (95% CI 
8.4–21.3)]. There was no significant trend over time in 30-day case fatality rates adjusted for 
age and sex [OR in 2012 vs. 1995: 0.83 (95% CI 0.27–2.52)] ( fig. 3 ;  table 3 ). There was no 
interaction between age and time (p = 0.57), or sex and time (p = 0.21), suggesting that the 
trends did not differ by age or sex.
 Discussion 
 We observed no significant change in incidence and case fatality rates of ICH over time. 
Incidence rates of ICH increased steeply with increasing age, and were higher in men compared 
with women. Previous studies have reported higher, however not always statistically signif-
icant, incidence rates of ICH among men  [4, 27] . In line with our study, one review showed 
that the male predominance in stroke incidence decreased with increasing age  [27] . 
 Incidence of ICH trends differ by country income level, with increasing incidence rates in 
low- to middle-income countries and decreasing rates in high-income countries  [20] . However, 
over the last three decades, results from high-income Western countries have shown diverging 
results. Two European population-based studies reported stable incidence rates  [7, 8] , 
whereas one Australian and one study from the USA reported a significant decrease in inci-
dence rates  [11, 12] . One population-based study from the Greater Cincinnati/Northern 
Kentucky region reported a significant increase in ICH rates from 1988 to 1999, driven by a 
change between 1988 and 1993/94  [15] . A subsequent publication from the same region 
showed stable incidence rates between 1993/94 and 2005  [9] . Three large register studies 
from the USA, Australia and Canada showed stable  [10] , decreasing  [14] and increasing  [16] 
admission rates, respectively. 
 Case fatality rates vary between studies, with reported case fatality rates ranging between 
13 and 61%, the lowest rates reported in publications from Japan  [4] . The case fatality rates 
in our cohort are in the lower range, and lower compared to two previously published studies 
from Norway  [28, 29] . There was no significant change in case fatality rates over time,
which is in line with results from a meta-analysis of studies published in the period 1980 and 
2008  [4] .
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 Strengths and Limitations 
 The major strengths of our study is the longitudinal, population-based design, high atten-
dance rates, and rigorous case validation. Our study is one of few studies which provide 
knowledge about trends in incidence of ICH in a population within a well-defined geographical 
area over a long-time span, including the last decade.
 There are, however, some limitations. The number of ICHs is low, leading to limited 
power to detect statistically significant changes in incidence and case fatality rates, especially 
in subgroup analyses. Cohort studies carry a risk of both selection bias and bias due to loss to 
follow-up. Although attendance rates in the Tromsø Study have been high, lower attendance 
rates have been among the youngest, among men and nonmarried individuals  [23] . In addition, 
lower attendance rates among the elderly and diseased may have influenced incidence and 
case fatality rates to some degree. Legal restrictions have prohibited the possibilities of 
detailed analyses of morbidity and mortality according to attendance. We regard the follow-
up of our participants as close to complete. Participants are followed up from the date of first 
attendance (independently of attendance to later surveys) until the first event, death or upon 
moving away from the municipality. 
 However, as case identification was retrospective, not hot pursuit, we may have missed 
some nonhospitalized, nonfatal cases. In addition, some nonhospitalized fatal cases of ICH 
may have been coded as nonhemorrhagic due to lack of imaging or autopsy, leading to an 
underestimation of the true incidence rates. There is a possibility that a higher focus on 
treatment of stroke during the last decades may have led to higher admission rates to the 
hospital, resulting in relative underestimation of incidence rates in the first part of the obser-
vation period. There is also a possibility for a higher utilization of CT/MRI scanning in the 
diagnostics of stroke patients during the last decades. However, CT scan has been available 
at our hospital since 1977, and is routinely performed as a screening procedure in all patients 
admitted for stroke or transient ischemic attack. 
 Studies from the UK and France suggest that stable incidence rates may be explained by 
a shift in the risk factor profile during the last decades with a decrease in ICHs associated with 
hypertension and a concomitant increase in ICHs associated with antithrombotic treatment 
in the elderly  [30, 31] . Information on the use of antithrombotic treatment was unfortunately 
not available in our study.
 Conclusion 
 We observed no significant change in incidence and case fatality rates in the period from 
1995 through 2012. 
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The impact of risk factor trends on
intracerebral hemorrhage incidence over
the last two decades—The Tromsø Study
Maria Carlsson1,2 , Tom Wilsgaard3, Stein Harald Johnsen1,4,
Liv-Hege Johnsen1,5, Maja-Lisa Løchen3, Inger Njølstad3 and
Ellisiv Bøgeberg Mathiesen1,4
Abstract
Background:Studies on the relationship between temporal trends in risk factors and incidence rates of intracerebral
hemorrhage are scarce.
Aims:To analyze temporal trends in risk factors and incidence rates of intracerebral hemorrhage using individual data
from a population-based study.
Methods:We included 28,167 participants of the Tromsø Study enrolled between 1994 and 2008. First-ever intracer-
ebral hemorrhages were registered through 31 December 2013. Hazard ratios (HRs) for intracerebral hemorrhage were
analyzed by Cox proportional hazards models, risk factor levels over time by generalized estimating equations, and
incidence rate ratios (IRR) by Poisson regression.
Results:We registered 219 intracerebral hemorrhages. Age, male sex, systolic blood pressure (BP), diastolic BP, and
hypertension were associated with intracerebral hemorrhage. Hypertension was more strongly associated with non-
lobar intracerebral hemorrhage (HR 5.08, 95% CI 2.86–9.01) than lobar intracerebral hemorrhage (HR 1.91, 95% CI
1.12–3.25). In women, incidence decreased significantly (IRR 0.46, 95% CI 0.23–0.90), driven by a decrease in non-lobar
intracerebral hemorrhage. Incidence rates in men remained stable (IRR 1.27, 95% CI 0.69–2.31). BP levels were lower
and decreased more steeply in women than in men. The majority with hypertension were untreated, and a high pro-
portion of those treated did not reach treatment goals.
Conclusions:We observed a significant decrease in intracerebral hemorrhage incidence in women, but not in men.
A steeper BP decrease in women may have contributed to the diverging trends. The high proportion of untreated and
sub-optimally treated hypertension calls for improved strategies for prevention of intracerebral hemorrhage.
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Introduction
In Western countries, intracerebral hemorrhage (ICH)
represents approximately 10–15% of all strokes.1
However, symptoms are more severe and outcome is
poorer compared with ischemic stroke (IS). Treatment
possibilities are limited and prevention remains the
major measure to reduce the burden of ICH.
Hypertension is the most important modifiable risk
factor for ICH.2–4 Whereas non-lobar ICH has been
associated with hypertensive arteriopathy, cerebral
amyloid angiopathy is an important cause of lobar
ICH.5 Hypertension seems to be more strongly asso-
ciated with non-lobar ICH.6 The association with
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cholesterol, diabetes mellitus (DM), body mass index
(BMI), smoking, alcohol consumption, and physical
activity is less clear.2–4 A dose-dependent relationship
with alcohol intake and an inverse association with
serum-cholesterol has been suggested.2–4 Treatment
with anticoagulants is associated with an increased
risk of ICH and treatment with antiplatelets probably
increases the risk to a small degree.2
In several Western countries, blood pressure (BP)
levels, smoking, and cholesterol levels have declined
during the last decades.7 Trends in alcohol use vary,
whereas BMI, DM prevalence, and use of anticoagu-
lant drugs have increased.7,8 Incidence trends of ICH
have been stable9–11 or decreasing12,13 in the majority of
previous publications from Western countries. Studies
on the association between risk factor trends and stroke
incidence using individual data from repeated surveys
with registration of premorbid risk factor levels are
scarce9,14,15 and the majority of these have covered
trends in total stroke incidence.14,15
Aims
We aimed to analyze temporal trends in premorbid risk
factors and incidence rates of ICH over the last two
decades using individual person-data from a popula-
tion-based study with repeated surveys.
Methods
The Tromsø study is an ongoing population-based study
with repeated study design.16 Eligible for our study were
28,251 registered inhabitants of Tromsø aged !30 years
who attended one or more of the three surveys con-
ducted in 1994–1995, 2001, and 2007–2008 (Table I,
Supplements). Individuals with prevalent ICH (n¼ 26)
or unclassified stroke (n¼ 58) were excluded, leaving
14,794 women and 13,373 men to be included. All indi-
viduals were followed up with registration of first-ever
ICH. Follow-up time was assigned from date of first
attendance until first-ever ICH, death, emigration from
Tromsø or to 31 December 2013, whichever came first.
Risk factors
Risk factors were registered at first date of attendance
and updated at the dates of attendance in the subse-
quent survey(s). Hypertension was defined as systolic
blood pressure (SBP) !140mm Hg and/or diastolic
blood pressure (DBP) !90mm Hg and/or treatment
with BP-lowering drugs. Non-fasting blood samples
were analyzed by standard methods at the University
Hospital of Northern Norway (UNN). Information on
DM, smoking status, alcohol use, and physical activity
was obtained from questionnaires (Supplements).
Use of medication
Information on use of BP-lowering and lipid-lowering
drugs was obtained from questionnaires (Supplements).
In addition, information about medication used on a
regular basis (antithrombotics included) was retrieved
through lists of brand names of medication, written by
the participants and checked by health personnel at the
study site. Information on the use of antithrombotic
drugs at the time of ICH was obtained retrospectively
from the medical record of each subject suffering an
ICH during follow-up.
Identification of ICH events and location of ICH
Monitoring of first-ever cases of selected cardiovascular
diseases among Tromsø Study participants has been
going on since the study start and is performed by link-
age to the discharge and out-patients diagnosis registers
at UNN, the only hospital serving the municipality,
and to the Causes of Death Registry of Norway,
using unique 11-digit personal identification numbers.
Cases were classified as ICH when a parenchymal hem-
orrhage was identified by computed tomography (CT),
magnetic resonance imaging (MRI) and/or autopsy.
Cases secondary to hemorrhagic transformation of IS,
trauma, brain surgery, hematologic disease, or brain
tumor were excluded. An independent endpoint com-
mittee reviewed each case by use of medical records
from the hospital (including autopsy reports). Dates
for death and emigration out of the municipality were
obtained from the Population Registry of Norway.
CT scans, MRI scans, and radiology and autopsy
reports were assessed retrospectively to record location
of the ICHs. Location was defined according to an ana-
tomical rating instrument and categorized as lobar,
non-lobar (deep/infratentorial), holohemispheric, or
other location (Supplements).5
Statistical analyses
Statistical analyses were performed using StataCorp
(2015. Stata Statistical Software: Release 14. College
Station, TX: StataCorp LP). Baseline means and propor-
tions of risk factors measured at the date of first entry to
the study were adjusted for age and sex of the study
sample, using linear and logistic regression models.
The association between risk factors and ICH was
assessed by calculating hazard ratios (HRs) using Cox
proportional hazards. The assumption of proportional
hazards was tested using Schoenfelds residuals and log–
log plots. In model 1, each independent variable was
adjusted for age and sex. In model 2, each independent
variable was adjusted for age, sex, SBP (except
for hypertension and DBP), total cholesterol, high-
density lipoprotein cholesterol (HDL cholesterol)
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(except for triglycerides), BMI, DM, daily smoking,
teetotalism, and leisure physical activity. To account
for dependencies between repeated measurements,
trends in risk factors and use of BP-lowering, lipid-
lowering and antithrombotic drugs were analyzed in
age- and sex-adjusted general estimated equations
models. Age- and sex-adjusted odds ratios (OR) for
treatment with antithrombotic drugs at time of ICH
were calculated by logistic regression.
Age- and sex-adjusted incidence rates were calcu-
lated by the direct method using the European standard
population of 2013 as reference. Incidence trends over
time were obtained from age- and sex-adjusted Poisson
regression models. Additional analyses stratified on sex,
pre-defined age groups (<75 years and !75 years), and
location were performed. Interaction between age and
time (year of ICH) and sex and time was tested by
including interaction terms (age# time, sex# time) in
the regression models. Non-linearity was tested using
fractional polynomials. Incidence rate ratios (IRRs)
between 2013 and 1995 were estimated from each
regression model.
Results
We registered 219 first-ever ICHs during a follow-up of
396,976 person-years, of which 40% were lobar, 51%
non-lobar, and 9% holohemispheric/other location.
Individuals with ICH were older, more likely to be
males, and had higher age- and sex-adjusted BP
levels at baseline compared with ICH-free individuals
(Table 1, Table IIa and IIb, Supplements). Among indi-
viduals with ICH, the crude prevalence of hypertension
at last attendance before ICH was 84%.
Associations between risk factors and incident ICH
Age, male sex, SBP, DBP, and hypertension were inde-
pendently associated with ICH (Table 2). There was no
association between ICH and serum lipids, BMI, DM,
Table 1. Baseline characteristicsa of participants with and without first-ever intracerebral hemorrhage (ICH) during follow-up,




(n¼ 219) p valueb
Age, years 48.5 (13.6) 63.7 (11.9) <0.001
Male sex 47.4 (13,250) 57.3 (123) 0.004
Systolic blood pressure (mm Hg) 134.0 (20.9) 142.7 (24.6) <0.001
Diastolic blood pressure (mm Hg) 78.5 (12.1) 83.7 (15.2) <0.001
Hypertensionc 33.6 (10,026) 59.0 (176) <0.001
Total cholesterol (mmol/L) 6.1 (1.3) 6.0 (1.2) 0.73
Triglycerides (mmol/L) 1.57 (1.04) 1.52 (0.97) 0.48
HDL-cholesterol (mmol/L) 1.49 (0.41) 1.49 (0.40) 0.79
Body mass index (kg/m2) 25.5 (4.0) 25.5 (4.0) 0.93
Diabetes mellitus 1.5 (575) 0.9 (6) 0.26
Daily smoking 34.8 (9747) 34.2 (64) 0.87
Teetotalism 9.9 (3510) 9.5 (48) 0.80
Physical activityd 29.7 (8401) 31.5 (48) 0.61
Use of blood pressure-lowering drugs 4.8 (1957) 5.2 (36) 0.62
Use of lipid-lowering drugs 1.2 (422) 1.0 (5) 0.69
aContinuous variables are presented as mean (SD); categorical variables are presented as % (n).
bp value for difference between individuals with and without first-ever intracerebral hemorrhage adjusted for age and sex.
cSystolic blood pressure !140 mm Hg and/or diastolic blood pressure !90 mm Hg and/or use of blood pressure-lowering drugs.
dStrenuous leisure physical activity >1 h/week.
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daily smoking, teetotalism, or physical activity. We
found no significant dose-dependent association with
alcohol intake and ICH: HR 1.02 (95% CI 0.72–1.44)
for moderate alcohol consumption and 1.63 (95% CI
0.64–4.16) for high alcohol consumption, respectively.
There was a significant association with age, SBP
and DBP and ICH of both lobar and non-lobar loca-
tion, whereas male sex was significantly associated with
non-lobar ICH only (Table III, Supplements).
Hypertension was more strongly associated with non-
lobar (HR 5.08, 95% CI 2.86–9.01) than with lobar
ICH (HR 1.91, 95% CI 1.12–3.25).
Individuals with drug-treated, well-controlled hyper-
tension (SBP <140mm Hg and DBP <90mm Hg)
had no significant increased risk of ICH compared
with those without hypertension (HR 1.74, 95% CI
0.79–3.84), whereas the risk was increased in individ-
uals with SBP !140mm Hg and/or DBP !90mm Hg
despite treatment with BP-lowering drugs (HR 3.43,
95% CI 2.12–5.55). A similar increased risk was seen
in those with untreated hypertension (HR 3.36, 95% CI
2.24–5.03).
Change in risk factor levels
BP levels, serum lipid levels, and smoking prevalence
decreased significantly over time, whereas BMI and
DM prevalence increased (Table 3). The proportion
of physically active individuals increased. Use of
BP-lowering, lipid-lowering, and antithrombotic drugs
increased. Women had lower BP than men in all sur-
veys, and the SBP decrease was steeper in women than
in men: from 138.2 (95% CI 137.7–138.5) to 131.0mm
Hg (95% CI 130.2–131.8) in women and from
140.5 (95% CI 140.1–140.8) to 136.1mm Hg (95% CI
135.2–136.9) in men (Table IVa and IVb, Supplements).
Among individuals with hypertension, the crude pro-
portions treated with BP-lowering drugs in 1994–1995
and 2007–2008 were 18% and 46%, respectively. In the
treated group, the proportion with well-controlled
hypertension was 21% in 1994–1995 and 35% in
2007–2008.
Twenty-five percent of ICH patients were treated
with anticoagulants and 28% with antiplatelets. There
was no significant change over time in use of






Age (14.3) 3.42 (2.94–3.98) 2.84 (2.38–3.40)
Male sex 1.76 (1.35–2.30) 1.86 (1.38–2.52)
Systolic blood pressure (21.9) 1.45 (1.28–1.64) 1.46 (1.29–1.66)
Diastolic blood pressure (12.0) 1.52 (1.37–1.70) 1.55 (1.39–1.74)
Hypertensiond 3.08 (2.10–4.54) 3.26 (2.20–4.85)
Total cholesterol (1.2) 1.06 (0.92–1.21) 1.01 (0.88–1.16)
HDL-cholesterol (0.4) 1.00 (0.87–1.15) 0.99 (0.85–1.14)
Triglycerides (1.0) 1.02 (0.89–1.17) 0.99 (0.85–1.16)
Body mass index (4.1) 1.00 (0.87–1.14) 0.93 (0.80–1.08)
Diabetes mellitus 1.15 (0.64–2.06) 1.14 (0.63–2.06)
Daily smoking 1.11 (0.81–1.52) 1.14 (0.83–1.58)
Teetotalism 1.07 (0.77–1.50) 1.04 (0.74–1.46)
Physical activitye 0.96 (0.69–1.33) 0.99 (0.71–1.38)
aHRs are expressed per SD increase in continuous variables and for presence vs. absence of categorical variables.
bUpdated at the date of attendance in the subsequent survey(s) in individuals who were still free of ICH.
cModel 1: adjusted for age and sex. Model 2: adjusted for age, sex, systolic blood pressure (except for hypertension and diastolic blood pressure) total
cholesterol, high-density lipoprotein cholesterol (HDL-cholesterol) (except for triglycerides), body mass index, diabetes mellitus, daily smoking,
teetotalism, and physical activity.
dSystolic blood pressure !140 mm Hg and/or diastolic blood pressure !90 mm Hg and/or use of blood pressure-lowering drugs.
eStrenuous leisure physical activity >1 h/week.
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antithrombotics at ICH onset (p for trend¼ 0.10)
(Table Va and Vb, Supplements).
Incidence of ICH over time
The incidence rates of ICH in the overall population
did not change significantly over time (IRR 0.81,
95% CI 0.52–1.27) (Table VI, Supplements).
However, analyses stratified on sex showed a significant
54% decrease in incidence in women (IRR 0.46, 95%
CI 0.23–0.90), whereas incidence in men remained
stable (IRR 1.27, 95% CI 0.69–2.31), p value for inter-
action 0.02. Analyses of predefined age groups showed
no significant change in incidence in individuals
aged <75 years or in individuals aged !75 years
(Table VI, Supplements). Analyses stratified on loca-
tion showed no significant trend for lobar (IRR 1.36,
95% CI 0.67–2.79) or non-lobar ICH (IRR 0.71, 95%
CI 0.38–1.33). However, for non-lobar ICH there was a
significant interaction between sex and time (p value
0.02). Sex-stratified analyses showed a significant 74%
reduction in non-lobar ICH in women, whereas
incidence in men were stable (Figure 1, Table VI,
Supplements).
Discussion
We showed a significant association with SBP, DBP,
hypertension, age and male sex, and ICH.
Hypertension was more strongly associated with non-
lobar than lobar ICH.
BP levels decreased significantly over time, in line
with trends in several Western countries.7
There was no significant change in incidence rates of
ICH in the overall population. However, trends diverged
between sexes; in women, incidence rates decreased sig-
nificantly, driven by a 74% decrease in non-lobar ICH,
whereas incidence rates in men remained stable. In line
with previous publications from the Tromsø Study,17 BP
levels were lower and deceased steeper over time in
women compared with men, which may have contribu-
ted to the diverging trends. Results from the majority of
Figure 1. Age-adjusted incidence rate ratios (IRR) of incident intracerebral hemorrhage in 2013 compared with 1995 stratified
on sex and location—the Tromsø Study.
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previous studies from Western countries have shown
stable9–11 or decreasing.12,13 incidence rates of ICH.
Publications on sex-specific trends in ICH incidence
are scarce and the results have been diverging.11,12,18
To the best of our knowledge, sex-specific trends in
ICH incidence according to location have not previously
been reported.
The authors of two previous studies from UK and
France suggested that a decrease in hypertension-asso-
ciated ICH may have been offset by an increase in ICH
associated with use of antithrombotic drugs.9,10 In both
studies incidence rates in individuals aged !75 years
increased, whereas incidence decreased in younger age
groups. In the French study, the increase in the elderly
was attributed to a two-fold increase in lobar ICH, con-
comitant with a rise in use of antithrombotics. We did not
observe any significant trend according to age-group or in
incidence rates of lobar ICH. Despite an overall increase
in antithrombotic use, we did not find any significant
change in the risk of use of antithrombotics at time of
ICH, which is in line with a previous Finnish study.8
Hypertension was present in 84% of ICH cases.
Whereas participants with drug-treated, well-controlled
hypertension did not have a higher risk of ICH com-
pared with individuals without hypertension, individ-
uals with uncontrolled hypertension, whether treated
or not, had a significantly increased risk of ICH.
Despite an increased use of BP-lowering drugs, less
than half of individuals who fulfilled the criteria for
hypertension in the last survey were treated and two-
thirds of these had uncontrolled hypertension, similar
to previous results in a large multinational study.19
Strengths and limitations
The strengths of this study are its prospective, longitudinal
design with repeated surveys, use of individual data and
updated risk factors, high attendance rates, and rigorously
validated cases. The relatively low number of ICHs in the
cohort precluded detailed subgroup analyses and may have
caused inability to detect significant associations between
risk factors and ICH. We cannot exclude that we have
missed some non-hospitalized, non-fatal cases. Increased
awareness of stroke and a higher degree of utilization of
CT and MRI over time may have led to an underestima-
tion of incidence rates in the beginning of the study-period.
Non-attendees tended to be younger, more likely to be
men and less likely to be married, indicating some degree
of selection bias. Legal restrictions precluded analyses of
mortality and morbidity in non-attendees.
Conclusions
We observed a significant decrease in the ICH incidence
in women, driven by a 74% decrease in non-lobar ICH.
Incidence rates in men remained stable. Hypertension
was the most important risk factor and stronger asso-
ciated with non-lobar than lobar ICH. BP levels
decreased more steeply in women than in men. The
majority of participants with hypertension were
untreated or did not reach treatment goals. Improved
strategies for detection and treatment of hypertension
for primary prevention of ICH are needed.
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The impact of risk factor trends on intracerebral hemorrhage incidence 
over the last two decades. The Tromsø Study.  





Blood pressure was measured using an automatic device with three recordings separated by a 
1-minute interval, after a 2-minute seated rest. The mean value of the two last recordings was 
used in the present study. Weight was measured with light clothing and no footwear, and 
height was measured in standing position. BMI was calculated as weight divided by the 
square of height (kg/m2). Diabetes mellitus was self-reported in questionnaires by answering 
the question: Do you have, or have you had diabetes mellitus?  
Smoking was defined as daily current smoker (cigarettes and/or pipe and/or cigarillos/cigars).  
Alcohol consumption was categorised as teetotalism, moderate alcohol consumption (1-7 
glasses per week in women, 1-14 glasses per week in men) and high alcohol consumption (>7 
glasses per week in women, >14 glasses per week in men). However, questions concerning 
the amount of alcohol intake differed between the surveys. Because of this, analyses of the 
association between the amount of alcohol intake and risk of ICH were based on answers 
from questionnaires in the surveys performed in 1994-95 and in 2001, whereas analysis of 
trends in alcohol intake was limited to teetotalism yes/no.  
Physical activity was defined as strenuous leisure physical activity (i.e. become sweaty and 
out of breath) for at least 1 hour per week. It was self-reported in the questionnaires; in 1994-
95 and in 2001 by answering the following questions: “How has your physical activity in 
leisure time been during this last year? Think of your weekly average for the year. Time spent 
going to work count as leisure time.” “Light activity (not sweating or out of breath): and 
“Hard physical activity (sweating/out of breath)”. For both questions, response categories 
were: Hours per week: 1) None, 2) < 1 hour, 3) 1-2 hours, 4) 3 or more hours per week.  In 
2007-08 the questions were: “How often do you exercise (e.g. walking, skiing, swimming or 
work out/do sports?”, response categories: 1) Never; 2) Less than once a week; 3) Once a 
week; 4) 2-3 times a week 5) almost daily “If you exercise – how hard do you exercise in 
average?”, response categories: 1) Easy – you do not become out of breath or sweaty; 2) You 
become out of breath or sweaty; 3) Hard - you become exhausted, “For how long time do you 
exercise in average? ”,  response categories: 1) Less than 15 minutes; 2) 15-29 minutes; 3) 30-
60 minutes; 4) More than 1 hour. Use of blood pressure-lowering drugs at attendance was 
self-reported in questionnaires by answering the following question: Do you use blood 
pressure-lowering drugs?  Response categories: 1) Now, 2) Previously, but not now, 3) Never. 
Use of lipid-lowering drugs was self-reported in questionnaires by answering the following 
question: Have you during the last 14 days used lipid lowering drugs? Response categories: 1) 
Yes 2) No. In 1994-95 this question was limited to individuals aged <70 years, and 
information from additional lists of the brand names of medication used on a regular basis 
was available only for participants aged 55-74 years and selected 5-10% samples of 
participants aged 25-54 and 75-85 years. A comparison of self-reported use of LLD in 
Tromsø 6 against data from the prescription database 6 months prior to the survey showed a 
kappa value of 0.94 (95% CI 0.93-0.95), a sensitivity of 98% and a specificity of 99% (Anne 
Elise Eggen, personal communication). 
 
 
Anticoagulants were defined as use of vitamin-K antagonists, novel oral anticoagulants, 
treatment with high dose heparin or high dose low molecular weighted heparin, or 
thrombolytic treatment of indications other than IS.  
 
 
Identification of ICH events and location of ICH  
Cases were retrieved by searching for International Classification of Disease (ICD) versions 8 
and 9 diagnosis codes 430-438 and ICD 10 diagnosis codes I60-I69. In addition, systematic 
text searches were made for the words “stroke”, “ischemic stroke” and “intracerebral 
hemorrhage” in the medical records of all participants with ICD 8-10 diagnosis codes 410-
414 and I20-I25, 798/R96, R98 and 799/R99.   
All CT and MRI scans were assessed by a senior consultant in neurology (MC). 
In cases where radiologic examinations were not available (n=35), location was assessed by 
radiology reports and/or autopsy reports. In uncertain cases, the scans were additionally 
validated by a neuroradiologist (LHJ) at the University Hospital of Northern Norway, and 
consensus made in cooperation with a senior consultant in neurology (EBM).  
Location of ICH was categorised as lobar, non-lobar (deep/infratentorial), uncertain and other 
location (intraventricular or located to the corpus callosum). Uncertain ICH was further 
categorised as probably lobar, probably deep, and holohemispheric. In analyses stratified on 
location, probable lobar and probable deep ICHs were included in the analyses as lobar and 
non-lobar ICH, respectively. Cases with multiple ICHs affecting solely lobar (n=7) or non-
lobar (n=3) regions were categorised according to location. Multiple ICHs affecting both 
regions (n=1), ICH located to the corpus callosum (n=2), intraventricular ICH (n=3), 
holohemispheric ICH (n=13) and ICH with missing location (the radiologic examination and 
radiologic report were not available at the time of the retrospective assessment) (n=1) were 
included in analyses of ICH overall, but excluded from analyses stratified on location. All 




Table I. Age span and attendance rates of eligible participants, and age- and sex distribution of attendees and non-attendees, 
by year of survey. The Tromsø Study 1994-2008. 
 
                        Men                       Women 
  Attendees  Non-attendees  Attendees  Non-attendees 












 n* Mean age 
(Years) 
Tromsø 4 (1994-95) 25-97 12,865 (69.6) 46.6  5615 40.9  14,293 (74.9) 47.2  4785 44.1 
Tromsø 5 (2001) 30-89 3511 (75.7) 59.9  1125 46.0  4619 (80.8) 59.4  1098 50.8 
Tromsø 6 (2007-08) 30-87 6054 (62.9) 57.5  3571 54.4  6930 (68.4) 57.5  3207 58.1 
 

































*Continuous variables are presented as mean (SD), categorical variables are presented as % (n) 
†Systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or use of blood pressure-lowering drugs 
‡Strenuous leisure physical activity >1 hour/week  
  
Table IIa. Crude baseline characteristics of participants with and without incident intracerebral hemorrhage (ICH) stratified 
by sex. The Tromsø Study. 
  No ICH ICH 








Age, years  48.2 (13.0) 48.7 (14.1) 61.5 (11.4) 66.5 (12.0) 
Systolic blood pressure, mm Hg  136.7 (17.8) 131.5 (23.1) 154.0 (22.8) 157.4 (26.6) 
Diastolic blood pressure, mm Hg  80.6 (11.4) 76.6 (12.5) 91.1 (12.8) 86.3 (17.6) 
Hypertension† 40.6 (5386) 31.6 (4640) 80.5 (99) 80.2 (77) 
Total cholesterol, mmol/L  6.1 (1.2) 6.0 (1.4) 6.3 (1.1) 6.9 (1.3) 
Triglycerides, mmol/L  1.79 (1.2) 1.36 (0.9) 1.69 (1.1) 1.64 (0.8) 
HDL-cholesterol, mmol/L 1.34 (0.4) 1.63 (0.4) 1.40 (0.3) 1.64 (0.4) 
Body mass index kg/m2  25.9 (3.5) 25.1 (4.4) 26.6 (3.9) 25.8 (4.1) 
Diabetes mellitus  2.1 (274) 2.1 (301) 3.3 (4) 2.1 (2) 
Daily smoking  35.4 (4688) 34.4 (5059) 29.3 (36) 29.2 (28) 
Teetotalism 8.5 (1125) 16.2 (2385) 11.4 (14) 35.4 (34) 
Physical activity‡ 35.9 (4753) 24.8 (3648) 30.9 (38) 10.4 (10) 
Use of blood pressure-lowering drugs 7.0 (933) 7.0 (1024) 16.3 (20) 16.7 (16) 
Use of lipid-lowering drugs 1.9 (248) 1.2 (174) 2.4 (3) 2.1 (2) 
 
 
Table IIb. Crude baseline characteristics of participants with and without incident intracerebral hemorrhage (ICH) stratified 

























*Continuous variables are presented as mean (SD), categorical variables are presented as % (n) 
†Systolic blood pressure ≥140 mm Hg and/or diastolic blood pressure ≥90 mm Hg and/or use of blood pressure-lowering drugs 
‡Strenuous leisure physical activity >1 hour/week 
 
 No ICH ICH 






≥75 years  
N=40 
Age, years  46.8 (11.7) 79.4 (3.9) 60.3 (10.3) 79.0 (3.2) 
Male sex  48.0 (12,696) 37.2 (554) 61.5 (110) 32.5 (13) 
Systolic blood pressure, mm Hg  132.4 (19.6) 160.9 (25.1) 152.5 (23.2) 168.7 (26.1) 
Diastolic blood pressure, mm Hg  78.1 (11.8) 85.4 (15.4) 88.7 (14.4) 90.5 (18.7) 
Hypertension† 33.2 (8788) 83.0 (1238) 76.5 (137) 97.5 (39) 
Total cholesterol, mmol/L  6.0 (1.3) 6.7 (1.4) 6.7 (1.3) 6.6 (1.2) 
Triglycerides, mmol/L  1.55 (1.04) 1.74 (1.06) 1.69 (1.02) 1.58 (0.69) 
HDL-cholesterol, mmol/L 1.49 (0.41) 1.53 (0.45) 1.49 (0.37) 1.58 (0.52) 
Body mass index kg/m2  26.1 (4.3) 25.5 (4.0) 26.5 (4.1) 26.2 (3.9) 
Diabetes mellitus  1.7 (446) 8.7 (129) 2.2 (4) 5.0 (2) 
Daily smoking  36.0 (9522) 15.1 (225) 34.1 (61) 7.5 (3) 
Teetotalism 10.8 (2861) 45.5 (649) 16.2 (29) 47.5 (19) 
Physical activity‡ 31.4 (8319) 5.5 (82) 25.1 (45) 7.5 (3) 
Use of blood pressure-lowering drugs 6.2 (1638) 21.4 (319) 12.8 (23) 32.5 (13) 
Use of lipid-lowering drugs 1.5 (403) 1.3 (19) 2.8 (5) 0.0 (0) 
 
 
Table III. Hazard ratios (HR)* for incident intracerebral hemorrhage according to location, by risk factors†. The Tromsø 
Study. 
 
*Hazard ratios are expressed per SD increase in continuous variables  
†Updated at the date of attendance in the subsequent survey(s) in individuals who were still free of ICH 
‡Model 1: adjusted for age and sex. Model 2: adjusted for age, sex, SBP (except for hypertension and DBP) total cholesterol, high-
density lipoprotein cholesterol (HDL-cholesterol) (except for triglycerides), body mass index (BMI), diabetes mellitus (DM), daily 
smoking, teetotalism and physical activity 
§Systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg and/or use of blood pressure-lowering drugs 
|| Strenuous leisure physical activity >1 hour/week 






HR (95% CI) 
Model 1‡ 
HR (95% CI) 
Model 2‡ 
HR (95% CI) 
Model 1‡ 
HR (95% CI) 
Model 2‡ 
Age  2.59 (2.09-3.22) 2.22 (1.71-2.89)  2.49 (2.06-3.01) 1.80 (1.42-2.29)  
Male sex 1.37 (0.90-2.09) 1.37 (0.86-2.18) 2.06 (1.40-3.02) 2.42 (1.57-3.73) 
Systolic blood pressure  1.28 (1.04-1.57) 1.29 (1.05-1.59) 1.82 (1.53-2.16) 1.82 (1.52-2.17) 
Diastolic blood pressure 1.22 (1.01-1.47) 1.22 (1.01-1.48) 1.85 (1.61-2.13) 1.89 (1.64-2.19) 
Hypertension§ 1.89 (1.12-3.18) 1.91 (1.12-3.25) 4.71 (2.71-8.19) 5.08 (2.86-9.01) 
Total cholesterol 1.17 (0.95-1.44) 1.18 (0.95-1.45) 1.26 (1.04-1.51) 1.14 (0.94-1.39) 
HDL-cholesterol 0.91 (0.73-1.14) 0.86 (0.68-1.09) 1.21 (0.93-1.36) 1.07 (0.88-1.31) 
Triglycerides  1.08 (0.89-1.30) 1.04 (0.84-1.29) 1.03 (0.86-1.24) 0.96 (0.78-1.18) 
Body mass index  0.92 (0.74-1.15) 0.84 (0.66-1.07) 1.02 (0.84-1.24) 0.90 (0.72-1.12) 
Diabetes mellitus 0.81 (0.25-2.57) 0.82 (0.26-2.63) 0.44 (0.11-1.80) 0.46 (0.11-1.87) 
Daily smoking 1.15 (0.72-1.84) 1.06 (0.65-1.74) 1.05 (0.69-1.60) 1.10 (0.71-1.71) 
Teetotalism 1.16 (0.69-1.96) 1.11 (0.65-1.90) 1.16 (0.72-1.88) 1.13 (0.69-1.85) 
Physical activity|| 0.85 (0.50-1.46) 0.89 (0.52-1.53) 1.08 (0.69-1.68) 1.11 (0.71-1.75) 
 
 
Table IVa. Cardiovascular risk factor levels in men by survey year. The Tromsø Study. 
 
 
Continuous variables are age- adjusted means with 95% CI. Categorical variables are age-adjusted prevalence (%) with 95% CI 
*Test for linear trend 
†Systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg and/or use of blood pressure-lowering drugs 
‡ Strenuous leisure physical activity ≥1 hour per week 
§ Use of antiplatelets and/or anticoagulants 










Relative change from 
1994 to 2008 (%) 
P-value* 
Age 46.9 (46.7-47.2) 54.0 (53.6-54.5) 58.8 (58.3-59.2)   
Systolic blood pressure, mm Hg 140.5 (140.1-140.8) 136.0 (135.1-136.9) 136.1 (135.2-136.9) -3 <0.001 
Diastolic blood pressure, mm Hg 82.0 (81.8-82.2) 80.0 (79.5-80.6) 80.0 (79.5-80.5) -2 <0.001 
Hypertension† 49.1 (48.1-49.8) 43.5 (40.7-46.3) 47.1 (44.4-49.7) -4 <0.001 
Total cholesterol, mmol/L 6.23 (6.21-6.25) 5.90 (5.84-5.96) 5.41 (5.36-5.47) -13 <0.001 
HDL-cholesterol, mmol/L 1.37 (1.36-1.38) 1.30 (1.29-1.32) 1.33 (1.32-1.35) -3 <0.001 
Triglycerides, mmol/L 1.77 (1.75-1.79) 1.72 (1.66-1.78) 1.71(1.65-1.76) -4 <0.001 
BMI, kg/m2 25.8 (25.7-25.8) 26.6 (26.5-26.7) 27.1 (26.9-27.2) 5 <0.001 
Diabetes mellitus 1.9 (1.6-2.2) 2.6 (2.0-3.5) 4.2 (3.2-5.5) 123 <0.001 
Daily smoking 36.0 (35.1-37.0) 31.2 (29.0-33.5) 21.6 (20.0-23.4) -40 <0.001 
Teetotalism 9.6 (9.0-10.1) 6.8 (5.8-7.9) 6.5 (5.6-7.5) -32 <0.001 
Physical activity‡ 31.5 (30.6-32.4) 44.8 (41.7-47.8) 46.9 (44.1-49.8) 49 <0.001 
Use of blood pressure lowering drugs 6.2 (5.8-6.7) 11.1 (9.5-13.0) 15.6 (13.5-17.9) 150 <0.001 
Use of lipid lowering drugs 1.1 (0.9-1.3) 7.6 (5.4-10.5) 11.4 (8.4-15.5) 970 <0.001 
Use of antithrombotic drugs§,|| 3.8 (3.3-4.3) 6.6 (5.2-8.4) 9.2 (7.3-11.5) 144 <0.001 
    Use of antiplatelets|| 3.3 (2.9-3.8) 6.1 (4.7-7.9) 8.0 (6.2-10.2) 139 <0.001 
    Use of anticoagulants|| 0.8 (0.6-1.0) 1.0 (0.6-1.7) 1.5 (0.9-0.2.7) 102 <0.001 
 
 
Table IVb. Cardiovascular risk factor levels in women by survey year. The Tromsø Study. 
 
Continuous variables are age-adjusted means with 95% CI. Categorical variables are age-adjusted prevalence (%) with 95% CI 
*Test for linear trend 
†Systolic BP ≥140 mm Hg and/or diastolic BP ≥90 mm Hg and/or use of blood pressure-lowering drugs 
‡ Strenuous leisure physical activity ≥1 hour per week 
§ Use of antiplatelets and/or anticoagulants  










Relative change from 
1994 to 2008 (%) 
P-value* 
Age 47.8 (47.5-48.0) 54.6 (54.1-55.1) 58.8 (58.3-59.3)   
Systolic blood pressure, mm Hg 138.2 (137.7-138.5) 131.8 (131.0-132.7) 131.0 (130.2-131.8) -5 <0.001 
Diastolic blood pressure, mm Hg 78.8 (78.6-79-0) 77.3 (76.8-77.8) 73.8 (73.3-74.3) -6 <0.001 
Hypertension† 39.5 (38.4-40.6) 33.3 (30.8-35.8) 36.2 (33.7-38.7) -9 <0.001 
Total cholesterol, mmol/L 6.36 (6.34-6.38) 6.02 (5.97-6.07) 5.52 (5.47-5.57) -13 <0.001 
HDL-cholesterol, mmol/L 1.65 (1.64-1.66) 1.54 (1.52-1.55) 1.63 (1.61-1.65) -1 <0.001 
Triglycerides, mmol/L 1.43 (1.42-1.45) 1.38 (1.34-1.42) 1.36 (1.32-1.40) -5 <0.001 
BMI, kg/m2 25.3 (25.2-25.4) 26.1 (25.9-26.2) 26.2 (26.0-26.3) 3 <0.001 
Diabetes mellitus 1.8 (1.5-2.0) 2.2 (1.6-2.9) 3.2 (2.4-4.2) 80 <0.001 
Daily smoking 33.2 (32.3-34.1) 30.8 (28.9-32.7) 23.7 (22.1-25.4) -29 <0.001 
Teetotalism 18.2 (17.5-18.9) 11.1 (10.0-12.4) 10.3 (9.3-11.4) -43 <0.001 
Physical activity‡ 16.9 (16.2-17.6) 30.5 (27.7-33.5) 42.1 (39.2-45.2) 149 <0.001 
Use of blood pressure lowering drugs 5.6 (5.2-6.0) 10.1 (8.7-11.8) 15.0 (13.1-17.1) 170 <0.001 
Use of lipid lowering drugs 0.6 (0.5-0.8) 4.8 (3.3-7.1) 7.9 (5.4-11.3) 1134 <0.001 
Use of antithrombotic drugs§,|| 1.5 (1.2-1.8) 2.9 (2.1-4.1) 4.2 (3.0-5.9) 184 <0.001 
    Use of antiplatelets|| 1.3 (1.1-1.6) 2.7 (1.8-3.9) 3.7 (2.6-5.4) 188 <0.001 
    Use of anticoagulants|| 0.3 (0.2-0.4) 0.4 (0.2-0.8) 0.5 (0.2-1.2) 105 <0.001 
 
 
Table Va. Odds ratios (OR) for use of antithrombotic drugs at time of first-ever intracerebral hemorrhage by time period. The 
Tromsø Study. 
 1994-2013 1994-2001 2002-2007 2008-2013 P for trend*  
n=219 n=59 n=72 n=88  
Antithrombotic drugs†‡ 110 (50) 23 (39) 37 (51) 50 (57)  
OR (95% CI) §  1 1.53 (0.73-3.22) 1.84 (0.90-3.76) 0.10 
Antiplatelets† 61 (28) 12 (20) 19 (26) 30 (34)  
OR (95% CI) §  1 1.29 (0.55-2.98) 1.80 (0.82-3.96) 0.13 
Anticoagulants† 55 (25) 11 (19) 18 (25) 26 (30)  
OR (95% CI) §  1 1.34 (0.57-3.17) 1.65 (0.73-3.76) 0.23 
 
*P-value for linear trend 
†Numbers are n (%)  
‡Antiplatelets and/or anticoagulants 




Table Vb. Odds ratios (OR) for use of antithrombotic drugs in men and women at time of intracerebral hemorrhage (ICH) by 
time period. The Tromsø Study. 
 
*P-value for linear trend 
†Numbers are n (%)  
‡Antiplatelets and/or anticoagulants 
§Adjusted for age 
  
 1994-2013 1994-2001 2002-2007 2008-2013 P for trend* 
Men n=123 n=30 n=39 n=54  
Antithrombotic drugs†‡ 72 (59) 15 (50) 23 (59) 34 (63)  
OR (95% CI)§  1 1.13 (0.41-3.13) 1.60 (0.60-4.23) 0.32 
    Antiplatelets† 41 (33) 9 (30) 12 (31) 20 (37)  
    OR (95% CI)§  1 0.92 (0.32-2.62) 1.24 (0.47-3.28) 0.66 
    Anticoagulants† 35 (28) 6 (20) 11 (28) 18 (33)  
    OR (95% CI)§  1 1.44 (0.46-4.51) 1.83 (0.63-5.32) 0.26 
Women n=96 n=29 n=33 n=34  
Antithrombotic drugs†‡ 38 (40) 8 (28) 14 (42) 16 (47)  
OR (95% CI)§  1 2.12 (0.70-6.39) 2.24 (0.76-6.60) 0.16 
    Antiplatelets† 20 (21) 3 (10) 7 (21) 10 (29)  
    OR (95% CI)§  1 2.47 (0.55-11.0) 3.51 (0.83-14.8) 0.09 
    Anticoagulants† 20 (21) 5 (17) 7 (21) 8 (24)  
    OR (95% CI)§  1 1.34 (0.37-4.84) 1.42 (0.41-4.94) 0.60 
 
 

















*Adjusted to age and sex by the direct method using the European standard population of 2013 as reference  






 Crude IR (95% CI) Adjusted IR* (95% CI) IRR (95% CI)† 
All 0.55 (0.48-0.63) 0.60 (0.52-0.68) 0.81 (0.52-1.27) 
      Men 0.66 (0.55-0.79) 0.80 (0.64-0.96) 1.27 (0.69-2.31) 
      Women 0.45 (0.37-0.56) 0.46 (0.36-0.55) 0.46 (0.23-0.90) 
      <75 years 0.31 (0.25-0.37) 0.30 (0.24-0.36) 0.89 (0.48-1.66) 
      ≥75 years 2.45 (2.04-2.96) 2.50 (2.02-2.98) 0.78 (0.41-1.48) 
Lobar ICH 0.22 (0.18-0.27) 0.24 (0.19-0.29) 1.36 (0.67-2.79) 
      Men 0.24 (0.18-0.33) 0.30 (0.21-0.40) 1.58 (0.58-4.29)   
      Women  0.20 (0.15-0.28) 0.20 (0.14-0.26) 1.17 (0.42-3.26) 
Non-lobar ICH 0.28 (0.23-0.34) 0.31 (0.25-0.36) 0.71 (0.38-1.33) 
      Men 0.36 (0.28-0.46) 0.44 (0.32-0.56) 1.34 (0.60-3.02) 























































































Do you have, or have you had:    
Are you being treated for:         
Do you use:    
Do you have get or discomfort in the chest when:
If you get pain or discomfort in the chest when
walking, do you usually:
If you stop or slow down, does the pain 
disappear:
If you get pain in the calf, then:        
Do you usually have:  
Exercise and physical exertion in leisure time.
If your activity varies much, for example 
between summer and winter, then give an average.
The question refers only to the last twelve months:
Tick “Yes” beside the description that fits best:
(include walking or cycling to place of work,       
Sunday walk/stroll, etc.)
(note: duration of activity at least 4 hours a week)
During the last year, have you had:   
Tick “Yes” beside description that fits best      
(e.g. fishing season, harvest)                         
Can you usually come home from work:          
If you smoke a pipe, how many packs of tobacco
(50 grams) do you smoke per week?
Do you smoke tobacco products other than       
cigarettes daily?
If “Yes”, how long is it since you stopped: 
If you do not smoke cigarettes at present, then:
(hand-rolled or factory made)                  
If the answer was “Yes” in the previous question,
then:
(hand-rolled or factory made)                  
(e.g. office work, watchmaker, light manual work)
(e.g. shop assistant, light industrial work, teaching)
(e.g. postman, heavy industrial work, construction)
(e.g. forestry, heavy farm-work, heavy construction)
A heart attack? ................................
Angina pectoris (heart cramp)? ...............
Any other heart disease? .....................
Hardened arteries in the legs? ...............
A cerebral stroke? .............................
Diabetes? .......................................
High blood pressure? ..........................
Nitroglycerine? .................................
Walking up hills or stairs, or walking fast on level ground?
Walking at normal pace at level ground?
Stop? .......................................
Slow down? .................................
Carry on at the same pace? ..............
Within 10 minutes? ........................
After more than 10 minutes? .............
Walking? .......................................
Resting? ........................................
Does the pain increase when you walk
Does the pain disappear when you stop? .....
Cough in the morning? .........................
Phlegm chest in the morning? .................
Walking, cycling, or other forms of         
exercise at least 4 hours a week? .........
Participation in recreational sports,       
heavy gardening, etc.? ......................
Participation in hard training or sports 
competitions, regularly several times a week? Have one or more of your parents or sistersor brothers had a heart attack (heart wound)
or angina pectoris (heart cramp)?
Are two or more of your grandparents of 
Finnish origin? ................................
Do you receive a complete or partial disability pension?
Are you at present on sick leave, or receiving
rehabilitation allowance? ......................
Have you within the last 12 months received
unemployment benefit? ........................
Is housekeeping your main occupation? ......
During the last 12 months, have you had
to move for work reasons? ...................
Heavy manual labour? ......................
Work that requires a lot of walking ..........
Mostly sedentary work? ....................
Are there periods during which your working
days are longer than usual? ..................
Every weekend? ................................
Every day? .....................................
Do you usually work shifts or at nights?       
Give the average number of packs per week.
A pipe? ........................................
Cigars or cigarillos? ..........................
How many cigarettes do you smoke, or did you, 
smoke daily? Give number of cigarettes per day
smoked daily? ..............................
How many years altogether have you
More than 5  years? ......................
1 to 5 years? ..............................
3 months to 1 year? ......................
Less than 3 months? ......................
Have you previously smoked cigarettes daily?
Do you smoke cigarettes daily? ...............








No. of tobacco  
packs
No. of cigarettes
No. of years   
faster or uphill? ...............................
Activity? ....................................
Reading, watching TV, or other sedentary
Work that requires a lot of walking and lifting?
Are two or more of your grandparents of   
Sami origin? ...................................
Yes
Do you get pain in the calf while:           
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Do you have, or have you had:    
Are you being treated for:         
Do you use:    
Do you have get or discomfort in the chest when:
If you get pain or discomfort in the chest when
walking, do you usually:
If you stop or slow down, does the pain 
disappear:
If you get pain in the calf, then:        
Do you usually have:  
Exercise and physical exertion in leisure time.
If your activity varies much, for example 
between summer and winter, then give an average.
The question refers only to the last twelve months:
Tick “Yes” beside the description that fits best:
(include walking or cycling to place of work,       
Sunday walk/stroll, etc.)
(note: duration of activity at least 4 hours a week)
During the last year, have you had:   
Tick “Yes” beside description that fits best      
(e.g. fishing season, harvest)                         
Can you usually come home from work:          
If you smoke a pipe, how many packs of tobacco
(50 grams) do you smoke per week?
Do you smoke tobacco products other than       
cigarettes daily?
If “Yes”, how long is it since you stopped: 
If you do not smoke cigarettes at present, then:
(hand-rolled or factory made)                  
If the answer was “Yes” in the previous question,
then:
(hand-rolled or factory made)                  
(e.g. office work, watchmaker, light manual work)
(e.g. shop assistant, light industrial work, teaching)
(e.g. postman, heavy industrial work, construction)
(e.g. forestry, heavy farm-work, heavy construction)
A heart attack? ................................
Angina pectoris (heart cramp)? ...............
Any other heart disease? .....................
Hardened arteries in the legs? ...............
A cerebral stroke? .............................
Diabetes? .......................................
High blood pressure? ..........................
Nitroglycerine? .................................
Walking up hills or stairs, or walking fast on level ground?
Walking at normal pace at level ground?
Stop? .......................................
Slow down? .................................
Carry on at the same pace? ..............
Within 10 minutes? ........................
After more than 10 minutes? .............
Walking? .......................................
Resting? ........................................
Does the pain increase when you walk
Does the pain disappear when you stop? .....
Cough in the morning? .........................
Phlegm chest in the morning? .................
Walking, cycling, or other forms of         
exercise at least 4 hours a week? .........
Participation in recreational sports,       
heavy gardening, etc.? ......................
Participation in hard training or sports 
competitions, regularly several times a week? Have one or more of your parents or sistersor brothers had a heart attack (heart wound)
or angina pectoris (heart cramp)?
Are two or more of your grandparents of 
Finnish origin? ................................
Do you receive a complete or partial disability pension?
Are you at present on sick leave, or receiving
rehabilitation allowance? ......................
Have you within the last 12 months received
unemployment benefit? ........................
Is housekeeping your main occupation? ......
During the last 12 months, have you had
to move for work reasons? ...................
Heavy manual labour? ......................
Work that requires a lot of walking ..........
Mostly sedentary work? ....................
Are there periods during which your working
days are longer than usual? ..................
Every weekend? ................................
Every day? .....................................
Do you usually work shifts or at nights?       
Give the average number of packs per week.
A pipe? ........................................
Cigars or cigarillos? ..........................
How many cigarettes do you smoke, or did you, 
smoke daily? Give number of cigarettes per day
smoked daily? ..............................
How many years altogether have you
More than 5  years? ......................
1 to 5 years? ..............................
3 months to 1 year? ......................
Less than 3 months? ......................
Have you previously smoked cigarettes daily?
Do you smoke cigarettes daily? ...............








No. of tobacco  
packs
No. of cigarettes
No. of years   
faster or uphill? ...............................
Activity? ....................................
Reading, watching TV, or other sedentary
Work that requires a lot of walking and lifting?
Are two or more of your grandparents of   
Sami origin? ...................................
Yes
Do you get pain in the calf while:           
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Together with the invitation to attend you received a questionnaire from the National Mass 
Radiography Service. You delivered this questionnaire at the examination.
Cardiovascular diseases are, however, a complex group of diseases. The causes are still partly 
unknown. In Tromsø we are therefore trying to obtain a more complete description of factors which 
may be of importance for the course of these diseases, such as diet, psychological pressure (“stress”), 
social conditions, and occurrence of disease in relatives. We hope you will take the trouble to 
complete this questionnaire as well, an return it to the Tromsø Board of Health in the enclosed 
envelope.
All information in connection with the mass x-ray examination will be treated as strictly 
confidential.
ADDITIONAL QUESTIONS FOR PERSONS ATTENDING 
THE MASS X-RAY EXAMINATION IN TROMSØ
What type of bread do you usually eat?
Tick the most appropriate box.
What type of butter of margarine do 
you usually eat?
Tick the most appropriate box.
What type of milk do you usually drink?  
Tick the most appropriate box.
How many slices of bread do you  
usually eat daily?
Tick the most appropriate box.
The drawings below show cubes of butter of margarine (actual size). 
Tick the box above the cube which best resembles the amount you spread on a slice of bread.
White bread (e.g. French bread) .......................
Ordinary bread (light texture) ...............
Less than two slices ....................................
2-6 slices .....................................................
7-12 slices ...................................................
13 or more slices ........................................
Full cream milk: ordinary type or curdled ......
Do not drink milk .......................................





Do not use butter or margarine .............
YES YES 
YES YES 
Whole meal (brown) bread ...................
Home-made (brown) bread ..................
Soft margarine spread ..............................
Skimmed milk: ordinary type or curdled.........
If in doubt, try buttering a slice.                 
YOUR OWN DIET
LABEL
Are you a teetotaller?
If “No”,
How often do you eat fruit or 
vegetables?
Tick the most appropriate box.      
How many cups of coffee do you 
usually drink daily?
Tick the most appropriate box.      
How many glasses/cups of milk do 
you usually drink daily?
Tick the most appropriate box.      
Approximately how often during the 
last 12 months have you drunk so 
much wine, beer or spirits that you 
got drunk?
Tick the most appropriate box.      
How often does your main meal 
consist of fish or fish dishes?







 How often do you usually drink beer?
Tick the most appropriate box.          
 How often do you usually drink wine?
 How often do you usually drink spirits?
Tick the most appropriate box.          
Tick the most appropriate box.            
How many times a month do you eat 
boiled or fried sausages, meat balls, 
other processed meat, etc.?
Tick the most appropriate box.      
Do not drink milk, or drink less 
than 1 glass/cup ................................. 
1-2 glasses/cups..................................
3-4 glasses/cups.................................
5 or more glasses/cups...... ...............




9 or more cups...................................
Never or just a few times a year.......
Once or twice a month.....................
About once a week...........................
2-3 times a week................................
More or less daily...............................
Have never been drunk, or have not been 
drunk during the last year .............................
A few times during the last year .............
Once or twice a month ..................................
Once or twice a week  ....................................
3 or more times a week ...........................
Less than once a week..............................
Once or twice a week...............................
3-4 times a week......................................
5-6 times a week......................................
7 times a week...........................................
Never eat fruit or vegetables.....................
A few time a year........................................
Once or twice a month..............................
About once a week....................................
2-3 times a week.........................................
More or less daily........................................
Never or less than once  
a month......................................................
Once or twice a month.............................
3-4 times a month (up to once a 
week)...........................................................
5-8 times a month (up to twice a 
week)...........................................................
More than 8 times a month (more 
than twice a week).....................................
Never or just a few times a year.......
Once or twice a month.....................
About once a week...........................
2-3 times a week................................
More or less daily...............................
Never or just a few times a year.......
Once or twice a month.....................
About once a week...........................
2-3 times a week................................
More or less daily...............................
Have you had a peptic ulcer?....................
Do you often have a gnawing pain in 
the upper part of your stomach? ............
Do you suffer much from heartburn or 
regurgitation of gastric juices? ................
Do you suffer much from wind and 
rumbling in your stomach? .....................
Do you often get cramps in your stomach?
Have you ever had your large intestine 
x-rayed? ......................................................
Have you ever had gallstones? .................
Have you had kidney stones or stones 
in the urinary tract? .................................
If yes, how many times? .........................
and, when did you have the last attack? ...
Have you ever had cancer? .....................
If yes, in what year was the disease 
discovered? ..............................................
Have you taken iron tablets during 
the past 14 days? ....................................
Have you had any infectious disease 
during the past 14 days? (influenza, 
common cold, vomiting, diarrhoea, etc.)
If yes, did you suffer from stiff joints 
in the mornings lasting more than 
30 minutes? ...........................................
Have you suffered from pains lasting 
more than 3 months, in the joints 
listed below during the last 3 years?
Have you suffered from morning 
stiffness in your back lasting more 
than 30 minutes? ..................................
Have you suffered from back pain 
during the past 12 months lasting for 
more than 4 weeks? ..............................
If yes, did the back pain improve if 
you exercised? .......................................
Have you ever had arthritis? (chronic 
rheumatoid arthritis) ...........................
Have you been on sick leave, or been unable 
to work due to allergic eczema on your 
hands at any time during the past 3 years? ....
Have you had allergy-induced eczema on 
your hands during the last 12 months? .....
Do you have, or have had you the skin 
disease psoriasis? .......................................
Have you made any changes in your diet 
during the last 5 years as regards the following 
food items?
Tick each item in the appropriate 
box.
OWN ILLNESSES PAST AND PRESENT
additional questions for persons Have you ever had?
Ordinary margarine or butter
Skimmed milk ........................
Lean meat ...............................
Full cream milk ......................
Soya margarine (soft) ............
Fatty meat ..............................
Sudden paralysis or numbness on one 
side of your face or body, in your 
hand or foot ...........................................
Sudden loss of ability to speak .............
Sudden loss of eye sight, complete or 
partial, or sudden onset of double vision
Knees .................................................
Elbows ...............................................


















How often do you take painkillers such 
as Globoid, Novid, Dispril, Albyl, etc.?
Tick the most appropriate box.
Have you changed the amount of physical 
exercise you take in leisure time during 
the last five years?
Tick the most appropriate box.
Have you used such painkillers during 
the last 14 days?.........................................
ILLNESS IN PARENTS AND SIBLINGS 
Have any of these relatives had:     
SOCIAL CONDITIONS AND 
PSYCHOLOGICAL PRESSURE (“STRESS”) Have you had difficulty sleeping in the 
past couple of weeks?
Tick the most appropriate box.
Have you felt unhappy and depressed 
during the last couple of weeks?
Tick the most appropriate box.
Have you felt unable to cope with your 
difficulties during the last couple of weeks?
Tick the most appropriate box.
Do you suffer from sleeplessness?
If yes, at what time of the year do you 
suffer from sleeplessness?
Tick the most appropriate box.
How was your family's financial 
situation when you were growing up?
Tick the most appropriate box.
How many years of education have you 
had? (including primary and secondary 
schools)
Cerebral stroke or brain haemorrhage .........
Diabetes ...........................................................
Arthritis (chronic rheumatoid arthritis)..........
Cancer ..............................................................
Kidney stones or stone in urinary tract........
Psoriasis ............................................................
Peptic ulcer ......................................................
None of the above mentioned illnesses ......
Not at all ....................................................
No more than usual .................................
Rather more than usual ............................





No particular time .................................
Especially during the polar night .........
Especially during the midnight  sun season
Especially in spring and autumn ..........
Difficult to fall asleep at night? .............
Wake up a lot during the night? ..........
Wake up very early in the morning? ...
Not at all ...................................................
No more than usual .................................
Rather more than usual ...........................
Much more than usual ............................
Not at all ...................................................
No more than usual ................................
Rather more than usual ...........................
Much more than usual ............................
As before ....................................................
More than before ......................................
Less than before .........................................
1-3 times a week ................................
1-3 times a month ............................
Seldom or never ................................







 no. of  
years 
father sister brother
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THE TROMSØ HEALTH SURVEY        
(Applies only to the person to whom the letter is addressed.) 
The health survey is coming now to your district. 
You find the time and place for attendance below.
You will find an orientation on the survey in the 
enclosed brochure.
We would like you to fill in the form on the back 
and take it with you to the survey.
We ask those possibly not attending to report their 
absence in the attached absence report. 
Yours sincerely
MUNICIPAL HEALTH AUTHORITY OF TROMSØ
COUNTY DOCTOR OF TROMS       UNIVERSITY OF TROMSØ
NATIONAL HEALTH SCREENING SERVICE
Birth date          Personal number                     Municipality                                                    Circuit number
Meeting place             Gender      Day and date                Time                  
First 
letter of 
last name   
MEASUREMENT 2 MEASUREMENT 3 MEASUREMENT 1 
  HEIGHT                WEIGHT  
  
Have one or more of your parents or siblings 
had a heart attack (heart wound) or angina 
pectoris (heart cramp)? …............................
Do you have, or have you had:    
Are you being treated for:             
Do you use:    
Do you get pain or discomfort in the chest when:
If you get pain or discomfort in the chest when
walking, do you usually:
If you stop or slow down, does the pain             
disappear:
Do you usually have:  
Exercise and physical exertion in leisure time.
If your activity varies much, for example between 
summer and winter, then give an average.     
The question refers only to the last year:
How often do you use salted meat 
or salted fish for dinner?
How often do you add extra salt to                  
your dinner?
What type of margarine or butter do you           
usually use on your bread?
What type of cooking fat do you 
normally use in your household?                            
If this survey suggests that you need a further   
medical examination, which general 
practitioner do you wish to be referred to?
During the last year, have you had:
What type of coffee do you usually drink daily?   
How many cups of coffee do you usually    
drink daily?
If you smoke a pipe, how many packs of             
tobacco (50 grams) do you smoke 
per week?
Do you smoke anything else other than cigarettes daily?
To be answered by those who smoke or
who have smoked previously:
If you answered “Yes”, how long is it since         
you stopped:
If you do not smoke cigarettes at present, 
then:
If the answer is “YES”, then:                                     
A heart attack? ................................................
Angina pectoris (heart cramp)?........................
A cerebral stroke? ...........................................
Diabetes? ........................................................
Less than 3 months? …....................................
3 months to 1 year? .........................................
1 -5 years? .......................................................
More than 5 years? ..........................................
How many years altogether have you
smoked daily? …...............................................
How many cigarettes do you smoke or 
did you smoke daily? …....................................
Give number of cigarettes per day ....................
(hand-rolled + factory made)
Coarsely ground coffee for brewing (boiled) ......
Finely ground filter coffee .................................
Instant coffee ....................................................
Caffeine free coffee ..........................................
Do not drink coffee ...........................................
Have you within the last 12 months received 
unemployment benefit? ….....................................
Are you at present on sick leave, or 
receiving rehabilitation benefit? .............................
Do you receive a complete or partial disability pension?
Do you usually work shifts or at
night?.....................................................................
Reading, watching TV, or other sedentary 
activity? .............................................................
Walking, cycling or other forms of 
exercise at least 4 hours a week? .....................
(include walking or cycling to
work, Sunday walk/stroll, etc.)
Participation in recreational sports, heavy
gardening, etc.? ................................................
(note: duration of activity at least 
4 hours a week)
Participation in hard training or sports 
competitions, regularly several times a week?...
Walking up hills or stairs, or walking 
fast on level ground? .......................................
Walking at normal pace at level ground?..........
Never or less than once a month ….................
Once a week or less ........................................
Twice a week or less .......................................
More than twice a week....................................
Do not use margarine or butter on bread …......
Butter ...............................................................
Hard Margarine ….............................................
Soft (soya) margarine spread............................
Butter/ margarine mixtures ...............................
Tick the most appropriate box.         
Tick the most appropriate box.         
Tick the most appropriate box.                   
Tick the most appropriate box.
                                                              
Tick the most appropriate box.         
Tick the most appropriate box.                   
Tick the most appropriate box.         




Carry on at the same pace? …........................
After less than 10 minutes? ….........................
After more than 10 minutes? ….......................
Cough in the morning? ....................................
Phlegm chest in the morning? ….....................
Rarely or never ................................................
Sometimes or often .........................................
Always or nearly always …...............................
Butter or hard margarine ..................................
Soft (soya) margarine or oil …..........................
Butter/ margarine mixtures …...........................
Do you smoke daily at present? …....................
Do you smoke cigarettes daily? …....................
(hand-rolled or factory made)
Have you previously smoked cigarettes daily?...
Cigars or cigarillos/cheroots? ….........................
A pipe? …...........................................................
Give the average number of packs per
week .................................................................
Do not drink coffee, or less than
one cup ............................................................
1 -4 cups ..........................................................
5 -8 cups ..........................................................
9 or more cups .................................................
Mostly sedentary work? ....................................
(e.g. office work, watchmaker, light manual work)
Work that requires a lot of walking? ..................
(e.g. shop assistant, light industrial work, teaching)
Work that requires a lot of walking and lifting?...
(e.g. postman, heavy industrial work, construction)
Heavy manual labour? ......................................
(e.g. forestry, heavy farm-work, heavy construction)
Is house-keeping your main occupation? ...
     
Has any one in your household (other than
yourself) been called in to a doctor for 
further medical examination after the 
previous cardiovascular disease survey? ….....
Write the doctor's name here?
No particular doctor
Yes No 











Cigarettes   
  Tobacco
   packets
Don't write here 
   FAMILY
         SYMPTOMS      
         EXERCISE       
         OWN ILLNESSES      
         SMOKING      
     COFFEE    
     EMPLOYMENT    
       FOLLOW-UP EXAMINATION       
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Cardiovascular heart  and circulatory diseases, on 
which the surveys of the 1974 and 1979-80 focused, 
are a very varied category of diseases whose causes 
are still partly unknown. In Tromsø we are therefore 
trying to obtain a more complete description of factors 
which may be important for the course of these 
diseases, such as diet, psychological pressure, 
“stress”, social conditions and the occurrence of 
disease in relatives. Such a description is also 
important in the search of factors that contribute to 
cancer, a group of diseases which also we try to 
combat in the coming years.
When you were called in, you received a 
questionnaire which you handed in at the survey. The 
present questionnaire asks for further information 
about your health and includes questions on various 
diseases and physical and psychological complaints. 
We have included questions on pregnancy, birth and 
menstruation.
How is your health?
Tick the box where “Yes” is appropriate.  
In addition, we are interested in obtaining information 
on the public use of medical health services in order to 
find out how to improve the health service.
We hope that you will take the trouble to fill in yet 
another questionnaire and return it to “Tromsø Board of 
Health” in the enclosed envelope. All information will be 
treated with strict confidentiality If you have any 
comments regarding the survey, you may write them 
down in the space provided on the last page of the 
questionnaire.
Yours sincerely
   Tromsø Board of Health       Department of medicine
          University of Tromsø
ADDITIONAL QUESTIONS TO 
THE TROMSØ HEALTH 
SURVEY 1986-87.
Do you have, or have you had:
Tick “Yes” or “No” for each question.          
How many times in the last 6 months have  
you had infections like a cold, influenza (flu)
diarrhoea/vomiting, or similar illnesses? .....
Have you had one of these infections in 
the past 14 days? ........................................
Have you during the last year used tablets/sprays 
or had injections for asthma or allergies?.................
Have you used any of the following 
medicines in the past 14 days?
Tick if none of the relatives have or have 
had any of those illnesses .......................
Tick for the relatives who have or have ever 
had any of the following illnesses:
Very bad ...................................................
Bad ...........................................................
Neither good nor bad, “middling” .............
Good ........................................................
Excellent ..................................................







Your appendix removed .........................
An operation for a stomach ulcer ...........









Gastric or duodenal ulcer .......................
Asthma ...................................................
Painkillers ................................................
Antipyretic drugs (to reduce fever) ..........
Eczema ointment ....................................







  GENERAL STATE OF HEALTH   ILLNESSES IN PARENTS OR SIBLINGS
   ILLNESSES 
    INFECTIONS 
   MEDICINES 
Yes
Yes  No 
 No Yes
Number 
Yes  No 
Yes  No 
Yes  No 
mother father brother Sister
   FISH  
   BREAKFAST 
   ALCOHOL  
   FRUIT 
    DIET 
CONTACT DUE TO OWN HEALTH OR ILLNESS    DINNER 
Yes  No   
Yes  No   
















How many visits have you made during the 
past year due to your own health or illness?
How often do you eat meat for dinner?
Tick the box where “Yes” is appropriate.
Number of hospital admissions in the past year
To a GP (general practitioner) ................
To a specialist (not hospital) ..................
Emergency GP .......................................
Medical officer at work ...........................
Physiotherapist .......................................
Chiropractor ............................................
Alternative practitioner  
(homoeopath, foot zone therapist, etc.) ..
Hospital outpatient department ..............
How many slices of bread do you usually eat 
daily?
Tick the box where “Yes” is appropriate.
What type of milk do you usually drink?
Tick the box where “Yes” is appropriate.
How many glasses/cups of milk do you usually 
drink daily?
Less than 2 slices ..................................
2 - 4 slices ..............................................
5 – 6 slices .............................................
7 – 12 slices ...........................................
13 or more slices ....................................
Do not drink milk .....................................
Full cream milk (ordinary or curdled) ......
Semi-skimmed milk .................................
Skimmed milk (ordinary or curdled) ........
Less than 1 glass/cup .............................
1 – 2 glasses/cups ..................................
3 – 4 glasses/cups ..................................
5 or more glasses/cups ..........................
How often do you eat cod/pollock or other 
lean fish for dinner or in a sandwich?
Tick the box where “Yes” is appropriate.
How often do you eat fatty fish such as herring, 
halibut, red fish, mackerel, salmon or trout for 
dinner or in a sandwich?
Tick the box where “Yes” is appropriate.
Do you take cod liver oil regularly?
Tick the box where “Yes” is appropriate.
Do you usually eat breakfast daily? ............
Less than once a week ............................
Once a week ............................................
Twice a week ...........................................
3 or more times a week ...........................
Less than once a week ............................
Once a week ............................................
Twice a week ...........................................
3 or more times a week ...........................
No ............................................................
During polar night ....................................
All year .....................................................
Not at all the past year ...........................
A few times .............................................
Once or twice a month ...........................
3 or more times a week ..........................
How often do you use fat like butter, 
margarine, mayonnaise, etc. with your 
dinner?
Tick the box where “Yes” is appropriate.
Do you usually eat vegetables with your 
dinner? .......................................................
How often do you usually eat fruit?
Tick the box where “Yes” is appropriate.
Are you a teetotaller?
If not,
 - How often do you usually drink beer?
Tick the box where “Yes” is appropriate.
Approximately how often have you during the 
last year  consumed alcohol corresponding to 
at least 5 small bottles of beer, a bottle of wine, 
or 1/4 bottle of spirits?
Tick the box where “Yes” is appropriate.
Less than once a week ...........................
Once or twice a week .............................
3 – 4 times a week ..................................
5 or more times a week ..........................
Less than once a week ..........................
Once or twice a week .............................
3 – 4 times a week ..................................
5 or more times a week ..........................
How often do you usually drink wine?
Tick the box where “Yes” is appropriate.
 - How often do you usually drink spirits?
Tick the box where “Yes” is appropriate.
Less than once a week ...........................
About once a week .................................
2 – 3 times a week ..................................
4 – 5 times a week ..................................
More or less ............................................
Never or just a few times a year ............
1 – 2 times a month ................................
About once a week .................................
2 – 3 times a week ..................................
More or less daily ....................................
Never or just a few times a year ............
1 – 2 times a month ................................
About once a week .................................
2 – 3 times a week ..................................
More or less daily ....................................
Never or just a few times a year ............
1 – 2 times a month ................................
About once a week .................................
2 – 3 times a week ..................................
More or less daily ....................................
  PHYSICAL ACTIVITY 
How often do you take part in physical activity 
lasting at least 20 minutes, which makes you 
perspire or become breathless?
Tick the box where “Yes” is appropriate.
Yes  No   
Yes  No   
Yes  No   
Yes  No   
Yes  No   
Yes  No   
Yes  No   
Yes  No   
Yes  No   
Yes  No   
  BACK AND JOINTS CONDITIONS
 NECK, HEAD AND SHOULDER COMPLAINTS
CHANGE IN DIETARY HABITS AND OTHER HABITS
  MARRIAGE / PARTNER 
   HOUSEHOLD
   SCHOOLING 
SLEEPLESSNESS/ LOSS OF CONSCIOUSNESS
   EMPLOYMENT 
If you usually take part in this type of activity at 
least weekly, how much time do you spend 
exercising?
Tick the box where “Yes” is appropriate.
Have you changed any of the following habits 
during the last 5 years: (Tick once for each 
question)
Rarely or never .......................................
Weekly ....................................................
Several times a week ..............................
Daily ........................................................
Less than 30 minutes a week .................
Between 30 minutes and 1 hour  a week
Between 1 and 2 hours a week ..............
More than 2 hours a week ......................
Dietary fat ..............................................
Soya margarine or oil .............................




Are you married or partner ........... .............
How old were you when you first married or 
Moved in with a partner? ............................
How many people live in your 
household?..................................................
Is anyone in your household 10 years 
or younger? ................................................
Does anyone in your household need special
care/assistance – other than the children? ....
How many years education have you had? 
(including primary and secondary schools) 
Have you had paid work the entire past year?




All or almost all ......................................
At least half ............................................
More than quarter ..................................
Less than quarter ...................................
How much house work do you normally do     
yourself?
Tick the box where “Yes” is appropriate.
During this last year have you suffered from  
back pain that has lasted longer than 4 weeks?
If yes, does the pain improve when you 
move around? .........................................
Have you suffered from morning stiffness 
in your back lasting more than 30 
minutes? ....................................................
During the past 3 years have you suffered   
from pain in any of the following joints 
lasting more than 30 minutes?
Knees ......................................................
Elbows ....................................................
Innermost finger joints ..........................
Other joints .............................................
If yes, have you suffered from stiff joints 
in the morning lasting more than 30 
minutes? ....................................................
How often do you suffer from headache?
Tick the box where “Yes” is appropriate.
Rarely of never .......................................
Once or more a month ...........................
Once or more a week .............................
Daily .......................................................
Rarely of never .......................................
Once or more a month ...........................
Once or more a week .............................
Daily .......................................................
How often do you suffer pain in the neck or   
shoulder?
Tick the box where “Yes” is appropriate.
Do the pains in your head, neck or shoulder 
reduce your ability to work?
Tick the box where “Yes” is appropriate.
Have your back, shoulder, and/or neck 
ever been x-rayed? ....................................
Little or no effect .....................................
To some degree ......................................
To a large degree ....................................
Cannot do ordinary work .........................
No particular time ...................................
Especially during the polar night .............
Especially during the midnight sun season
Especially in spring and autumn .............
Have you ever suffered from sleeplessness?
If yes, what time of the year does it affect you 
most? Tick the box where “Yes” is appropriate.
Have you at any time during the last 12 
months suffered from tiredness that has 
affected your work performance? ..............
Have you suffered from sudden loss of 
consciousness in the past year? ................
Have you noticed sudden changes in your 














 before  Less 
If you have major personal problems, do 
you expect to get help and support from 
your spouse or family? ...............................
In the last year, have you for a long time 
felt a need to seek help with personal 
problems, without doing so? ......................
During the past 2 weeks have you felt 
unable to cope with your problems?
Tick the box where “Yes” is appropriate.
Do you ever feel lonely?
Tick the box where “Yes” is appropriate.
During the past 2 weeks have you felt unhappy
or depressed?
Tick the box where “Yes” is appropriate.
Very often ...............................................
Sometimes ..............................................
Rarely or never .......................................








How old were you when you started 
menstruating? ............................................
When did your last period start? ................
How many days usually pass from the first 
day of one period to the first day of your 
next period (the time lapsed between the 
start of two periods) ..................................
Do/ did you menstruate regularly? ............
Do you usually take painkillers during 
menstruation? ............................................
Do you have any of the following complaints 
before your period:
- Are you depressed or irritable?
Tick the box where “Yes” is appropriate.
Hardly at all ..........................................
Noticeably ............................................
Very much so .......................................
Hardly at all ..........................................
Noticeably ............................................
Very much so .......................................
- Are your breasts painful?
Tick the box where “Yes” is appropriate.
- Do you have swollen hands/feet, put on 
weight, or feel bloated?
Tick the box where “Yes” is appropriate.
Hardly at all ..........................................
Noticeably ............................................
Very much so .......................................
Do the complaints disappear when you get 
your period? ...............................................
For these complaints, do you use?
     - diuretics? ............................................
     - other medications? .............................
How many children have given birth to? ....
How old were you when you got pregnant 
for the first time? ........................................
Do you use or have you ever used oral 
contraceptive pills or an intrauterine device? ........
If yes, for how many years altogether have 
you used:
    The pill? ..................................................
    An intrauterine device? ...........................
How old were you when you started using:
    The pill? ..................................................
    An intrauterine device? ...........................
If you have stopped taking the pill, did 6 
months or more pass without 
menstruating without you being pregnant?
Did you have to stop taking the pill due 
to high blood pressure? ..............................
How many times have you had a cervical 
smear test in the last 3 years? ....................
How many years is it since you had your 
last cervical smear test? ............................
MENSTRUATION
THE REMAINING SECTION OF THE 




   CERVICAL SMEAR TEST
   REACTION TO PROBLEMS
Yes  No   
Yes  No   
Yes  No  
Yes  No 
Yes  No 
Yes  No  
Yes  No 
 years    
 day  month  year




 number  




 years  
 Number of tests  
 years  
Yes  No   




Thank you for the help! Remember to post the questionnaire today!
The Tromsø survey 1986-1987
Your comments: ......................................... 
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      The Health Survey is coming to Tromsø. 
This leaflet will tell you when and where. You will 
also find information about the survey in the enclosed 
brochure. 
     We would like you to fill in the form overleaf and 
take it with you to the examination. 
    The more people take part in the survey, the more 
valuable its results will be. We hope, therefore, that 
you will be able to come. Attend even if you feel 
healthy, if you are currently receiving medical 
treatment, or if you have had your cholesterol and 
blood pressure measured recently. 
Yours sincerely, 
Municipal Health Authorities 
Faculty of Medicine - University of Tromsø 
National Health Screening Service 
 Electoral ward No. Municipality  Social security No.Date of birth     
HEALTH SURVEY 
Invitation                                                                  
   
Welcome to the Tromsø Health Survey!                 
“THIS IS YOUR
       CHANCE”
“THIS IS A REAL 
OPPORTUNITY- TAKE IT!”
 What is your current state of health? 
 Do you have, or have you had: 
 Do you use blood pressure lowering drugs? 
Have you during the last year suffered from pains 
and/or stiffness in muscles and joints that have 
lasted continuously for at least 3 months? 
 Have you in the last two weeks felt: 
How has your physical activity in leisure time been during this 
last year? 
How many cups of coffee do you drink daily?      
Are you a teetotaller?                        
How many times a month do you normally drink      
alcohol?        
 Did any of the adults at home smoke while 
you were growing up? 
 Do you currently, or did you previously, live together
 with daily  smokers after your 20th birthday? 
 If "YES", for how many years in all? .............
 How many hours a day do you normally spend 
in smoke-filled rooms? .....
Do you yourself smoke: 
If you previously smoked daily, how long 
is it since you quit?.........................................
If you currently smoke, or have smoked     
previously:       
How many glasses of beer, wine or spirits do you        
normally drink in a fortnight?
What type of margarine or butter do you usually use on     
bread?     
What is the highest level of education you have completed?
What is your current work situation?           
How many hours of paid work do you have per 
week? 
Do you receive any of the following benefits? 
Have one or more of your parents or      
siblings  had a heart attack or had
angina (heart cramp)? ..............................
          
    
Tick one box only. 
Poor  




Angina pectoris (heart cramp)   













 Put 0 if you do not spend time in smoke-filled rooms. 
Cigarettes daily?    
Cigars/ cigarillos daily?    
A pipe daily?
How many cigarettes do you or did you  
usually smoke per day?    
How old were you when you began  
daily smoking?
How many years in all have you smoked  
daily?   
Think of your weekly average for the year. 
Time spent going to work counts as leisure time. 
Light activity (not       
sweating/out of breath)  
Hard activity (sweating/
out of breath) ..........
Coarsely ground coffee for brewing
Other coffee
Hours per week
None    Less than 1 1-2   3 or more
Put 0 if you do not drink coffee daily.     
Put 0 if less than once a month.  .....
Do not count low-alcohol beer. 
Tick one box only. 
Do not count low-alcohol beer. 
Put 0 if less than once a month. 
Don't use butter/margarine 
Butter .............
Hard margarine 
Soft margarine ....... 
Butter/margarine mixtures
Light margarine  
7-10 years primary/secondary school,          
modern secondary school
Technical school, middle school, vocational   
school, 1-2 years senior high school 
High school diploma                                       
(3-4 years)........................




Unemployed, on leave without payment
Sickness benefit (sick leave) 






   Cups      
   Cups      
    Times  
Glasses Glasses Glasses 
Beer Wine 
 
  Spirits    
 No. of     
hours  
   Years   
cigarettes
Age
        years
   Years   
   Years   
   Hours   











No  A little
  
   A lot 
  Very 
  much




EDUCATION/WORK            SMOKING
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    The main aim of the Tromsø Study is to improve our 
knowledge about cardiovascular diseases in order to aid 
prevention. The survey is also intended to improve our 
knowledge of cancer and other general conditions, such as 
allergies, muscle pains and mental conditions.  We would 
therefore like you to answer some questions about factors 
that may be relevant for your risk of getting these and other 
illnesses. 
   This form is a part of the Health Survey, which has been 
approved by the Norwegian Data Inspectorate and the 
Regional Board of Research Ethics. The answers will only 
be used for research purposes and will be treated in strict 
confidence. The information you give us may later be stored 
along with information from other public health registers in 
accordance with the rules laid down by the Data Inspectorate 
and the Regional Board of Research Ethics. 
  If you are in doubt about what to answer, tick the box that 
you feel fits best. 
  The completed form should be sent to us in the enclosed 
pre-paid envelope. 
Thank you in advance for helping us. 
Yours sincerely, 
Faculty of Medicine  National Health 
University of Tromsø Screening Service
 
If you do not wish to answer the questionnaire, tick the 
box below and return the form. Then you will not receive 
reminders. 
I do not wish to answer the questionnaire ..................................
 Date for filling in this form:................................
 Day  Month  Year
In which Norwegian municipality did you live  at the age of 1 year? 
If you did not live in Norway, give country of residence instead of municipality.
How was your family's financial situation during your 
childhood? 
Very good ..............................................................
How many of the first three years of your life   
How many of the first 15 years of your life                  
 Who do you live with?                
Good ........................................................................
Difficult .....................................................................
Very difficult  .............................................................
 - did you live in a town/city? .......................................
 - did your family have a cat or dog in the home? .......
 - did you live in a town/city? .......................................





Yes No  
Yes No  
Yes No  
Yes No  
Yes  No   Tick once for each item and give the number .       
 Spouse/partner ............................................
 Other people over 18 years .........................
 People under 18 years ................................
How many of the children attend day care/kindergarten? ....




Terraced /semi-detached house ........................
Other ..................................................................
 How big is your house? ..................................................
 Approximately what year was your house built? ............
 Has your house been insulated after 1970?...............
 Do you live on the lower ground floor/basement? .....
 If "Yes", is the floor laid on concrete? ...................
What is the main source of heat in your home?   
Number   
Electric heating ......................................................
Wood-burning stove .................................................
Central heating system using:                  
Paraffin ...................................................................
Electricity ................................................................
Do you have fitted carpets in the living room? ............
Is there a cat in your home? .......................................
Is there a dog in your home? ......................................
If you have paid or unpaid work, how would you describe   
 your work? 
Mostly sedentary work? .........................................
(e.g. office work, mounting) 
Work that requires a lot of walking? ..........................
(e.g. shop assistant, light industrial work, teaching)  
Work that requires a lot of walking and lifting? ..........
(e.g. postman, nursing, construction) 
Heavy manual work? .................................................
(e.g. forestry, heavy  farm-work, heavy construction) 
Can you decide yourself how your work should be         
organised? 
No, not at all ..........................................................
To a small extent ......................................................
 Who do you live with?   Yes, to a large extent ................................................
Are you on call, do you work shifts or nights?.............
Do you do any of the following jobs (full- or part-time)?




Yes, I decide myself ..................................................
       HOME   
      WORK
CHILDHOOD/YOUTH
The Tromsø Health Survey                            
   ILLNESS IN THE FAMILY  
   USE OF HEALTH SERVICES   
YOUR OWN ILLNESSES        SYMPTOMS      
Do you cough about daily for some periods of the year?
Have you ever had: 
Tick one box only for each item. Give your age at the time. 








Have you you ever had, or do you still have: 







Fibromyalgia/fibrositis/chronic pain syndrome .........





Allergy and hypersensitivity: 




Other hypersensitivity (not allergy) ....................
How many times have you had a cold, influenza (flu),
vomiting/diarrhoea, or similar in the last six months? 
Have you had this in the last 14 days?.......................
Tick for the relatives who have or have ever
had any of the following diseases: 
Tick "None" if none of your relatives have had the disease.               
Cerebral stroke or brain haemorrhage








age when they got
diabetes ..................................
If "Yes":     
Is your cough productive ? ..............................
Have you had this kind of cough for as long as
3 months in each of the last two years? ............
Have you had episodes of wheezing in your chest?
If "Yes", has this occurred:      
Tick one box only for each item.     
At night ................................................................
In connection with respiratory infections ..................
In connection with physical exertion ........................
In connection with very cold weather .......................
Have you noticed sudden changes in your pulse 
or heart rhythm in the last year?.................................
How often do you suffer from sleeplessness? 
Never, or just a few times a year .........................
1-2 times a month .....................................................
Approximately once a week ......................................
More than once a week .............................................
If you suffer from sleeplessness, what time       
of the year does it affect you most? 
No particular time of year ...................................
Especially during the polar night .............................
Especially during the midnight sun season .............
Especially in spring and autumn ..............................
Have you in the last year suffered from sleeplessness
to the extent that it has affected your ability to work?...
How often do you suffer from headaches? 
Rarely or never .....................................................
Once or more a month ...............................................
Once or more  a week ...............................................
Daily ...........................................................................
Does the thought of getting a serious illness ever 
worry you? 
Not at all ...............................................................
Only a little ................................................................
Some .........................................................................
Very much .................................................................
How many visits have you made during the past year 
due to your own health or illness:
Tick 0 if you have not had such contact 
To a general practitioner (GP)/Emergency GP ............
To a psychologist or psychiatrist .....................................
To an other medical specialist (not at a hospital) ............
To a hospital out-patient clinic .....................................
Admitted to a hospital ......................................................
To a medical officer at work .............................................
To a physiotherapist ....................................................
To a chiropractor .............................................................
To an acupuncturist .........................................................
To a dentist ..................................................................
To an alternative practitioner (homoeopath, foot zone therapist, etc.) 
To a healer, faith healer, clairvoyant  ..............................
Number of times 
the past year
Yes  No  
Yes  No  
Yes  No  
Yes  No  
Yes  No  
Age    
times     
Mother Father Brother Sister Child None  
Gastric/duodenal ulcer surgery ....................
MEDICATION AND DIETARY SUPPLEMENTS            FOOD HABITS           
       FRIENDS      
Have you for any length of time in the past year used any of the 
following medicines or dietary supplements daily or almost daily? 
Indicate how many months you have used them. 
Put 0 for items you have not used. 
Medicines
Painkillers ............................................................







Dietary supplements            
Iron tablets ...........................................................
Calcium tablets or bonemeal ...................................
Vitamin D supplements ............................................
Other vitamin supplements ..................................
Cod liver oil or fish oil capsules ...............................
Have you in the last 14 days used the following             
medicines  or dietary supplements? 
Tick one box only for each item. 
Medicines            
months
good
friends    
Painkillers           .............................................................
Antipyretic drugs (to reduce fever) ...........................
Migraine drugs .........................................................
Eczema cream/ointment ..........................................
Heart medicines (not blood pressure) ......................




Other drugs for nervous conditions ..........................
Antacids ...............................................................
Gastric ulcer drugs ...................................................
Insulin .......................................................................
Diabetes tablets ........................................................





Calcium tablets or bonemeal ...................................
Vitamin D supplements ............................................
Other vitamin supplements ..................................
Cod liver oil or fish oil capsules ................................
- jam and other sweet spreads .......
confidentially with and who give you help when you need it? 259
Do not count people you live with, 
but do include other relatives!  
How many of these good friends do you have 
contact with at least once a month? .........................
Do you feel you have enough good friends? ...........
How often do you normally take part in organised   
gatherings, e.g. sewing circles, sports clubs, 
political meetings, religious or other associations?     
Never, or just a few times a year .........................
1-2 times a month ....................................................
Approximately once a week .....................................
More than once a week ............................................ Waffles, cakes, etc. ..................
Chocolate .......................................
Sugar-free ("Light") soft drinks .....








- lean fish (e.g. cod)  ....................
- fatty fish (e.g. salmon/redfish)
- sausage/meatloaf/ meatballs .....
Dinner with
- unprocessed meat......................
Breakfast cereal/ oat meal, etc. ...
Boiled or fried egg ........................
Yoghurt ....................................
How many times per week do you normally eat the following foodstuffs? 
How many good friends do you have whom you can talk
What kind of fat is normally used in cooking         
(not on the bread) in your home? 
A catering portion is enough for about
If you use butter or margarine on your bread, how many slices does   
a small catering portion normally cover? By this, we mean the 






Tick one or two boxes! 
The bread I eat is most similar to:
Sleeping pills 
How much (in number of glasses, cups, potatoes or slices) do you   
usually eat or drink daily of the following foodstuffs? 
Tick one box for each foodstuff. 
Full milk (ordinary or curdled) (glasses)
Semi-skimmed milk .........................
(ordinary or curdled) (glasses)
Tea (cups) .......................................
Orange juice (glasses) ....................
Potatoes .....................................
Slices of bread in total 
(incl. crisp-bread) ............................
Slices of bread with 
- fish 
(e.g. mackerel in tomato sauce) .....
- lean meat                    
(e.g. ham) .......................................
- fat meat                       
(e.g. salami) ....................................
- cheese (e.g. Gouda/ Norvegia) .........
- brown cheese ...............................







  Coarse 
brown  
   Crisp 
  bread 
Skimmed milk (ordinary or curdled) (glasses)
Tick a box for all foodstuffs listed. 
slices   
 Less 
 than 1 
 More 
than 6 
  Never 
 Less 
 than 1 
  almost  
daily 










What kind of bread (bought or hom -made) do you usually eat?         
      ALCOHOL
How often do you usually drink   
Never, or just a few times a year .......
1-2 times a month ..............................
About once a week ............................
2-3 times a week ...............................
More or less daily ..............................
Approximately how often during the last year have you consumed 
alcohol corresponding to at least 5 small bottles of beer, a bottle 
of wine, or 1/4 bottle of spirits?            
Not at all the last year ...............................................
A few times ...............................................................
1-2 times a month .....................................................
1-2 times a week ......................................................
3 or more times a week ............................................
For approximately how many years has your alcohol       
consumption been as you described above? ..................
- before age 20 ..................................................
years
   spirits?   wine?beer?
 TO BE ANSWERED BY WOMEN ONLY 
      MENSTRUATION   
      PREGNANCY     
      WEIGHT REDUCTION   
      URINARY INCONTINENCE       
      CONTRACEPTION AND ESTROGEN  
- later .................................................................
If you have lost weight deliberately, about how many                 
kilos have you ever lost at the most? 
- before age 20 ..............................................................
- later .............................................................................
What weight would you be satisfied with 
(your "ideal weight")? ....................................................
How often do you suffer from urinary incontinence?
Never ...................................................................
Not more than once a month ...................................
Two or more times a month .....................................
Once a week or more ..............................................
Your comments:            
Do you use, or have you ever used: 
Oral contraceptive pills (incl. minipill) ...
Hormonal intrauterine device ....................
Estrogen (tablets or patches) ..............
Estrogen (cream or suppositories) ............
If you use oral contraceptive pills, hormonal intrauterine device,                 
or estrogen, what brand do you currently use? 
If you use or have ever used oral contraceptive pills: 
How many years in total have you taken the pill? .....
If you have given birth, how many years did you 
take the pill before your first delivery? .......................
If you have stopped taking the pill: 
       Age when you stopped? .....................................
Thank you for the help! Remember to mail the form today! 
The Tromsø Health Survey 
How old were you when you started                       
menstruating? ................................................................
If you no longer menstruate, how old were
you when you stopped menstruating? ...........................
you ever stopped having menstruation for      
6 months or more? ...................................................
If "Yes", how many times? ..................................
If you still menstruate or are pregnant:                         
What date did your last menstruation period begin?
Do you usually use painkillers to                       
relieve period pains? ............................................
How many children have you given birth to? .............
Are you pregnant at the moment? ....................
Have you during pregnancy had 
high blood pressure and/or proteinuria? ...........
If "Yes", during which pregnancy? 
High blood pressure ....................................
Proteinuria ...................................................
If you have given birth, fill in for each child the year of birth 
and approximately how many months you breastfed the child. 
Child Year of birth:  
About how many times have you deliberately tried to 
lose weight? Write 0 if you never have. 
Apart from pregnancy and after giving birth, have        
Yes  No 
day/month/year
 times  
  No Yes 
years
years
Number of months 
breastfed:
Yes  No 
Yes  No 
 children  
 Don't know  
 Pregnancy
First         Later  
Age when you started to take the pill? ......................
  times  
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 The main aim of the Tromsø Study is to improve our 
knowledge about cardiovascular diseases in order to aid 
prevention. The survey is also intended to improve our 
knowledge of cancer and other general conditions, such as 
allergies, muscle pains and mental conditions. Finally, the 
survey should give knowledge about the older part of the 
population. We would therefore like you to answer the 
questions below. 
    This form is a part of the Health Survey, which has been 
approved by the Norwegian Data Inspectorate and the 
Regional Board of Research Ethics. The answers will only 
be used for research purposes and will be treated in strict 
confidence. The information you give us may later be stored 
along with information from other public health registers in 
accordance with the rules laid down by the Data 
Inspectorate and the Regional Board of Research Ethics. 
     If you are in doubt about what to answer, tick the box that 
you feel fits best. 
     The completed form should be sent to us in the enclosed 
pre-paid envelope. 
Thank you in advance for helping us. 
Yours sincerely, 
Faculty of Medicine National Health 
University of Tromsø Screening Service 
 If you do not wish to answer the questionnaire, tick the box below 
and return the form. Then you will not receive reminders. 
I do not wish to answer the questionnaire ..................................
 Date for filling in this form: ..............................
Day   Month   Year
 Who do you live with?      
 Tick once for each item and give the number.        Yes    No   Number
Spouse/partner ..............................................
Other people over 18 years ...........................
People under 18 years ...................................
 What type of house do you live in? 
Villa/ detached house ....................................
Farm ...................................................................
Flat/apartment ...................................................
Terraced /semi-detached house ......................
Other ...................................................................
How long have you lived in your present home? .............
 Is your home adapted to your needs? .............
 If "No", do you have problems with: 
Living space ...................................................
Variable temperature, 





Other (please specify) ...................................
Spouse/partner Would y  like to move into a retirement home? ..
How will you describe the type of work you had for the last 5-10   
years before you retired? 
Mostly sedentary work? ..........................................
(e.g. office work, mounting)     
Work that requires a lot of walking? .........................
(e.g. shop assistant, housewife, teaching) 
Work that requires a lot of walking and lifting? .......
(e.g. postman, nurse, construction) 
     
Did you do any of the following jobs    
(full-time or part-time)? 




How old were you when you retired? ............................
What kind of pension do you have? 
Basic state pension ..............................................
An additional pension ...........................................





Yes   No 
Years 
years  









How was your family's financial situation during your              
childhood? 
If you did not live in Norway, give country instead of municipality
 
In which Norwegian municipality did you live at the age of 1year?  
CHILDHOOD/YOUTH  
PREVIOUS WORK AND FINANCIAL SITUATION 
   HOME    
Tromsø Health Survey 
for the over 70s 
Heavy manual work .....................................................
(e.g. forestry, heavy farm-work, heavy construction)
Yes   No 
Yes   No 
Yes   No 
Yes   No 
Yes   No 
 No A
 little 
   ILLNESS IN THE FAMILY       HEALTH AND ILLNESS    
   YOUR OWN ILLNESSES    
    SYMPTOMS      
Tick for the relatives who have or have ever had 
any of the following diseases: 
Has your state of health changed in the last year?
 
Yes, it has got worse ..............................................
No, unchanged ...........................................................
Yes, it has got better ..................................................
How do you feel your health is now compared to       
others of your age? 
Much worse .............................................................
A little worse ...............................................................
About the same ..........................................................
A little better ...............................................................
Much better .................................................................
Have you ever had:                
Hip fracture ....................................................
Have you ever had:      Wrist /f rearm fr cture ..................................
Whiplash  .......................................................
Injury requiring  hospital admission ...........
Gastric ulcer  .................................................
Duodenal ulcer  .............................................
Gastric/duodenal ulcer surgery ...................
Have you ever had, or do you have: 
Tick one box only for each item. Give your age at the time. 
If you have had the condition several times, how old were 
you last time? 
Neck surgery ..................................................
Tick one box only for each item. 
Cancer  ......................................................................






Fibromyalgia/fibrositis/chronic pain syndrome ......
Psychological problems for which you have sought help 
Thyroid disease ..........................................................
Liver disease ............................................................







Allergy and hypersensitivity 
Atopic eczema (e.g. childhood eczema) .............
Hand eczema .........................................................
diarrhoea/vomiting or similar in the last 6 months?
Food allergy ...........................................................
Other hypersensitivity (not allergy) ....................
How many times have you had a common cold, influenza (flu), 
times    
Hey fever ............................................................
Have you had this in the last 14 days? .................
Tick "None" if none of your relatives have had the disease.                  
Mother Father Brother Sister Child  None 
Cerebral stroke or brain haemorrhage  









- age when they got
diabetes ..........................................
Do you cough about daily for some periods 
of the year? ..................................................................
If “Yes”:     
Is your cough productive? ................................
Have you had this kind of cough for as long 
as 3 months in each of the last two years? ......
Have you had episodes with wheezing in your chest?
If "Yes", has this occurred:        
Tick one box only for each item. 
At night ....................................................................
In connection with respiratory infections ................
In connection with physical exertion .......................
In connection with very cold weather ...................
Have you noticed sudden changes in your pulse 
or heart rhythm in the last year? ................................
Have you lost weight in the last year? ......................
If “Yes”:   
How many kilograms? ............................................
How often do you suffer from sleeplessness? 
Never, or just a few times a year ...........................
1-2 times a month .......................................................
Approximately once a week .......................................
More than once a week ...............................................
If you suffer from sleeplessness, what time of 
the year does it affect you most? 
No particular time of year ......................................
Especially during the polar night ..............................
Especially during the midnight sun season ............
Especially in spring and autumn ..............................
Do you usually take a nap during the day? ....
Do you feel that you usually get enough sleep? 
Do you suffer from: 
Dizziness .......................................................
Poor memory ....................................................
Lack of energy ..................................................
Constipation .................................................
 Age  
  A lot 
     BODILY FUNCTIONS       
MEDICATION AND DIETARY SUPPLEMENTS
   FAMILY AND FRIENDS   
 USE OF HEALTH SERVICES  
Does the thought of getting a serious illness ever 
worry you?             
Not at all ..................................................................
Only a little ..................................................................
Some ............................................................................
Very much ...................................................................
Can you manage the following everyday 
activities on your own without help from 
others? 
Walking indoors on one level ......................
Walking up/down stairs ....................................
Walking outdoors ..............................................
Walking approx. 500 metres ............................
Going to the toilet .............................................
Washing yourself ..........................................
Taking a bath/shower .......................................
Dressing and undressing .................................
Getting in and out of bed .................................
Eating .................................................................
Cooking ..........................................................
Doing light housework (e.g. washing up) ..........
Doing heavier housework (e.g. cleaning floor) 
Go shopping ......................................................
Take the bus ......................................................
Can you hear normal speech 
(if necessary with hearing aid)? .......................
Can you read (if necessary with glasses)? .....
Are you dependent on any of the following aids? 
Walking stick ................................................
Crutches ...........................................................




How many visits have you made during the past year   
due to your own health or illness: 
Put 0 if you have not had such contact 
To a general practitioner (GP)/emergency GP ........
To a psychologist or psychiatrist .................................
To an other medical specialist (not at a hospital) .......
To a hospital out-patient clinic .................................
Admitted to a hospital ....................................................
To a physiotherapist ......................................................
To a chiropractor .......................................................
To a acupuncturist .........................................................
To a dentist .....................................................................
To a chiropodist .........................................................
To an alternative practitioner (homoeopath, foot zone therapist, etc.)
To a healer, faith healer, clairvoyant ............................
Do you have home aid? 
Private ...........................................................
Municipal ..........................................................
Do you receive home nursing care? ...................
Are you pleased with the health care and home
assistance services in the municipality? 
Assigned family GP .................................
Home nursing care ......................................
Home assistance services ..........................
Do you feel confident that you will receive health 





Have you for any length of time in the last year used any of the 
following medicines or dietary supplements daily or almost daily? 
Indicate how many months you have used them. 








Heart medicines (not blood pressure) ...............
Insulin .......................................................................
Diabetes tablets  ......................................................
Drugs for hypothyroidism (Thyroxine) .............
Cortisone tablets .....................................................
Remedies for constipation .....................................
Dietary supplements: 
Iron tablets ...........................................................
Vitamin D supplements ...........................................
Other vitamin supplements ....................................
Calcium tablets or bone meal ............................
Cod liver oil or fish oil capsules ............................
Do you have close relatives who can give 
you help and support when you need it? .......




How many good friends do you have whom you  
can talk confidentially with and who give you 
help when you need it? ...............................................
Do not count people you live with, but do include 
other relatives! 
Do you feel you have enough good friends?
Do you feel that you belong to a community (group of people) 
who can depend on each other and who feel committed to each 
other (e.g. a political party, religious group, relatives, neighbours, 
work place, or organisation)? 
Strong sense of belonging ...................................
Some sense of belonging .........................................
Not sure ......................................................................













 No  Yes 
Number of times




 No  Yes 


















        FOOD HABITS           
     WELL BEING       
     MENSTRUATION       
       PREGNANCY        
        ESTROGEN           
How often do you normally take part in organised gatherings, 
e.g. sewing circles, sports clubs, political meetings, religious 
or other associations? 
Never, or just a few times a year ..........................
1-2 times a month ......................................................
Approximately once a week .....................................
More than once a week .............................................
How many meals a day do you normally eat      
(dinner and bread meals)? ...............................................
How many times a week do you eat warm dinner? ........
What kind of bread (bought or home-made) do you              
usually eat? 
Tick one or two boxes. 
The bread type is most similar to:
What kind of fat is normally used in cooking 






How much (in number of glasses, cups, potatoes or slices) do you   
usually eat/drink daily the following foodstuffs? 
Tick one box for each foodstuff. 
Milk of all types (glasses) ..................
Orange juice (glasses) ...........................
Potatoes ..................................................
Slices of bread in total (incl. crispbread)
Slices of bread with 
fish (e.g. mackerel in tomato sauce) 
cheese (e.g. Gouda/Norvegia) ...................
smoked cod caviare .......................
How many times per week do you normally 
eat the following foodstuffs? 
Tick for all foodstuffs listed. 
Yoghurt .........................................
Boiled or fried egg ...........................
Breakfast cereal/oatmeal, etc. .........
Dinner with   
unprocessed meat ........................
fatty fish (e.g. salmon/red-fish)
lean fish (e.g. cod) ....................
vegetables (fresh or cooked) .......
Carrots (fresh or cooked) ................
Cauliflower/cabbage/broccoli .........
Apples/pears ....................................
Oranges, mandarins, etc. ............
Your comments:       
How content do you generally feel with growing old? 
Good ........................................................................
Quite good ..................................................................
Up and down ..............................................................
Bad ...............................................................................
What is your view of the future?        
Bright ......................................................................
Not too bad .................................................................
Quite worried ..............................................................
Dark ..............................................................................
How old were you when you started  
menstruating? ................................................................
TO BE ANSWERED BY WOMEN ONLY  
How old were you when you stopped menstruating? 
How many children have you given birth to? ........
If you have given birth, fill in for each child the year of birth 
and approximately how many months you breastfed the child. 
If you have given birth to more than 6 children, note their birth 
year and number of months you breastfed at the space provided 
below for comments.   
Child  Year of birth: Number of months    
breastfed:  
Children
Have you during pregnancy    
had high blood pressure and/or             
proteinuria? .......................................................
If "Yes", during which pregnancy? 
High blood pressure ..................................
Proteinuria ..................................................
  First    Later   
Pregnancy      
 No  Yes 
Do you use, or have you ever used estrogen:              
Tablets or patches ...........................................
Cream or suppositories ...................................
If you use estrogen, what brand do you currently use?     
Now  Previously  Never
years 
years 
 Never   
 Less  
   than 1     




 Less    
 than 1  
None  
 White





  Coarse   
brown  
   Crisp   
  bread  
 Number  
Thank you for the help! Remember to mail the form today! 
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5.3 (Municipality) (County) (Country)
9.3 (Business) 9.4 (Occupation) 14.7 (Mark)






Fibromyalgia/chronic pain syndrome ......
Psychological problems for which you  
have sought help  ............................................
A heart attack .........................................
Angina pectoris (heart cramp) ................
Cerebral stroke/brain haemorrhage .........
2.1 Have you suffered from pain and/or stiffness in 
muscles and joints during the last 4 weeks?
(Give duration only if you have had problems)
5.1 How long altogether have you lived in the county?
(Put 0 if less than half a year)
5.2 How long altogether have you lived in the municipality?
(Put 0 if less than half a year)
5.3 Where did you live most of the time before the age of 16?
(Tick one option and specify)
Same municipality ....
Another municipality
in the county .............. Which one:
Another county in Norway Which one:
Outside Norway ........ Country::
5.4 Have you moved within the last five years?
No Yes, one time Yes, more than once
1           2       3
NoYes
1.1 What is your current state of health? (Tick one only)
Poor Not so good Good Very good
1                  2               3           4
1.4 Do you get pain or discomfort in the chest when:
Walking up hills, stairs or walking fast on level ground?
1.6 If you stop, does the pain disappear within
10 minutes? ...........................................................
1.7 Can such pain occur even if you are at rest?........
1.5 If you get such pain, do you usually:
Stop? Slow down? Carry on at the same pace?









Upper part of your back... 
Lumbar region .................
Hips, legs, feet ................
Other places ....................











2.2 Have you ever had:
Fracture in the wrist/forearm  ...................
Hip fracture?..............................................
1. YOUR OWN HEALTH 3. OTHER COMPLAINTS
4. USE OF HEALTH SERVICES
5. CHILDHOOD/YOUTH AND AFFILIATION
6. BODY WEIGHT
2. MUSCULAR AND SKELETAL COMPLAINTS
3.1 Below is a list of various problems. Have you experienced 
any of this during the last week (including today)?
(Tick once for each complaint)
Sudden fear without reason ....................
Felt afraid or anxious ..............................
Faintness or dizziness ............................
Felt tense or upset ..................................
Tend to blame yourself ...........................
Sleeping problems ..................................
Depressed, sad ......................................
Feeling of being useless, worthless ........
Feeling that everything is a struggle ......










1             2            3           4
4.1 How many times in the last 12 months have you been to/used:
(Tick once for each line)
General practitioner (GP) .......................
Medical officer at work ...........................
Psychologist or psychiatrist ....................
(private or out-patient clinic)
Other specialist (private or out-patient clinic)
Emergency GP (private or public) ..............
Hospital admission .................................











6.1 Estimate your body weight when you
were 25 years old: kg
1.3 Have you noticed attacks of sudden changes in  









7. FOOD AND BEVERAGES 8. SMOKING
9. EDUCATION AND WORK
7.1 How often do you usually eat these foods?
(Tick once per line)
7.2 What type of fat do you usually use? (Tick once per line)
7.3 Do you use the following dietary 
supplements:
8.1 How many hours a day do you normally spend
in smoke-filled rooms? Number of total hours
8.2 Did any of the adults smoke at home 
while you were growing up? .................................
8.3 Do you currently, or did you previously live
together with a daily smoker after your
20th birthday? 
8.4 Do you/did you smoke daily? ..................
If NEVER: Go to question 9 : (EDUCATION AND WORK)
8.5 If you smoke daily now, do you smoke:
8.6 If you previously smoked daily, how
long is it since you quit? Number of years











Cod liver oil, fish oil capsules ..............
Vitamins and/or mineral supplements?
7.4 How much of  the following do you usually drink?
(Tick once per line)
7.5 Do you usually drink soft drink: with sugar 1 without sugar      2
7.6 How many cups of coffee and tea do you drink daily?
(Put 0 for the types you don't drink daily)
7.7 Approximately how often have you during the last year 
consumed alcohol? (Do not count low-alcohol and alcohol-free beer)
7.8 When you drink alcohol, how many
glasses or drinks do you normally drink? number
7.9 Approximately how many times during the last
year have you consumed alcohol equivalent to




















Yes, daily Sometimes No
1               2             3              4              5             6
Full milk, full-fat curdled milk, 
yoghurt ..................................
Semi-skimmed milk, semi-skimmed 
curdled milk,low-fat yoghurt ......
Skimmed milk, skimmed 
curdled milk ..............................
Extra semi-skimmed milk ......
Juice .....................................
Water ....................................
Mineral water (e.g. Farris, 
Ramløsa etc)
Cola-containing soft drink .....














1 2            3            4            5
Filtered coffee ..........................................................
Boiled coffee/coarsely ground coffee for brewing .....



















1              2        3 4
5               6        7 8
7.10 When you drink, do you normally drink:(Tick one or more)
Beer Wine Spirits 
9.1 How many years of education
have you completed? Number of years
(Include all the years you have attended school or studied)
9.2 Do you currently have paid work?
9.3 Describe the activity at the workplace  where 
you had paid work for the longest period in the
last 12 months. (e.g. Accountancy firm, school, paediatric  
department, carpentry workshop, garage, bank, 
grocery store, etc.)
Business:
If retired, enter the former business and occupation.
Also applies to 9.4
9.4 Which occupation/title have or had you at this workplace?
(e.g. Secretary, teacher, industrial worker, nurse,
carpenter, manager, salesman, driver, etc.)
Occupation:
9.5 In your main occupation, do you work as self-employed, 
as an employee or family member without regular salary?
9.6 Do you believe that you are in danger of losing 
your current work or income within the next 
two years? ...........................................................
9.7 Do you receive any of the following benefits?
Yes No





Sickness benefit (are on sick leave) .......................
Old age pension, early retirement (AFP) or
survivor pension ..................................................... 
Rehabilitation/reintegration benefit .........................
Disability pension (full or partial) .............................
Unemployment benefits during unemployment .......
Social welfare benefits ............................................
Transition benefit for single parents ........................
How many cigarettes do you or did you
normally smoke per day? Number of cigarettes
How old were you when you began
daily smoking? Age in years
How many years in all have you
smoked daily? Number of years
Yes       No
Yes No
Yes, full-time Yes, part-time No1                    2                  3




(not sweating/out of breath)...
Hard physical activity
(sweating/out of breath).........
Blood pressure lowering drugs ...................
Cholesterol-lowering drugs .........................
Reading, watching TV or 
other sedentary activity? ......................................... .........
Walking, cycling or other forms of  
exercise at least 4 hours a week? .....................................
(Include walking or cycling
to work, Sunday walk/stroll,etc.)
Participation in recreational sports, heavy gardening, etc.?
(Note: duration of activity at least 4 hours a week)
Participation in hard training or sports competitions, 
regularly several times a week? ........................................
None Less than 1 1-2 3 or more
10.1 How has your physical activity in leisure time been 
during this last year?
Think of a weekly average for the year.
Time spent going to work is count as leisure time. Answer both questions.
11.3 How much interest do people show for what you do?
(Tick only once)
11.4 How many associations, sport clubs,groups, religious
        communities or similar do you take part in?  Number
(Write 0 if none)
11.5 Do you feel that you can influence what happening
in your local community where you live? (Tick only once)
12.1 Have one or more of your parents or siblings
had a heart attack (heart wound) or
angina pectoris (heart cramp)? ..........................
12.2 Tick for the relatives who have or have
had any of the illnesses: (Tick for each line)
Cerebral stroke or 
brain haemorrhage .......
Heart attack




12.3 If any relatives have diabetes, at what age did they get
diabetes (if for e.g. many siblings, consider the one who 
got it earliest in life):
11.2 How many good friends do you have? Number of friends
Count the ones you can talk confidentially with
and who can give you help when you need it.
Do not count people you live with, but do include
other relatives.
10.2 Describe exercise and physical exertion in your leisure time.
If your activity varies much e.g. between summer and winter, 
then give an average. The question refers only to the last year.
(Tick the most appropriate box)
1 2 3                 4
10. EXERCISE AND PHYSICAL ACTIVITY
11. FAMILY AND FRIENDS
12. ILLNESS IN THE FAMILY
13. USE OF MEDICINES
14. THE REST OF THE FORM IS TO
BE ANSWERED BY WOMEN ONLY
13.1 Do you use:
14.1 How old were you when you  
started menstruating? Age in years
14.2 If you no longer menstruating, how old were
you when you stopped menstruating? Age in years
14.3 Are you pregnant at the moment?
14.4 How many children have you 
        given birth to? Number of 
children
14.5 Do you use, or have you ever used?
(Tick once for each line)
13.2 How often have you during the last 4 weeks used
the following medicines?
(Tick once for each line)
13.3 For those medicines you have checked in points 13.1 and 























Mother's age Father's age Brother's age Sister's age Child's age
Father Brother Sister Child
None
of these
Yes, some Yes, a little No Never tried




With medicines, we mean drugs purchased at pharmacies.
Supplements and vitamins are not considered here.
Painkillers non-prescription ....




Other prescription medicines ...
Oral contraceptive pills/mini pill/
contraceptive injection ................
Hormonal intrauterine device (IUD)
(not ordinary IUD)..
Estrogen (tablets or patches) .....
Estrogen (cream or suppositories)
State the name and the reason that you are taking/have taken
these (disease or symptom):











Name of the medicine: Reason for use of Up to 1 year
(one name per line) the medicine 1 year or more
If there is not enough space here, you may continue on a separate sheet that you attach
How long have you
used the medicine
Yes No Uncertain Above fertileage 



























but not now Never
14.6 If you use/have used prescription estrogen:
How long have you used it? Number of years
14.7 If you use contraceptive pills, mini pill, contraceptive 
injection, hormonal IUD or estrogen, what brand do you use?
1 2 3 4
1          2                    3        4                 5
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Do not write here:









Fibromyalgia/chronic pain syndrome .....
Psychological problems for which you 
have sought help ....................................
A heart attack .........................................
Angina pectoris (heart cramp) ................
Cerebral stroke/brain haemorrhage ........
Have one or more of your parents or siblings had:
NoYes
What is your current state of health? (Tick only once)
Poor Not so good Good Very good
1                  2               3           4
Do you get pain or discomfort in the chest when:
Walking up hills, stairs, or walking fast on level ground?
If you stop, does the pain disappear 
within 10 minutes? .............................................
Can such pain occur even if you are at rest?....
If you get such pain, do you usually:
Stop? Slow down? Carry on at the same pace?






A heart attack (heart wounds) or




E1. YOUR OWN HEALTH E3. COMPLAINTS
E4. TEETH, MUSCLE AND SKELETON
E5. EXERCISE AND PHYSICAL ACTIVITY
E6. BODY WEIGHT
E2. ILLNESS IN THE FAMILY
Below is a list of various problems.
Have you experienced any of this during the last week
(including today)?
(Tick once for each line)
Sudden fear without reason ..........
Felt afraid or anxious ....................
Faintness or dizziness ..................
Felt tense or upset ........................
Tend to blame yourself ..................
Sleeping problems.........................
Depressed, sad .............................
Feeling of being useless, worthless ..
Feeling that everything is a struggle










  1 2 3 4
How many teeth have you lost/extracted? Number of teeth
(disregard milk-teeth and wisdom teeth)
Estimate your body weight when you 
were 25 years old: kg.
Have you been bothered by pain and/or stiffness in 
muscles and joints during the last 4 weeks?
Neck / shoulders ....................
Arms, hands..........................
Upper part of the back ..........
Lumbar regions ....................








Have you ever had:
Fracture in wrist/forearm? ........................
Hip fracture?............................................
Have you fallen down during the last year? (Tick once only)
NoYes




(not sweating/out of breath).....
Hard physical activity
(sweating/out of breath)............
Less than 1None 1-2 3 or more
How has your physical activity been during this last year?
Think of a weekly average for the year.
Answer both questions.
1                   2 3                 4
Hours per week
1              2                 3Tick for the relatives who have or have
had any of the illnesses: (Tick for each line)
Cerebral stroke or 
brain haemorrhage ...
Heart attack




If any relatives have diabetes, at what age did they get 
diabetes (if for e.g. many siblings, consider the one who 




Mother's age Father's age
Brother's 
age Sister'sage Child's age








Fat fish (e.g. salmon, 
trout, mackerel, herring)
E7. EDUCATION
E8. FOOD AND BEVERAGES
E9. SMOKING
E10. BODILY FUNCTIONS AND SAFETY
How often do you usually eat these foods?
(Tick once for each line)
Do you use dietary supplements:
How many hours a day do you normally spend
in smoke-filled rooms? Number of total hours
Did any of the adults smoke at home
while you were growing up? ........................... 
Do you currently, or did you previously live
together with a daily smoker after your 20th 
birthday?
Do you/did you smoke daily? .................
If you have NEVER smoked daily;
Go to question E11  (BODILY FUNCTIONS AND SAFETY)
If you smoke daily now, do you smoke:
If you previously smoked daily, how
long is it since you quit? Number of years
If you currently smoke, or have smoked 
previously:
Cod liver oil, fish oil capsules ................
Vitamins and/or mineral supplements ...
How much of the following do you usually drink?













1               2                 3                 4                 5                 6
Yes, daily Sometimes No
Full milk, full-fat curdled 
milk, yoghurt ...........................
Semi-skimmed milk, semi-skimmed 
curdled milk, low-fat yoghurt .......
Skimmed milk, skimmed 
curdled milk .........................
Extra semi-skimmed milk ....
Juice ...................................
Water ..................................














1 2 3                4                 5
123
1                   2      3      4
How many years of education have 
you completed? Number of years
(include all the years you have attended school or studied)
Would you feel safe by walking alone in the evening
in the area where you live?
When it comes to mobility, sight and hearing, can you:
(Tick once for each line)
Do you because of chronic health problems have
difficulties with: (Tick once for each line)
Take a 5 minute walk
in fairly high pace? ................
Read ordinary text in newspaper,
if necessary with glasses? .........
Hear what is said in a
normal conversation? ............
Move around in your home? .................
Get out of your home by yourself? .......
Participate in organization or other 
leisure time activities? ..........................
Use public transport? ............................












How many cigarettes do you or did you 
normally smoke per day? Number of cigarettes
How old were you when you began 
daily smoking? Age in years
How many years in all have 
you smoked daily? Number of years














Approximately, how often have you during the last year  
consumed alcohol? (Do not count low-alcohol and alcohol-free beer)
When you drink alcohol, how many 
glasses or drinks do you normally drink? Number
Approximately how many times during the last 
year have you consumed alcohol equivalent to
5 glasses or drinks within 24 hours? Number of times
Filtered coffee ...........................................................
Boiled coffee/coarsely ground coffee for brewing .....



















1              2        3 4
5               6         7 8
Number of cups
How many cups of coffee and tea do you drink daily?
(Put 0 for the types you do not drink daily)
Name of the medicine: Reason for use of Up to One year
(one name per line): the medicine: 1 year or more
Blood pressure lowering drugs .............
Cholesterol-lowering drugs ...................
Drugs for osteoporosis ..........................
Insulin.....................................................
Tablets for diabetes ................................
How much interest do people show for what you do?
(Tick only once)
How many associations, sport clubs, 
groups, religious communities, 
or similar do you take part in? Number 
(write 0 if none)
Do you live: At home? In an institution/shared apartment?
Do you live with:
Spouse/ partner?.......................
Other people? ...........................
How many good friends do you have?
Count the ones you can talk confidentially with
and who can give you help when you need it.
Do not count people you live with, but do include
your children and other relatives........................
How many times in the last 12 months
have you been to/used:
(Tick once for each line)
Are you confident that you 
will receive health care and 
home assistance if you need it?
E11. USE OF HEALTH SERVICES
E12. FAMILY AND FRIENDS
E13. CHILDHOOD/YOUTH AND AFFILIATION
E14. USE OF MEDICINES
E15. THE REST OF THE FORM IS TO
BE ANSWERED BY WOMEN ONLY
Do you use?
(Tick once for each line)
How old were you when you  
started menstruating? Age in years
How old were you when you 
stopped menstruating? Age in years




Do you use, or have you ever used estrogen?
How often have you during the last 4 weeks used the 
following medicines?














1      2          3               4                   5
With medicines, we mean drugs purchased at pharmacies. 
Supplements and vitamins are not considered here
Painkillers non-prescription........ 




Other prescription medicines ....
Tablets or patches .....................
Cream or suppositories .............










If there is not enough space here, you may continue on a separate sheet that you attach.
How long have you
used the medicine
Never Previously Now
If you use estrogen, which brand you use now?
Have you ever used contraceptives pills? ......
1 2 3 4
A general practitioner (GP) ..............
Specialist (private or out-patient clinic)
Emergency GP (private or public).....
Hospital admission ...........................
Home nursing care ..........................
Physiotherapist ................................
Chiropractor .....................................







How long altogether have you lived  in the county?
How long altogether have you lived in 
the municipality?
Where did you live most of the time before the age of 16?
(Tick one option and specify)
Same municipality.........
Another municipality
in the county.................. Which one:
Another county in Norway Which one:
Outside Norway ........... Country:
Have you moved during the last five years?
No Yes, once Yes, more than once







































State the name of the medicines you are using now and the 
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1.1 In which municipality did you live at the age of 1 year?
(If you have not lived in Norway, state country of residence
instead of the municipality)







T1. NEIGHBORHOOD AND HOME
Additional questions to the health survey
in Troms and Finnmark 2001-2002
The main aim of the Tromsø Study is to improve our 
knowledge about cardiovascular diseases in order to aid 
prevention. The study is also intended to improve our 
knowledge of cancer and other general conditions, such 
as allergies, muscle pains and mental conditions. We 
would therefore like you to answer some questions about 
factors that may be relevant for your risk of getting these 
and other illnesses. This form is part of the Health Survey, 
which has been approved by the Norwegian Data 
Inspectorate and the Regional Board of Research Ethics. 
The answers will only be used for research purposes and 
will be treated strictly confidential. 
The information you give us may later be linked with
information from other public health registers in accordance
with the rules laid down by the Data Inspectorate and the
Regional Board of Research Ethics.
If you are unsure about what to answer, tick the box that 
you feel fits best.
The completed form should be sent to us in the enclosed 
prepaid envelope. Thank you in advance for helping us.
Yours sincerely
National Health 
Screening ServiceUniversity of Tromsø
If you do not wish to answer the questionnaire, tick the box 
below and return the form. Then you will not receive reminders.
I do not wish to answer the questionnaire
T1. NEIGHBORHOOD AND HOME (cont.)







1.8 How often do you normally take part in organised
gatherings, e.g. sewing circles, sports clubs,  
political meetings or other associations?
(Tick only once)
Never, or just a few times a year .....................
1-3 times a month ............................................
Approximately once a week .............................
More than once a week ....................................
Mostly sedentary work?
(e.g. office work, mounting) ..............................
Work that requires a lot of walking?
(e.g. shop assistant, light industrial work, teaching)
Work that requires a lot of walking and lifting?
(e.g. Postman, nursing, construction) ...............
Heavy manual labour?










1.3 How big is your house? m2 (gross)
Yes
1.4 Are you bothered by: (Tick once for each line)
Moisture, drought or coldness in your home 
Other forms of bad indoor climate  ..........
Traffic noise (cars or aircraft) ...................
Other noise (industrial, construction, etc.) .....
Neighbour noise .......................................
Drinking water quality ...............................
Air pollution from traffic ............................








Yes   No
1.6 What do you consider yourself as?
(Tick for one or more alternatives)
2.1 If you have paid or unpaid work, how would you
describe your work? (Tick only once)
No, not at all ....................................................
To a small extent .............................................
Yes, to a large extent .......................................





2.2 Can you decide yourself how your work (paid
or unpaid) should be organised? (Tick only once)
2.3 Are you on call, do you work 
shifts or nights?









1.5 What home language did your grandparents have?
(Tick for one or more alternatives)







T5. FOOD AND DIETARY SUPPLEMENTS
T6. BODY WEIGHT
T7. ILLNESSES AND INJURIES
3.1 Do you smoke?
If “Yes, sometimes”,
What do you smoke?
If YES:
How many years altogether have you
used snuff?
4.5 Have you, in one or more periods in the last 
5 years consumed so much alcohol that it has
inhibited your work or social life?
5.4 Do you use the following dietary supplements?
7.1 Have you ever had:
Tick once for each question. Also give the age 
at the time. If you have had the condition 
several times, how old were you the last time
Iron tablets .....................................
Calcium tablets or bonemeal .........
Vitamin D supplements ..................



















Atopic eczema (e.g. childhood eczema)
Hand eczema........................................
Food allergy .........................................





Peptic ulcer surgery ......................
Neck surgery .................................
Prostate surgery ............................










1          2    3                  4
6.1 Do you currently try to change your
body weight?
No
Yes, I try to
gain weight
Yes, I try to 
lose weight
1            2    3
No 1-2 times More than 2 times
1          2   3
1                 2         3














7.2 Do you have, or have you ever had:
(Tick once for each question)
Yes, daily
Cigarettes Pipe Cigar/cigarillos
Yes, sometimes No, never
5.3 How important is it for you to have a healthy diet?
1   2                  3          4
Very Somewhat Little Not
3.2 Have you used or do you use snuff daily?
Yes, now Yes, previously Never
Yes   No
4.1 Are you a teetotaller?..................................
Yes   No
5.1 Do you usually eat breakfast every day?...
7.3 Have you had common cold, influenza,
gastroenteritis, etc. during the last 14 days?
7.4 Have you during the last 3 weeks had
common cold, influenza, bronchitis, 
pneumonia, sinusitis, or other respiratory
infection?......................................................
7.5 Have you ever had bronchitis or 
pneumonia?..................................................
7.6 Have you during the last 2 years had 
bronchitis or pneumonia? (Tick only once)
4.2 How many times a month do you
normally drink alcohol?..................
(Do not count low-alcohol beer.
Put 0 if less than once a month)
4.3 How many glasses of beer, wine or spirits
do you normally drink in a fortnight?
(Do not count low-alcohol beer.
Put 0 if you do not drink alcohol)
Number of times
years
4.4 For approximately how many years
has your alcohol consumption been at 
the same level you described above? years
5.2 How many times a week do you
eat a warm dinner?.......................................
6.2 What weight would you be satisfied .....




T8. SYMPTOMS T8. SYMPTOMS (continue)
T9. MEDICINES
8.2 Do you cough about daily for periods of the year?
If YES:
8.11 Do you usually sleep during the day?...........
8.12 How often do you suffer from urinary incontinence?
Never ................................................................
Not more than once a month ............................
Two or more times a month ..............................
Once a week or more .......................................
8.1 Have you in the last two weeks felt:
(Tick once for each question)
8.5 Do you get short-winded in the following situations?
(Tick once for each question)
While walking fast on level ground
or slight up hills .....................................................
While walking calmly on 
level ground ..........................................................
While washing or dressing yourself ......................
While resting .........................................................
8.6 Do you have to stop because of short-windedness
while walking in your own pace on level ground?...
Is your cough productive? ................................
Have you had this kind of cough for as long 
as 3 months in each of the last two years?......





Yes   No
8.4 Do you get pain in the calf while walking ..........
If YES:
How long can you go
before you notice the pain?...............
8.13 Are you able to walk down 10 steps without 
holding on to something (e.g. a handrail) ....
8.14 Do you use glasses?.......................................
8.15 Do you use a hearing aid?..............................
8.16 How is your memory?
(Tick once for each question)
Do you forget what you just have
heard or read?.....................................................
Do you forget where you have placed things?.....
Is it more difficult to remember now than earlier?..
Do you more often write memos now than earlier?
If “YES” on one of these questions;
Is this a problem in your daily life?................
Drugs for
osteoporosis....................
Tablets for diabetes ........
Drugs for hypothyroidism
(thyroxine) ......................
Yes   No
Yes   No
Yes   No
8.7 Have you during the last year suffered from
pain and/or stiffness in muscles and joints
that have lasted continuously for 
at least 3 months?...............................................
If YES:
Has the complaint reduced your leisure 
time activity? .......................................................
For how long has the complaint endured in total?
Yes   No
Yes   No
Yes   No




Has the complaint reduced your ability to work during 
the last year? (Also applies to domestic workers and 
pensioners (Tick once)
Have you been on sick leave due to these
complaints during the last year?................
No/insignificantly To some extend Significantly reduced Do not know
1               2        3  4
Yes   No
Do not
work
9.1 Do you use, or have you used any of
the following medicines:
9.2 Do you use any medicines which you take 
as injections? ...................................................
If YES:
Give the name of the medicines (for injection):





used 1st time Never
used
meter
8.8 How often do you suffer from sleeplessness?
(Tick only once)
Never, or just a few times a year .......................
1-3 times a month ..............................................
Approximately once a week ..............................









8.9 If you suffer from sleeplessness monthly or more
frequently, what time of the year does it affect you most?
No particular time of the year ............................
Especially during the polar night ........................
Especially during the midnight sun season ........
Especially in spring and autumn .........................
8.10 Have you in the last year suffered from 
sleeplessness to the extend that it has 
affected your ability to work ? ........................
Yes   No
Yes   No
Yes   No
Yes   No




Nervous or worried .....................
Bothered by anxiety.....................
Confident and calm ....................
Irritable.........................................
Happy and optimistic ..................
Down/depressed ........................
Lonely..........................................
8.3 Have you had episodes with wheezing in the chest?
If YES:
Has this occurred: (Tick once for each question)
At night ..................................................................
In connection with respiratory infections ...............
In connection with physical exertion ......................
In connection with very cold weather .....................
T10. ILLNESS IN THE FAMILY
T11. MOBILE TELEPHONE
























12.2 If you still have mensturate or are pregnant:
What date did your last menstruation start?
12.5 Do you use or have you used oral 
        contraceptive pills?..............................
If YES:
How old were you when 
you started taking the pill?..................
How many years in total
have you taken the pills?.... Number of years
If you have given birth:
How many years did you take the pill 
before your first delivery?...  Number of years
If you stopped taking the pill:
How old were you when you stopped?....
12.6 Apart from pregnancy and after giving
birth, have you ever stopped having
menstruation for 6 months or more?.
If YES:
How many times?........................
12.7 How is your current menstruation status?
I have not had menstruation in the last year
I have regular menstruation ........................
I have irregular menstruation ......................
12.8 When you were 25-29 years old, how many days
usually passed between the start of two periods?
The periods were of approximately
equal length every time?...............
How many days did a typical
menstrual bleeding period last?...
Thank you for the help!
Remember to mail the form today!
(If more children, use additional sheet)
12.4 Do you use or have you used prescribed
estrogen (tablets or patches)?..................
If YES:
How old were you when 
you started taking estrogen ? .............
If you stopped using estrogen,
How old were you when 






10.1 Tick for the relatives who have or have ever had
any of the diseases: (Tick for each line)
10.2 How many siblings and children do you have?
10.3 Do you usually do extra caring work because
of illness etc. in your close family?
Heart attack (heart wound)
Angina pectoris (heart cramp)
High blood pressure ........
Aneurysm.........................








Mother FatherBrother Sister Child Noneof these
Number
Brothers Sisters Children
Yes, daily/almost daily Yes, sometimes No
1                2        3
11.1 Do you have (own, rent, etc.) a mobile telephone?
If Yes:
What do you use your mobile telephone for, and how 
often do you use it?(Tick once for each line)
T12. THE REST IS TO BE ANSWERED BY WOMEN ONLY
12.1 If you have given birth, fill in each child's birth year and 
how many months you breastfed after delivery.
(If you did not breastfeed, write 0)
Number of months







Yes, always Yes, sometimes
30 or
more
10-29 2-9 1 or
less
Never
Number of times per day
No
1                2         3
12345
Yes   No10.4 Do you/your family receive home aid 
or home nursing care?.................................
10.5 Is your mother alive? .......
10.6 Is your father alive? ........




12.3 If you no longer menstruate; why did
your periods stop? (Tick once)
It stopped by itself ............................................
Uterus surgery .................................................
Surgically removed both ovaries ......................
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c Neither good nor bad
c Bad 
c Very bad
2 How is your health compared to others in your age?
c Much better
c A little better
c About the same
c A little worse
c Much worse
3 Do you have, or have you had? Yes  No
Age first
time
Heart attack .............................................. c c
Angina pectoris ........................................ c c
Stroke/brain hemorrhage..................... c c
Atrial fibrillation ..................................... c c
High blood pressure ............................... c c
Osteoporosis .............................................. c c
Asthma ......................................................... c c
Chronic bronchitis/Emphysyma/COPD .... c c
Diabetes mellitus .................................... c c
Psychological problems (for which you 
have sought help )
c c
Low metabolism........................................ c c
Kidney disease, c c
Migraine ....................................................... c c
4 Do you have persistent or constantly recurring
pain that has lasted for 3 months or more?
c Yes c No
5 How often have you suffered from sleeplessness during 
 the last 12 months? 
c Never, or just a few times
c 1-3 times a month
c Approximately once a week
c More that once a week
6 Below you find a list of different situations.  
Have you experienced some of them in the last week







Sudden fear without reason c c c c
You felt afraid or 
worried ........................................ c c c c
Faintness or dizziness ........... c c c c
You felt tense or
upset ............................................. c c c c
Easily blamed yourself .......... c c c c
Sleeping problems .................. c c c c
Depressed, sad ......................... c c c c
You felt useless,
worthless ..................................... c c c c
Feeling that life is a struggle c c c c
Feeling of hopelessness with 
regard to the future .............. c c c c
7 Have you during the past year visited:
If YES; how many times?
Yes No   No. of times
General practitioner (GP) .................... c c
Psychiatrist/psychologist ...................... c c
Medical specialist outside hospital 
(other than general practitioner/psychiatrist) c c
Physiotherapist ..........................................c c
Chiropractor ............................................... c c
Alternative medical practitioner
(homeopath, acupuncturist, foot zone therapist, 
herbal medical practitioner, laying on hands 
practitioner,  healer, clairvoyant, etc.)
c c
Dentist/dental service ........................... c c
The form will be read electronically. Please use a blue or black pen 
You can not use comas, use upper-case letters.
2007 – 2008 Confidential
9 Have you undergone any surgery during the last 3 years?
c Yes c No
8 Have you during the last 12 months been to  
a hospital? Yes  No  No. of times
Admitted to a hospital ........................... c c
Had consultation in a hospital without admission;
At psychiatric out-patient clinic c c
At another out-patient clinic ..... c c
USE OF HEALTH SERVICES
HEALTH AND DISEASES
not including urinary 
tract  infection (UTI)
complaint
19 What is your main occupation/activity? (Tick one)
c Full time work c Housekeeping
c Part time work c Retired/benefit recipient
c Unemployed c Student/military service
10 Do you take, or have you taken some of the  






Drugs for high blood pressure c c c
Lipid lowering drugs ................. c c c
Drugs for heart disease .......... c c c
Diuretics ........................................ c c c
Medications for 
osteoporosis .................................c c c
Insulin ............................................ c c c
Tablets for diabetes ................. c c c
Drugs for metabolism
Thyroxine/levaxin .................... c c c
11 How often have you during the last 4 weeks used











prescription ......... c c c c
Painkillers non- 
prescription .......... c c c c
Sleeping pills ........ c c c c
Tranquillizers  ..... c c c c
Antidepressants  ..c c c c
12 State the names of all medications -both those 
on prescription and non-prescription drugs- you 
have used regularly during the last 4 weeks.  
Do not include vitamins, minerals, herbs, natural  
remedies, other nutritional supplements, etc. 
When attending the survey centre you will be  
asked whether you have used antibiotics or  
painkillers the last 24 hours. If you have, you  
will be asked to provide the name of the drug,  
strength, dose and time of use. 
13 Who do you live with? (Tick for each question 
and give the number)
Yes No Number
Spouse/cohabitant ................................ c c
Other persons older than 18 years.. c c
Persons younger than 18 years ........ c c
14 Tick for relatives who have or have had
Parents Children Siblings
Myocardial infarction ..................... c c c
Myocardial infarction before 60 years c c c
Angina pectoris ................................. c c c
Stroke/brain haemorrhage .......... c c c
Osteoporosis  ..................................... c c c
Stomach/duodenal ulcer .............. c c c
Asthma ................................................. c c c
Diabetes mellitus ............................. c c c
Dementia ............................................. c c c
Psychological problems ................. c c c
Drugs/substance abuse ................. c c c
15 Do you have enough friends who can give you 
help when you need it?  
c Yes c No
16
Do you have enough friends whom you can talk 
confidentially with? 
c Yes c No
17 How often do you normally take part in 
organised gatherings, e.g. sports clubs, political 
meetings, religious or other associations? 
c Never, or just a few times a year
c 1-2 times a month
c Approximately once a week
c More than once a week
WORK, SOCIAL SECURITY AND INCOME 
18 What is the highest level of education you have 
completed? (Tick one)
c Primary, 1-2 years secondary school
c Vocational school
c High secondary school (A-level)
c College/university less than 4 years
c College/university 4 years or more
FAMILY AND FRIENDS
If the space is not enough for all medications, use an additional 
paper of your own.
USE OF MEDICINE
25 How often do you exercise?  (With exercise we mean
for example walking, skiing, swimming or 
training/sports) 
c Never
c Less than once a week
c Once a week
c 2-3 times a week
c Approximately every day
36 How many years in all have you smoked daily? 
Number of 
years
35 How old were you when you began smoking daily?
Number of 
years
22 Do you work outdoors at least 25% of the time, or  
in cold buildings (e.g. storehouse/industry  
buildings)?
c Yes c No
23 If you have paid or unpaid work, which statement  
describes your work best?
c Mostly sedentary work
(e.g. office work, mounting)
c Work that requires a lot of walking
(e.g. shop assistant, light industrial work, teaching)
c Work that requires a lot of walking and lifting
(e.g. postman, nursing, construction)
c Heavy manual labour
24
c Reading, watching TV, or other sedentary 
activity.
c Walking, cycling, or other forms of exercise
at least 4 hours a week (here including walking or  
cycling to place of work, Sunday-walking, etc.)
c Participation in recreational sports, heavy gardening, 
etc. (note:duration of activity at least 4 hours a week)
c Participation in hard training or sports 
competitions, regularly several times a week.
26 How hard do you exercise on average?
c Easy- do not become short-winded or sweaty
c You become short-winded and sweaty
c Hard- you become exhausted
29 How many units of alcohol(a beer, a glass of wine or 
a drink) do you usually drink when you drink alcohol?
c 1-2 c 5-6 c 10 or more
c 3-4 c 7-9






27 For how long time do you exercise every time on average?
c Less than 15 minutes c 30-60 minutes
c 15-29 minutes c More than 1 hour
30 How often do you drink 6 units of alcohol or more  
in one occasion?
c Never
c Less frequently than monthly
c Monthly
c Weekly
c Daily or almost daily
28 How often do you drink alcohol?
c Never
c Monthly or more infrequently
c 2-4 times a month
c 2-3 times a week
c 4 or more times a week
21 What was the households total taxable income last
 year? Include income from work, social benefits
and similar
c Less than 125 000 NOK c 401 000-550 000 NOK
c 125 000-200 000 NOK c 551 000-700 000 NOK
c 201 000-300 000 NOK c 701 000 -850 000 NOK 
c 301 000-400 000 NOK c More than 850 000 NOK
34 If you currently smoke, or have smoked before: 








31 Do you smoke sometimes, but not daily?
c Yes c No




c Full disability pension
c Partial disability pension
c Unemployment benefits
c Transition benefit for single parents
c Social welfare benefits
37 Do you use or have you used snuff or chewing tobacco?
c No, never c Yes, sometimes
c Yes, previously c Yes, daily
PHYSICAL ACTIVITY
ALCOHOL AND TOBACCO
Old-age, early retirement or survivor pension
Sickness benefit (are in a sick leave)
Rehabilitation benefit
Describe your exercise and physical exertion in 
leisure time. If you activity varies much, for 
example between summer and winter, then give 
an average. The question refers only to the last 
year. (Tick the one that fits best)
48 If you have given birth, fill in for each child: 
 birth year, birth weight and months of  
breastfeeding (Fill in the best you can)
Child Birth year Birth weight in grams








39 How many units of fruits or vegetables do you eat
on average per day? (units means for example
a fruit, a cup of juice, potatoes, vegetables)
Number of units
38 Do you usually eat breakfast every day?
c
40 How many times per week do you eat hot dinner? 
Number
42 How much do you normally drink the following?  







yoghurt ....................... c c c c c
Juice ............................ c c c c c
Soft drinks
with sugar ................. c c c c c
44 How often do you usually eat cod liver and roe? 
(i.e. “mølje”)
c Rarely/never c 1-3 times/yearc 4-6 times/year
























4 or more 
glasses 
/day
Do you currently use any prescribed drug  
influencing the menstruation? 
45 Do you use the following supplements? 
Daily  Sometimes  No
Cod liver oil or fish oil capsules ......... c c c
Omega 3 capsules (fish oil, seal oil) ........ c c c
Vitamins and/or mineral supplementsc c c
47 How many children have you given birth to?
Number
49 During pregnancy, have you had high blood  
pressure?  
c Yes c No
52 If yes, which pregnancy?
c The first c Second or later
53 Were any of your children delivered prematurely  
(a month or more before the due date) because  
of preeclampsia?
c Yes c No
55 How old were you when you started  
menstruating? 
Age
51 During pregnancy, have you had proteinuria?  
c Yes c No
50 If yes, which pregnancy?
c The first c Second or later
54 If yes, which child?
1st child 2nd child 3rd child 4th child 5th child 6th child
c c c c c c
43 How many cups of coffee and tea do you drink 
daily? (Put 0 for the types you do not drink daily)
Number of cups
Filtered coffee ...............................................
Boiled coffee (coarsely ground coffee for brewing)
Other types of coffee ..................................
Tea ......................................................................
56
Oral contraceptives, hormonal 
IUD or similar ........................................... c Yes c No
Hormone treatment for  
menopausal problems ........................... c Yes c No
46 Are you currently pregnant? 
c Yes c No c Uncertain
When attending the survey centre you will get a  
questionnaire about menstruation and possible use  
of hormones. Write down on a paper the names of  
all the hormones you have used and bring the paper  
with you. You will also be asked whether your  
menstruation have ceased and possibly when and  
why. 
 
41 How often do you usually eat these products? 
(Tick once for each line)
Potatoes .............................. c c c c c
Pasta/rice .......................... c c c c c
Meat (not processed) ............ c c c c c
Processed meat
(sausages/meatloaf/meatballs) c c c c c
Fruits, vegetables, berriesc c c c c
Lean fish ............................. c c c c c
Fat fish  ............................... c c c c c
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- part of The Tromsø Survey
 
- part of The Tromsø Study   
FILL OUT THE FORM IN THIS WAY:
The form would be read by machine, it is therefore important that you tick appropriately:
 
Correct 
 √ Wrong 
 rWrong 
If you tick the wrong box, correct by filling the box like this
Write the numbers clearly  1 2 3 4 5 6 7 8 9 0
Correct 
Wrong 
Use only black or blue pen, do not use pencil or felt tip pen
7 4
r
7   4
3
1.6 To allow you to show us how good or bad 
your state of health is we have made a 
scale (almost like a thermometer) where 
the best state of health you can imagine is 
marked 100 and the worst 0. We ask you to 
show your state of health by drawing a line 
from the box below to the point on the 
scale that best fits your state of health.   















1. DESCRIPTION OF YOUR HEALTH STATUS
Mark the statement that best fits your 
state of health today by ticking once in 
one of the boxes under each of the five 
groups below: 
1.03 Usual activities (e.g. work, study, housework,
family or leisure activities)
I have no problems with performing my
usual activities 
I have some problems with performing my
usual activities 
I am unable to perform my usual 
activities 
1.04 Pain and discomfort
I have no pain or discomfort
I have moderate pain or discomfort
I have extreme pain or discomfort
1.01 Mobility 
I have no problems in walking 
about 
I have little problems in walking about
I am confined to bed
1.02 Self-care 
I have no problems with self-care
I have some problems washing or 
dressing myself 
I am unable to wash or dress myself
1.05 Anxiety and depression
I am not anxious or depressed
I am moderately anxious or depressed




2.01 Where did you live  at the age of 1 year?
In Tromsø (with present municipal borders)
In Troms, but not Tromsø
In Finnmark 
In Nordland 
Another place in Norway
Abroad 
2. CHILDHOOD/YOUTH AND AFFILIATION
2.05 How many siblings and children do 
you have/have you had? 
Number of siblings ......................................
Number of children .....................................
2.02 How was your family's financial





2.07What was/is the highest completed education for your parents and your spouse/cohabitant?




Primary 7-10 years, 1-2 years secondary school ............................
Vocational school ................................................................................................
High secondary school (A level) .................................................................
College or university (less than 4 years) .............................................
College or university (4 years or more) ................................................
2.06 Is your mother alive?
Yes No
If NO: her age when she died .............
Is your father alive?
Yes No
If NO: his age when he died ................
2.04 What do you consider yourself as? (Tick 





2.03 What is the importance of religion 





3.03 I consider my occupation to have the following social status in the society:






3.01 Below are three statements about satisfaction with life as a whole. Then there are two 
statements about views on your own health. Show how you agree or disagree with 
each of the statements by ticking in the box for the number you think fits best for you.
(tick once for each statement) Completely
disagree  1     2     3     4     5     6     7
In most ways my life is close to my ideal ................. .. .. .. ...
My life conditions are excellent ....................................
I am satisfied with my life .................................................
I have a positive view of my future health .............
By living healthy, I can prevent serious diseases
3.02 Below are four statements concerning your current job conditions, or if you are not
working now, the last job you had. (Tick once for each statement)
 
My work is tiring, physically or mentally ................
1 2 3 4 5 6 7
I have sufficient influence on when and how 
my work should be done ..................................................
I am being bullied or harassed at work .................. ...........................................................
I am being treated fairly at work ..............................
3. WELL BEING AND LIVING CONDITIONS









Been tormented, or threatened with violence ................
Been beaten, kicked at or victim of other types of violence
Someone in your close family have used alcohol or
drugs in such a way that it has caused you worry ..........
If you have experienced anything of the above, how much are you affected by that now?








4.01 Have you during the last month 
experienced any illness or injury?
Yes No
4. ILLNESS AND WORRIES
4.03Do you become breathless in the following 
situations? (tick once for each question)
Yes  NoWhen you walk rapidly on level 
ground or up a moderate slope .............
When you walk calmly on level 
ground ...................................................................
While you are washing or dressing ......
At rest ....................................................................
4.04 Do you cough about daily for some 
periods of the year?
Yes No
If YES: Is the cough usually productive?
Yes No
Have you had this kind of cough for as long 
as 3 months in each of the last two years? 
Yes No
4.02 Have you noticed sudden changes in your 
pulse or heart rythm in the last year? 
Yes No
4.09 Below, please answer a few questions
about your memory: (tick once for each 
question)
Yes  No
Do you think that your memory
has declined? ....................................................
Do you often forget where you 
have placed your things? ..........................
Do you have difficulties finding 
common words in a conversation? ......
Have you problems performing 
daily tasks you used to master? ............
Have you been examined for 
memory problems? ........................................
If YES: have you during the same period?
(Tick once for each line)
Yes  No
Been to a general practitioner ..............
Been to a medical specialist ...................
Been to emergency department ...........
Been admitted to a hospital ....................
Been to an alternative  practitioner
(chiropractor, homeopath or similar) .............
If YES to at least one of the first four questions
above: Is this a problem in your daily life?
Yes No
4.05How often do you suffer from sleeplessness? 
(tick once)
Never, or just a few times a year
1-3 times a month
Approximately once a week
More than once a week
If you suffer from sleeplessness monthly or 
more often, what time of the year does it 





4.06 Have you had difficulty sleeping during 
the past couple of weeks? 
Not at all
No more than usual
Rather more than usual
Much more than usual
4.07 Have you during the last two weeks felt 
unhappy and depressed?
Not at all
No more than usual
Rather more than usual
Much more than usual
4.08 Have you during the last two weeks felt
unable to cope with your difficulties?
Not at all
No more than usual
Rather more than usual
Much more than usual
7
4.17 If you have had abdominal pain or 
discomfort during the last year:
Yes  No
Was it located in your upper stomach?.
Were you bothered as often as once a
week or more during the last 3 months?... 
Became better after bowel movement?...
Are the symptoms related to more 
frequent or rare bowel movements  
than normally? ....................................................
Are the symptoms related to more
loose or hard stool than normally?............. 
Do the symptoms appear after a meal? ....
4.15Have you ever experienced infertility 
for more than 1 year?
Yes No
If Yes: was it due to: Do not 
knowYes No
A condition concerning you?......
A condition concerning your 
partner?.........................................................
4.14 Do you have or have you ever had some 
of the following:




4.19 For women: Have you ever had a 
miscarriage?
Yes No Do not know
If Yes: number of times .........................
4.16 To which degree have you had the following 
complaints during the last 12 months?









4.20For men: Have your partner ever had 
a miscarriage?
Yes No Do not know
If Yes: number of times .........................
4.22Have you been diagnosed with 
Dermatitis Herpetiformis (DH)? 
Yes No Do not know
4.21 Is your diet gluten-free?
Yes No Do not know
4.11 Have you suffered from pain and/or 
stiffness in muscles or joints during 
the last 4 weeks  
No A little   A lot
Neck, shoulder .......................
Arms, hands .............................
Upper part of the back .....
The lumbar region ...............
Hips, leg, feet ........................
Other places ............................
4.10 Have you during the last last year suffered 
from pain and/or stiffness in muscles or 
joints in your neck/shoulders lasting for 
at least 3 consecutive months?
(tick once for each line)
No A little   A lot
Neck, shoulder......................
Arms, hands............................




4.12 Have you ever had: Age 




4.18 Have you ever had: Age
last timeYes  No
Stomach ulcer ......................
Duodenal ulcer ....................




4.27 What kind of headache are you 
suffering from?
Migraine Other headache
4.28 How many days per month do you 
suffer from headache? 
Less than one day
1-6 days 
7-14 days
More than 14 days
4.26 Have you been suffering from 
headache the last year?
Yes No
If No: go to section 5, food habits
4.30 What is the intensity of your headache? 
Mild (do not hinder normal activity) 
Moderate (decrease normal activity) 
Strong (block normal activity) 
4.31 What is the duration of the headache  
usually?
Less than 4 hours
4 hours – 1 day
1-3 days
More than 3 days
4.29 Is the headache usually:
(tick one for each line)
Yes   No
Pounding/pulsatory pain ..............
Pressing/tightening pain ............. 
Unilateral pain (right or left) ........ 
4.33 Before or during the headache, do you 
have a transient:
Yes  No
Visual disturbances? (flickering,  
blurred vision, flashes of light)....................
Unilateral numbness in your face 
or hand? ...........................................................
Deterioration by moderate physical 
Activity? ...........................................................
 
Nausea and/or vomiting? ......................
4.34 Describe how many days you have been 
away from work or school during the 
last month due to headache?
Number of days ............................................
4.32 If you suffer from headache, when during






4.23 Have you been diagnosed with coeliac 
disease, based on a biopsy from your 
intestine taken in an endoscopy 
examination?
Yes No Do not know
4.24 Do you have your natural teeth?
Yes No
4.25 How many amalgam tooth fillings do 
you have/have you had?
0 1-5 6-10 10+
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5. FOOD HABITS









Fresh water fish (not farmed) .........................................................
Salt water fish (not farmed) ............................................................
Farmed fish  (salmon, trout, char) ...................................................
Tuna fish (fresh or canned) ................................................................
Fish bread spread ...............................................................................
Mussels, shells ......................................................................................
The brown content in crabs ........................................................
Whale or seal meat ...........................................................................
Pluck (liver/kidney/heart) from reindeer or elk/moose..
Pluck (liver/kidney/heart) from ptarmigan/grouse .............
5.02 How many time during the year do/did you usually eat the following? (number of times)
In adulthood In childhood
Mølje (cod or pollack meat, liver, and roe)(Number of times per year) ...
Gulls egg (Number of eggs per year) .................................................................................
Reindeer meat (Number of times per year) .................................................................
Local mushroom and wild berries (blueberries/lingonberries/cloudberries)
(Number of times per year)
5.03 How many times per month do you eat 
canned (tinned) foods (from metal boxes)? 
Number ...............................................................
5.04 Do you take vitamins and/or mineral 
supplements?
Yes, daily Sometimes Never 










3 times per day 
or more
Dark chocolate .......................................
Light chocolate/milk chocolate ....
Chocolate cake ......................................
Other sweets ........................................... 










3 times per  
day or more
5.06 If you eat chocolate, how much do you usually eat each time?
Compared with the size of a Kvikk-Lunsj sjokolade (a chocolate brand in the market) and describe how 
much do you eat in relation to it.






8.01 How many hours per week, do you do the 
following leisure- or professional activities: 
Automobile repair/paint, ceramic work, 
painting/solvents, hair dressing, glazier,
electrician. (Put 0 if you do not engage in
such leisure or professional activities)  
Number of hours per week on average .........
8.02 Do you use hair color preparations
Yes No
If Yes: How many times per year? ..
7.01 Have you involuntary lost weight during 
the last 6 months?
Yes No
If Yes: how many kilograms? ..............
7.03 Are you satisfied with your present body 
weight?
Yes No
7.02 Estimate your body weight when you were 
25 years old: 
Number of kilograms ..........................
7.04 What weight would you be satisfied with 
(your "ideal" weight)? 
Number of kilograms ...........................
Never




6.02 Have you or someone else been injured because of your 
Drinking? ...................................................................................................................... 
Has a relative, friend, doctor, or other health care worker been






6.01 How often have you in the last year:
Never Monthly Weekly
Not been able to stop drinking alcohol 
when you have started? ....................................... 
Failed to do what was normally expected
of you because of drinking? ................................
Needed a drink in the morning to get 
yourself going after a heavy drinking session?
Had feeling of guilt or remorse after 
drinking? ..........................................................................
Not been unable to remember what happened 
the night before because of your drinking? ..... .............
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9.09 All in all, have you experienced that it is 







9. USE OF HEALTH SERVICES
9.01 Have you ever experienced that disease
has been inadequately examined or treated,
and that this had serious consequences?  
Yes, this has happened to me
Yes, this has happened to a close relative
(child, parents, spouse)
No
If Yes, where do you think the reason of the
problem is? (tick once or more):    
With a general practitioner
With an emergency medical doctor
With a private practising specialist
With a hospital doctor
With another health personnel
With an alternative practitioner
with more than one person due to the failure  
of procedures and collaboration
9.03Have you ever complained about a treatment
you have got?
Have never a reason for complaining
Have considered complaining, but 
did not do that
Have complained verbally
Have complained in writing
9.04 How long have you had your current
general practitioner/other physician?
Less than 6 months
6 to 12 months
12 to 24 months
More than 2 years
9.02Have you ever felt persuaded to accept
an examination or treatment that you do
not want?
Yes No
If Yes, do you think this has had unfortunate
health-related consequences?
Yes No
9.05 At the last visit to the general practitioner,
did the doctor(s) speak to you in a way so 
you understand them? Answers to a scale 
from 0 to 10, where 0 = they were difficult 
to understand and 10 = they were always 
easy to understand
0  1  2  3  4  5  6  7  8  9  10
9.06 How would you characterize the treatment
or counselling, you got the last time you 
were with a doctor? Answer on a scale from 
0 to 10, where 0 = very bad treatment, and 
10 = very good treatment
9.07 Do you have during the last 12 months 
experienced that it has been difficult to be
referred to special investigations (like X-ray
or similar) or to specialized health service





9.08 Have you during the last 12 months 
experienced that it is difficult to be referred





0  1  2  3  4  5  6  7  8  9  10
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9.13 Have you during the last 12 months used
herbal medicine, natural means or 
natural medicines?
Yes No
9.10 Have you during the last 12 months  
been to examination or treatment in 
specialized health service?
Yes No
9.14 Have you during the last 12 months used
meditation, yoga, qi gong or thai chi as 
own treatment?
Yes No
9.12 Have you ever before 2002 undergone 
an operation in hospital or specialist clinic?
Yes No
9.11 How would you characterize the 
treatment or advice you got last time 
you were with a specialist? Answer on a 
scale from 0 to 10, where 0 = very poor 
and 10 = very good
If Yes, did the doctor(s) speak to you so 
that you understood them? Answer on a 
scale from 0 to 10, where 0 = they were 
difficult to understand and 10 = they 
were always easy to understand
0  1  2  3  4  5  6  7  8  9  10
0  1  2  3  4  5  6  7  8  9  10
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10. USE OF ANTIBIOTICS
10.01 Have you used antibiotics during the last 12 months? (all penicillin-like medicine in the 
form of tablets, syrups or injections)
Yes No Do not remember
If YES: What did you get the treatment for? 
Have you taken many antibiotic treatments, 
tick for each treatment.
Treatment
 1
● Urinary tract infection (bladder infection, cystitis) .....
● Respiratory tract infection (ear, sinus, throat or
lung infection, bronchitis) ....................................................................................................................................................
● Other ..........................................................................................
Treatment duration: number of days ............................
How did you acquire the antibiotics for treatment?
Have you acquired many treatments, tick for each one.
With prescription from a doctor/dentist ......................
Without contacting a doctor/without prescription:
· Purchase from a pharmacy abroad .........................
· Purchase over the internet  .........................................
· Remnants from earlier treatment at home ......
· From family/friends .........................................................
· Other ways ..............................................................................
10.02 Do you have antibiotics at home?
Yes No
10.03 Would you consider using antibiotics 
without consulting your doctor? 
Yes No
If YES:is this after an agreement with your 
doctor for treatment of chronic or frequently 
recurring disease? 
Yes No
If No: how did you acquire this antibiotic?
(Multiple ticks are possible)
Purchased from a pharmacy abroad ....
Purchased over the internet .....................
Remnants from earlier treatment .........
From family/friends .......................................
Other ways ...........................................................
If YES: which conditions would you treat in 























11. YOUR CIRCADIAN RHYTHM
Then I go to bed at ....................................................................................................................................
I get ready to fall asleep at .................................................................................................................
Number of minutes I need to fall asleep ....................................................................................................
I wake up at ....................................................................................................................................................
With help of: Alarm clock External stimulus (noise, family members etc.) By myself
Number of minutes I need to get up .............................................................................................................
Then I go to bed at ....................................................................................................................................
I get ready to fall asleep at .................................................................................................................
Number of minutes I need to fall asleep ....................................................................................................
I wake up at ....................................................................................................................................................
With help of: Alarm clock External stimulus (noise, family members etc.) By myself
Number of minutes I need to get up .............................................................................................................
11.02 Number of days per week which you cannot freely choose when you sleep (e.g. work days)?
0  1  2  3  4  5  6  7
We will ask you some questions about your sleeping habits
11.03 Number of days per week which you can freely choose when you sleep (e.g. free days or holidays)
11.01 Have you worked in a shift work schedule during the last 3 months? 
Yes No
0  1  2  3  4  5  6  7
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12.07 Have you recurring large acne/abscesses
that are tender/painful and often form 
scars in the following places? 
(tick once for each line) 
Yes  No
Armpits ...............................................................
Under the breasts .......................................
Stomach groove/the navel ....................
Around the genitalia ..................................
Around the anus ........................................... ...............................
The groin ..........................................................
If Yes: How many times in average per year did 
you take antibiotics during the period you were 
most affected (tick once) 
1-2 3-4 More than 4 times
12.05 Have you often or always any of the 
following complaints? (tick once for each line)
Yes  NoSwelling in the ankles or legs, 
particularly in the evenings ...................
Varicose veins .................................................
Eczema (red, itchy rash) on
your legs .............................................................
Leg pain when you walk, but 
is relieved when you stand still .................. ................
12.04 Have you or have you ever had the following
skin disorders? (tick once for each line)
Yes  No
Psoriasis ................................................................
Atopic eczema (children's eczema) .........................
Recurrent hand eczema .............................
Recurrent pimples/spots for 
several months ..................................................
Leg or foot ulcer that did not heal
for 3-4 weeks ....................................................
12. SKIN AND DERMATOLOGY
If Yes for the question on leg and/or foot
 ulcer, do you have the ulcer today?
Yes No
12.03 Have you ever taken any antibiotics 
(penicillin and similar medicines) 
because of a skin disease, for example
infected eczema, acne, non-healing leg 
ulcers, recurrent  abscess?
Yes No
12.01 How often do you usually take a shower 
or a bath? (tick once)
2 or more times daily
1 time daily
4-6 times per week
2-3 times per week
Once a week
Less than once a week
12.02 How often do you during a day usually 





More than 20 times
12.06 Have you ever had the following diagnoses





If Yes, did you get any of the following 




Surgical drainage .......................................... ..............................
A larger surgical intervention 
including skin removal ...............................
Surgical laser treatment ..........................




The following pages with questions should not be answered by all. If you have answered yes 
to one or more of questions below, we ask you to move on to the follow-up questions on the 
topic or topics you have answered yes to. The first four topics are from the first questionnaire 
and the last question  is from this form.
We have for the sake of simplicity highlighted topics with different colors so that you will find 
the questions that applies to you.
If you answered YES to that you have: long-term or recurrent pain that has lasted for 3 months 
or more, please answer the questions on page 19 and 20. The margin is marked with green.
If you answered YES to that you have undergone any surgery during the last 3 years,
please answer the questions on page 21 and 22. The margin is marked with purple.
If you answered YES to that you're working outdoors at least 25% of the time, or in facilities 
with low temperature, such as warehouse/industrial halls, please answer the questions on page 23
The margin is marked with red.
If you answered YES to that you have used non-prescription pain relievers, please answer
questions on page 24. The margin is marked with orange.
If you answered YES to that you have or have ever had skin problems (such as psoriasis, atopic
eczema, non-healing leg or foot ulcerl, recurrent hand eczema, acne or abscesses), please
answer the questions on page 25. The margin is marked with yellow.
If you have answered NO to these five questions, you are finished with your answers. The 
questionnaire is to be returned in the reply envelope you were given at the survey. The postage 
is already paid.
Should you wish to give us written feedback on either the questionnaire or The Tromsø Survey
in general, you are welcome to that on page 26.
Do you have any questions, please contact us by phone or by e-mail. You can find the contact 
information on the back of the form. THANK YOU for taking the time to the survey and
to answer our questions.
INFORMATION TO FOLLOW-UP QUESTIONS
19
13.01 How long have you had this pain?
Number of years months










13.02 How often do you have this pain?
Every day Once a month or more
Once a week or more Less than once a month
13.05 Which kind of treatment have you received for the pain? (Tick for all types of pain 








(homeopathy, healing, aromatherapy, etc. Treatment at a pain clinic
Surgery Another treatment
You answered in the first questionnaire that you have protracted or constantly recurrent 
pain that has lasted for 3 months or more. Here, we ask you to describe the pain a little closer.
13. FOLLOW-UP QUESTIONS ON PAIN
13.04 What do you believe is the cause of the pain? (Tick for all known causes) 
Accident /acute injury Fibromyalgia  
Long-term stress Angina pectoris 
Surgical intervention/operation Poor blood circulation 
Herniated disk (prolapse) /lumbago Cancer 
Whiplash Nerve damage/neuropathy 
Migraine/headache Infection 
Osteoarthritis Herpes zoster 
Rheumatoid arthritis Another cause (describe below)
Bechterews syndrome Don't know
Describe the other cause:
..........................................................................................................................................................................................................
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13.06 On a scale of 0 to 10, where 0 corresponds to no pain and 10 corresponds to the worst 




to sleepTo what degree does the pain 
interfere with your sleep?  ............................................
0 1 2 3 4 5 6 7 8 9 10
Can not do
anythingTo what degree does the pain 
interfere with performing common
activities at home and at work?  .............................
0 1 2 3 4 5 6 7 8 9 10
How strong is the pain when it is in 
its strongest intense? .........................................................





painHow strong would you say that the 
pain usually is? ....................................................................









14. FOLLOW-UP QUESTIONS ON SURGERY
In the first questionnaire you answered that you have undergone an operation during the last 3
years.
Below, please describe the operation. If you have undergone several operations during the  
last 3 years, these questions concern the last surgery you underwent.
14.02 Where in your body did you have surgery?
(If you were operated simultaneously in several
places in the body, tick more than once)








· Another surgery in
  the chest region .............................
Surgery in the stomach/pelvis
· Stomach/intestines .....................
· Inguinal hernia ...............................
· Urinary tract/reproductive organs
· Gall bladder/biliary tract .......
· Another surgery in the
  stomach/pelvis ...............................










14.03 Reason for the surgery:
Acute illness/trauma ...................................
Planned non-cosmetic operation .........
Planned cosmetic operation ...................
14.04 Where did you have the surgery?
Tromsø hospital ..............................................
Harstad hospital .............................................
Other public hospital ..................................
Private clinic ....................................................
14.01 How many times have you undergone surgery during the last 3 years? 
Number  ......................................................................................................................................................................................
14.05 How long time is it since you had surgery?
Number 
of years ..... Months ......
14.06 Do you have reduced sensitivity in an area 
near the surgical scar?
Yes No
14.07 Are you hypersensitive to touch, heat or 
cold in an area near the surgical scar? 
Yes No
14.08 Does slight touch from clothes, showering 
or similar cause discomfort/pain?
Yes No
14.09 If you had pain at the site of surgery before 
you had surgery, do you have the same  
type of pain now? 
Yes No
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14.10 The pain at the site of surgery: Answer on a scale from 0 to 10, where 0=no pain and 





painHow strong pain did you have at the 
site of surgery before you had surgery .....
0 1 2 3 4 5 6 7 8 9 10
How strong pain do you normally  
have at the site of surgery now ...........
0 1 2 3 4 5 6 7 8 9 10
How strong pain do you normally
have at the site of surgery when it
is most intense ................................................












15.06Have you during the last 12 months been 
involved in an accident which required medical
treatment where cold was an important factor?
Yes  No
At work ...........................................................
In leisure time ............................................
15.02 For how long have you been exposed to 
cold air below 0ºC during the last winter?
Leisure/hobbies (hours/week) .................
Work (hours/week) .........................................
Outdoors, with suitable clothing
(hours/week) .....................................................
Outdoors, without suitable clothing
(hours/week) ......................................................
Indoors, with no heating (hours/week)
In cold, with wet clothing
(hours/week) ......................................................
Contact with cold objects/tools
(hours/week) .....................................................
15. FOLLOW-UP QUESTIONS ABOUT WORK IN COLD ENVIRONMENT
In the first questionnaire you answered yes to that you work in cold environments. Here are  
some follow-up questions that we hope you will answer.




15.05Have you had itching and/or rash in relation
to cold exposure?
Yes No
15.07 Do you experience any of the following 
symptoms while you are in a cold environment?
If so, at what temperature do the symptoms
occur?
Yes No  Under °C
Breathing problems ............
Wheezy breathing ...............
Mucus secretion from lungs
Chest pain ................................









15.08 How does a cold environments and cold-related symptoms influence your performance?
Decrease No effect Improve 
Concentration .......................................................................................................
Memory .....................................................................................................................
Finger sensitivity (feeling) ...............................................................................
Finger skill  (motor) ...............................................................................................
Control of movement (for example tremor) .............................................
Heavy physical work ........................................................................................
Long-lasting physical work ...........................................................................





Performing other activities 
outdoors ..................................................... ...
15.04 Have you during the last 12 months had a 
frostbite with blisters, sores or skin injury?
Yes No





16. USE OF NON-PRESCRIPTION PAINKILLERS MEDICATIONS
Paracetamol: (Pamol, Panodil, Paracet, 
Paracetamol, Pinex)
Not used
Less than every week
Every week, but not daily
daily
How much you take usually daily
when you use the medications?
(number of tablets, suppositories) ..............
16.01 What types of non-prescription painkiller
medications have you used?
Ibuprofen: (Ibumetin, Ibuprofen, Ibuprox, Ibux)
Not used
Less than every week
Every week, but not daily
Daily
How much you take usually daily
when you use the medications?
(number of tablets, suppositories) ..............
Acetylsalicylates:(Aspirin,Dispril, Globoid)
Not used
Less than every week
Every week, but not daily
Daily 
How much you take usually daily
when you use the medications?
(number of tablets) .........................................
Naproxen: (Ledox, Naproxen)
Not used
Less than every week
Every week, but not daily
Daily
How much you take usually daily
when you use the medications?
(number of tablets) .........................................






16.02 For which complains do you use non-









Phenazone with caffeine: (Antineuralgica, 
Fanalgin, Fenazon-koffein, Fenazon-koffein sterke) 
Not used
Less than every week
Every week, but not daily
daily
How much you take usually daily
when you use the medications?
(number of tablets) .........................................
16.05 Do you combine the treatment with the use
of prescribed pain-relief medications?
Yes No
16.03 Do you think you have experienced side 
effects of some of the medications? (tick 





Phenazone with caffeine ......................
In the first questionnaire you answered that you had used non-prescription painkillers (analgesic) 
medications in the last 4 weeks. Here are some follow-up questions we hope you will answer.
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17. FOLLOW-UP QUESTIONS ABOUT SKIN DISEASES
On page 15 in this questionnaire you answered that you have or have had a skin disease. 
Here are some follow-up questions we hope you will answer.
17.08 How old were you when you got 
abscesses for the first time?
0-12 years 26-35 years
13-19 years 36-50 years  
20-25 years Older than 50 years
17.07 How many episodes of abscesses
do you usually have per year? (tick once)
0-1 4-6
2-3 More than 6
17.09 If you no longer have abscesses, how
old were you when it disappeared?
0-12 years 26-35 years
13-19 years 36-50 years  
20-25 years Older than 50 years
17.06 Here is a list of factors that might 
trigger or exacerbate abscesses, tick for 







Answer on a scale from 0 to 10, where 0 corresponds to no symptoms and 10 correspond 







· How much are you affected 
 by your psoriasis today? ...............................
0 1 2 3 4 5 6 7 8 9 10
· How much are you affected by
 your psoriasis when it is most severe?  .............
17.02 Atopic eczema
· How much are you affected by
 your atopic eczema today? .......................
· How much are you affected by your
 atopic eczema when it is most severe?
 
17.03 Hand eczema
· How much are you affected by
 your hand eczema today? ..........................
· How much are you affected by your
 hand eczema when it is most severe? ......
17.04 Acne 
· How much are you affected by
 your acne today? ............................................
· How much are you affected by
 your acne when it is most severe? ....
17.05 Abscesses
· How much are you affected by
 your abscesses today? ..............................
· How much are you affected by your
 abscesses when it is  most severe? ..
Should you wish to give us a written feedback on either the questionnaire or The Tromsø
Study in general, you are welcome to it here:
FEEDBACK








Institute of community medicine, University of Tromsø
9037 TROMSØ
Telephone:  77 64 48 16
Telefax: 77 64 48 31
email: tromsous@ism.uit.no
The Tromsø Study
Department of community medicine, University of Tromsø
9037 TROMSØ
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